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Abstract
Neurodegenerative diseases are an emerging global health crisis, with the projected global cost of
dementia alone expected to exceed $1 trillion, or >1% of world GDP, by 2018. However, there are no
disease-modifying treatments for the major neurodegenerative diseases, such as Alzheimer’s disease,
Parkinson’s disease, frontotemporal lobar degeneration (FTLD), and amyotrophic lateral sclerosis.
Therefore, there is an urgent need for a better understanding of the pathophysiology underlying these
diseases. While genome-wide association studies (GWAS) have identified ~200 genetic variants that are
associated with risk of developing neurodegenerative disease, the biological mechanisms underlying
these associations are largely unknown. This dissertation investigates the mechanisms by which
common genetic variation at TMEM106B, a GWAS-identified risk locus for FTLD, influences disease risk.
First, using genetic and clinical data from thirty American and European medical centers, I demonstrate
that the TMEM106B locus acts as a genetic modifier of a common Mendelian form of FTLD. Second, I
investigate the role of increased TMEM106B expression levels, which have been reported both in FTLD
patients and in individuals carrying the TMEM106B risk allele, in FTLD pathogenesis. I demonstrate that
microRNA-132, the most dysregulated microRNA in a genome-wide screen of FTLD and control brains,
directly represses TMEM106B expression in human cells, and likely contributes to the elevated
TMEM106B levels seen in disease. I then combine statistical approaches, bioinformatics, and
experimental approaches in order to functionally characterize all candidate GWAS causal variants at the
TMEM106B locus. This approach identifies a noncoding variant, rs1990620, which affects CTCFmediated long-range chromatin interactions between distal regulatory elements, as the likely causal
variant responsible for altering TMEM106B expression levels and disease risk. These results provide a
plausible mechanism by which TMEM106B genotype and expression levels influence FTLD risk and
clinical progression, and provide a general framework for elucidating the biological mechanisms
underlying a disease-associated risk locus. Such an approach will be necessary in order to translate the
thousands of loci associated with disease risk by GWAS into mechanistic understanding and therapeutic
advances.
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ABSTRACT
GENETIC REGULATION OF TMEM106B IN THE PATHOGENESIS OF FRONTOTEMPORAL
LOBAR DEGENERATION
Michael D. Gallagher
Alice S. Chen-Plotkin

Neurodegenerative diseases are an emerging global health crisis, with the projected global
cost of dementia alone expected to exceed $1 trillion, or >1% of world GDP, by 2018. However,
there are no disease-modifying treatments for the major neurodegenerative diseases, such as
Alzheimer’s disease, Parkinson’s disease, frontotemporal lobar degeneration (FTLD), and
amyotrophic lateral sclerosis. Therefore, there is an urgent need for a better understanding of the
pathophysiology underlying these diseases. While genome-wide association studies (GWAS) have
identified ~200 genetic variants that are associated with risk of developing neurodegenerative
disease, the biological mechanisms underlying these associations are largely unknown. This
dissertation investigates the mechanisms by which common genetic variation at TMEM106B, a
GWAS-identified risk locus for FTLD, influences disease risk. First, using genetic and clinical data
from thirty American and European medical centers, I demonstrate that the TMEM106B locus acts
as a genetic modifier of a common Mendelian form of FTLD. Second, I investigate the role of
increased TMEM106B expression levels, which have been reported both in FTLD patients and in
individuals carrying the TMEM106B risk allele, in FTLD pathogenesis.

I demonstrate that

microRNA-132, the most dysregulated microRNA in a genome-wide screen of FTLD and control
brains, directly represses TMEM106B expression in human cells, and likely contributes to the
elevated TMEM106B levels seen in disease. I then combine statistical approaches, bioinformatics,
and experimental approaches in order to functionally characterize all candidate GWAS causal
variants at the TMEM106B locus. This approach identifies a noncoding variant, rs1990620, which
affects CTCF-mediated long-range chromatin interactions between distal regulatory elements, as
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the likely causal variant responsible for altering TMEM106B expression levels and disease risk.
These results provide a plausible mechanism by which TMEM106B genotype and expression levels
influence FTLD risk and clinical progression, and provide a general framework for elucidating the
biological mechanisms underlying a disease-associated risk locus. Such an approach will be
necessary in order to translate the thousands of loci associated with disease risk by GWAS into
mechanistic understanding and therapeutic advances.
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PREFACE
This body of work aims to understand how expression levels of the gene TMEM106B, and
the cellular regulation of these levels, are involved in the disease frontotemporal lobar degeneration
(FTLD). FTLD is one of many fatal neurodegenerative diseases for which there are currently no
effective treatments. Improving our understanding of what causes FTLD will help facilitate the
development of therapeutic interventions. In this introduction, I will provide an overview of FTLD,
discuss the role of common genetic variation in risk for complex diseases, and describe the
discovery and initial characterization of TMEM106B as a genetic risk factor for FTLD.
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CHAPTER 1: INTRODUCTION
1.1 PART I: Frontotemporal lobar degeneration: causes and mechanisms
1.1.1

Frontotemporal lobar degeneration
Frontotemporal lobar degeneration (FTLD) is a genetically and clinically heterogeneous

group of diseases that are characterized by the progressive degeneration of the frontal and
temporal lobes of the brain. Diagnosed clinically as frontotemporal dementia (FTD), FTLD is the
second most common cause of dementia in individuals under age 65, and results in progressive
deficits in behavior, executive functions, and/or language (Bang et al., 2015; Seelaar et al., 2011).
In addition, up to 40% of FTLD patients experience symptoms of motor neuron disease, with 1015% qualifying for a secondary diagnosis of amyotrophic lateral sclerosis (ALS) (Bang et al., 2015).
As the disease progresses, clinical symptoms worsen, and neurodegeneration expands throughout
the frontal and temporal lobes. Patients with end-stage disease display difficulties with eating,
moving, and swallowing (Bang et al., 2015). Death usually occurs within ~8 years after symptom
onset, and is typically caused by pneumonia or other secondary infections (Bang et al., 2015).
There is currently no way to prevent, treat or cure FTLD, necessitating a better understanding of
the causes and pathophysiology of this disease.
1.1.2

Epidemiology
The prevalence of FTLD is difficult to estimate due its heterogeneous clinical presentation

and frequent misdiagnoses (Bang et al., 2015). In fact, diagnostic certainty usually relies on
autopsy-confirmed FTLD-associated brain pathology.

Various studies have estimated the

prevalence of FTLD in Western countries to be roughly 10-20 per 100,000 persons in the 45-64
age group (Hodges et al., 2003; Knopman and Roberts, 2011; Lambert et al., 2014). FTLD
accounts for 3-26% of dementia cases in individuals under 65, making it the second most common
early-onset dementia, after Alzheimer’s disease (AD) (Bang et al., 2015).
1.1.3

Neuropathology
The neuropathological features of FTLD include neuronal loss, gliosis, microvascular

changes, and protein aggregation (Bang et al., 2015; Seelaar et al., 2011). Protein aggregation in

the brain is a common theme among the various neurodegenerative diseases, and different
diseases are defined in part by the specific protein makeup of the aggregates seen in patient brains
(Eisele et al., 2015). There are three major neuropathological subtypes of FTLD: ~50% of cases
display neuronal cytoplasmic inclusions of TAR DNA-binding protein of 43kDa (TDP-43); the
majority of the remaining cases exhibit various forms of neuronal and glial aggregates containing
the microtubule associated protein tau (MAPT); the remaining ~5% display aggregates consisting
mostly of the fused in sarcoma (FUS) protein (Bang et al., 2015; Seelaar et al., 2011). The role of
these aggregates in FTLD pathogenesis is currently unknown, and is an area of intense
investigation.
1.1.4

Genetic causes and risk factors
Genetics plays a complex role in FTLD. Roughly 30-50% of individuals with FTLD have a

family history of dementia (familial cases), but only 10-20% of cases are transmitted in clear
Mendelian inheritance patterns (Mendelian cases) (Benussi et al., 2015). Moreover, the Mendelian
disease-causing mutations are not fully penetrant, and are sometimes seen in individuals with no
family history of dementia (sporadic cases) (Figures 1.1 and 1.2) (Benussi et al., 2015; Tan et al.,
2017). Roughly 40-60% of the familial cases can be attributed to mutations in the MAPT, GRN,
and C9orf72 genes, while rarer disease-causing mutations occur in the TDP-43 (TARDBP), valosincontaining protein (VCP), and charged in multivesicular body protein 2B (CHMP2B) genes (Figure
1.1B) (Bang et al., 2015; Benussi et al., 2015; Tan et al., 2017).
Whereas other common neurodegenerative diseases, such as AD and ALS, are typically
sporadic with rare cases due to highly penetrant Mendelian mutations (Kalia and Lang, 2015;
Kiernan et al., 2011; Scheltens et al., 2016), FTLD appears to be more genetically heterogeneous.
As mentioned above, the mutations that cause Mendelian FTLD are incompletely penetrant (Figure
1.2), and the age at disease onset varies considerably between patients (Benussi et al., 2015).
Thus, it is likely that other genetic and environmental factors modify the penetrance and clinical
manifestation associated with these mutations.
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Figure 1.1. The prevalence of FTLD-causing mutations.
The prevalence of FTLD-causing mutations in (A) sporadic and (B) familial FTLD cases. “Other”
mutations occur in the VCP, CHMP2B, and TARDBP genes. Gray slices of the pie charts
indicate sporadic (A) and familial (B) cases that do not have any of the indicated mutations.
Charts are based on data from Benussi et al., 2015, Frontiers in Aging Neuroscience.
In addition to disease-causing mutations, two genome-wide association studies (GWAS)
have been performed to identify genetic risk factors for FTLD. A GWAS conducted at the University
of Pennsylvania was performed using only FTLD cases with TDP-43 pathology (FTLD-TDP), and
a genome-wide significant association was found on chromosome 7p21, at the TMEM106B locus
(Van Deerlin et al., 2010). This association has been independently replicated (Finch et al., 2011;
Hernandez et al., 2015; van der Zee et al., 2011). A second GWAS was performed using a clinically
defined FTLD cohort (thus likely representing various neuropathological forms of FTLD), and a
significant association with risk for FTLD was found at chromosome 6p21.3, at the HLA locus
(Ferrari et al., 2014). The lack of association with genetic variation at the TMEM106B locus in the
clinical FTLD GWAS suggests that distinct disease mechanisms may underlie neuropathologicallydefined FTLD, versus clinically-defined FTLD that results from multiple potential neuropathologies.
1.1.4.1 MAPT
The first Mendelian FTLD-causing mutations were found in the MAPT gene (Hutton et al.,
1998; Poorkaj et al., 1998; Spillantini et al., 1998). MAPT encodes the microtubule associated
protein tau (MAPT), which promotes microtubule assembly and stability. MAPT is highly expressed
in neurons and localizes mainly to axonal processes, although it is expressed at lower levels in glial
cells as well (Mackenzie and Neumann, 2016). In the human brain, alternative splicing of MAPT
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produces six protein isoforms, three of which contain three amino acid repeats (3R tau), and three
of which contain four amino acid repeats (4R tau) (Mackenzie and Neumann, 2016). More than 50
autosomal dominant mutations in MAPT have been discovered in FTLD patients, comprising ~10%
of Mendelian FTLD cases (Bodea et al., 2016; Mackenzie and Neumann, 2016). The two major
classes of mutations are 1) missense or deletion mutations in exons 9-13 that impair the
microtubule-stabilizing function of MAPT and 2) intronic and coding mutations that affect the
splicing of exon 10, resulting in alterations of the 3R:4R MAPT ratios (Mackenzie and Neumann,
2016). These mutations have been detected in a small number (0-3%) of sporadic FTLD cases,
suggesting either incomplete penetrance or de novo mutation (Benussi et al., 2015) (Figure 1.1A).
All FTLD cases caused by MAPT mutations display MAPT-associated neuropathology, and
are thus referred to as “FTLD-tau”. Most FTLD-tau cases, however, are not caused by MAPT
mutations, implicating other mechanisms in MAPT-associated neuropathology in FTLD (Bodea et
al., 2016). In FTLD-tau, abnormal intracellular inclusions of hyperphosphorylated MAPT occur in
neurons, and in some cases, glia (Bodea et al., 2016). These inclusions result in the mislocalization
of MAPT from the axons to the cell body (soma) and dendrites. Interestingly, other forms of MAPT
aggregates, called neurofibrillary tangles, are one of the hallmark neuropathological features of AD
(Bodea et al., 2016).
The mechanisms by which MAPT mutations and aggregates cause FTLD and other
neurodegenerative diseases are unknown. Normal phosphorylation of MAPT may be required for
normal interactions with microtubules, whereas hyperphosphorylation, associated with disease
states, sequesters MAPT from axons and results in conformational changes and eventual
aggregation (Bodea et al., 2016). While various MAPT knockout animal models have been created,
the existence of compensatory genes in some lower organisms has made it difficult to draw
conclusions regarding MAPT function (Bodea et al., 2016).

Consequently, much of our

understanding of the role of MAPT in neurodegeneration has come from transgenic rodent models.
While expression of human wild-type (WT) MAPT in rodents causes only mild phenotypes,
including MAPT hyperphosphorylation and mislocalization, expression of FTLD-associated MAPT
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Figure 1.2. Estimated penetrance and frequencies of FTLD-associated mutations and
risk variants.
The estimated penetrance and frequencies among FTLD patients is plotted for all known FTLDcausing mutations, as well as a typical, fully penetrant Mendelian mutation, typical GWASidentified risk factors, and TMEM106B risk variants. Values on the x-axis represent percentages
(e.g. 0.2=20%), whereas values on the y-axis are relative (0=never causes disease, 1=always
causes diseases). Penetrance estimates are based on Benussi et al., 2015, Frontiers in Aging
Neuroscience. Since risk factors do not cause disease, but rather affect risk, their estimated
penetrance is zero. Also note that while GWAS risk variants typically have allele frequencies of
at least ~1% in the general population, they can theoretically be much more common due to
lack of negative selection pressures and other factors.
mutations causes neurofibrillary tangles, neuronal loss, gliosis, and motor symptoms (Bodea et al.,
2016). However, the molecular mechanisms and cellular pathways by which this occurs in animal
models and human disease are unknown.
1.1.4.2 GRN
The second Mendelian cause of FTLD to be discovered was mutations in the GRN gene,
which encodes progranulin (PGRN), a secreted growth factor that functions in inflammation, wound
repair, neuronal viability, and cancer. PGRN is expressed in many cell types, including neurons
and glia, and is upregulated in activated microglia and astrocytes (Petkau and Leavitt, 2014). When
PGRN is secreted, extracellular proteases cleave the protein into smaller granulin peptides. Fulllength PGRN and cleaved granulins appear to have opposing and complex roles in
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neuroinflammation (Mackenzie and Neumann, 2016; Petkau and Leavitt, 2014).

PGRN also

facilitates neurite outgrowth, neurogenesis, and neuronal survival, and neurons are at least partially
dependent upon PGRN secretion by glial cells (Martens et al., 2012; Petkau and Leavitt, 2014;
Raitano et al., 2015). At least 69 loss-of-function mutations in GRN have been discovered,
accounting for 10-20% of familial FTLD cases (Cruts et al., 2006; Gass et al., 2006) (Figure 1.1B),
and all result in PGRN haploinsufficiency (Rademakers et al., 2012).

Most disease-causing

mutations create a premature stop codon, resulting in nonsense-mediated decay of the mature
transcript. Other mutations impair the trafficking and eventual secretion of PGRN, highlighting the
important role of PGRN secretion in normal brain function (Kleinberger et al., 2013; Petkau and
Leavitt, 2014). As with MAPT mutations, all disease-causing GRN mutations display autosomal
dominant inheritance patterns (Petkau and Leavitt, 2014).

Interestingly, a functional single

nucleotide polymorphism (SNP) in the GRN 3’ untranslated region, rs5848, alters GRN mRNA
levels by disrupting a binding site for the microRNA miR-659. The allele of rs5848 that preserves
the miR-659 binding site results in reduced PGRN levels, and has been reported to increase risk
for FTLD-TDP (Rademakers et al., 2008). However, attempts to replicate this association have
produced conflicting results (Chen et al., 2015; Rollinson et al., 2011b; Simon-Sanchez et al.,
2009).
All FTLD cases caused by GRN mutations (GRN+ FTLD) display TDP-43 neuropathology
(FTLD-TDP) (Petkau and Leavitt, 2014). TDP-43, which is normally a predominantly nuclear
protein, mislocalizes to the cytoplasm in FTLD-TDP, becomes hyperphosphorylated and
ubiquitinated, and forms intraneuronal aggregates (Ratti and Buratti, 2016). These aggregates are
thought to contribute to disease by impairing the normal function of TDP-43 and/or conferring a
toxic gain-of-function (Ratti and Buratti, 2016). In addition, FTLD-TDP brains display severe gliosis
in affected brain regions. PGRN is drastically upregulated in these regions, so much so that GRN+
FTLD-TDP individuals have higher PGRN levels in the frontal cortex than healthy individuals, who
have two functional copies of the GRN gene (Chen-Plotkin et al., 2010b).

Thus, PGRN

haploinsufficiency may cause disease in part by disrupting the neuroinflammatory response,
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although it is difficult to determine whether this phenotype is a cause of disease, a result of disease,
or both. As mentioned above, GRN mutations are incompletely penetrant (Figure 1.2), and FTLD
symptoms can manifest anywhere from ~35 to ~89 years of age (Benussi et al., 2015) in mutation
carriers. These observations suggest that other genetic and environmental factors influence GRN+
FTLD-TDP manifestation.
Several animal models of GRN+ FTLD-TDP have been created.

Surprisingly,

heterozygosity of Grn in mice (which causes FTLD-TDP in humans) produces no obvious
phenotype, despite 75% amino acid similarity between the human and mouse orthologues. Grn
knockout mice do display some FTLD-relevant phenotypes, such as gliosis, ubiquitinated (but
usually TDP-43-negative) neuronal inclusions, and subtle behavioral phenotypes, but do not
develop overt neurodegeneration (Filiano et al., 2013; Ma et al., 2016; Martens et al., 2012; Petkau
and Leavitt, 2014; Tanaka et al., 2013a; Tanaka et al., 2013b; Wils et al., 2012; Yin et al., 2010a;
Yin et al., 2010b). Paradoxically, in humans, homozygous GRN null individuals develop an entirely
different syndrome, neuronal ceroid lipofuscinosis, which is a fatal lysosomal storage disease
(Smith et al., 2012). Thus, animal models of GRN+ FTLD-TDP may be of limited utility, and have
not elucidated the mechanisms underlying the human disease, although they do suggest a potential
lysosomal role for GRN in disease.
Since GRN+ FTLD-TDP results from PGRN haploinsufficiency, cell-based studies have
also been carried out to investigate the effects of the loss of PGRN on neuronal health. One study
in particular demonstrated that exposing rat neurons to conditioned medium from Grn knockout
microglia caused neuronal death, suggesting a role for microglial PGRN in maintaining neuronal
health (Martens et al., 2012). Other reports have further implicated PGRN in microglial function,
including endocytosis and in vivo synaptic pruning (Lui et al., 2016; Pickford et al., 2011). PGRN
deficiency also appears to result in altered lysosomal function (thus linking loss of PGRN to the
lysosomal storage diseases seen in PGRN null humans) and an increase in Wnt signaling
pathways (Alquezar et al., 2016; de la Encarnacion et al., 2016; Rosen et al., 2011; Tanaka et al.,
2017).
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Finally, GRN has also been implicated in other neurodegenerative diseases. Specifically,
GRN overexpression and knockdown have been shown to alleviate and enhance the toxic effects
of amyloid beta protein, respectively, in an AD mouse model (Minami et al., 2014). Moreover, the
rs5848 GRN variant, which has been reported to affect risk for FTLD-TDP, may also affect risk for
AD (Lee et al., 2011; Sheng et al., 2014), although these results require replication.
In summary, GRN is a common Mendelian cause of FTLD-TDP, accounting for 10-20% of
all FTLD-TDP cases (Gass et al., 2006). All FTLD-causing GRN mutations act through a loss-offunction mechanism, implicating restoration of PGRN levels as a potential therapeutic target. GRN
has complex roles in inflammation, wound repair, neuronal viability, autophagy, and other
processes, and its effects appear to act in both cell autonomous and non-cell autonomous manners
(Petkau and Leavitt, 2014). Improving our understanding of the role of GRN in FTLD is an important
basic and translational research goal.
1.1.4.3 C9orf72
In 2011, hexanucleotide repeat expansion (HRE) mutations in the C9orf72 gene were
discovered to be the most common cause of FTLD, ALS, and the combined syndrome FTLD/ALS
(DeJesus-Hernandez et al., 2011; Renton et al., 2011). While most normal individuals have 2-20
GGGGCC (G4C2) repeats at the 5’ end of the C9orf72 gene (corresponding to the promoter region
for one transcript variant and the first intron for the other two transcript variants of this gene),
individuals with disease have hundreds to thousands of repeats, and these HREs cause disease
in an autosomal dominant manner (DeJesus-Hernandez et al., 2011; Renton et al., 2011; Todd and
Petrucelli, 2016). Similar to GRN and MAPT mutations, penetrance is incomplete (Figure 1.2),
and age at disease onset varies considerably (Benussi et al., 2015). While the normal function of
C9orf72 is not known, several studies have suggested a role in endosomal trafficking and
autophagy (Farg et al., 2014; Sellier et al., 2016; Sullivan et al., 2016; Ugolino et al., 2016; Webster
et al., 2016; Yang et al., 2016).
Both FTLD and ALS cases caused by C9orf72 HREs display TDP-43 pathology (C9orf72+
FTLD-TDP), similar to GRN+ FTLD-TDP and most sporadic ALS cases (Al-Sarraj et al., 2011;
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Neumann et al., 2006). Thus, FTLD and ALS display neuropathological overlap, in addition to
genetic and clinical overlap. C9orf72+ FTLD-TDP cases also display inclusions negative for TDP43 but positive for Nucleoporin 2 (p62), a protein complex associated with the nuclear envelope,
throughout the central nervous system (Al-Sarraj et al., 2011). The mechanism by which the
C9orf72 HRE causes disease has been an area of intense investigation in recent years. Many
studies have supported toxic-gain-of-function mechanisms, but loss of normal C9orf72 function
may also play a role in disease. I briefly summarize these studies below.
The presence of hundreds to thousands of G4C2 repeats in the C9orf72 promoter and first
intron (depending on the transcript variant) has been proposed to negatively affect C9orf72
transcription (DeJesus-Hernandez et al., 2011). In support of this, studies have reported reduced
C9orf72 transcript and protein levels in patient cells and brain tissue (Ciura et al., 2013; DeJesusHernandez et al., 2011; Donnelly et al., 2013; Gijselinck et al., 2012; Tran et al., 2015). However,
the effects of these reduced levels in patients are unknown, as C9orf72 knockdown and knockout
have produced conflicting results in animal models. For example, reduction of C9orf72 levels in
both C. elegans and zebrafish result in neuronal and behavioral defects (Ciura et al., 2013; Therrien
et al., 2013); however, similar knockdown experiments in mice did not produce similar phenotypes.
C9orf72 knockout mouse models have reproducibly displayed altered immune responses,
(specifically, enlarged spleen and lymph nodes, lysosomal accumulation, and neuroinflammation),
but no neurodegeneration or related phenotypes (Atanasio et al., 2016; Jiang et al., 2016; Koppers
et al., 2015; Lagier-Tourenne et al., 2013; O'Rourke et al., 2016; Sudria-Lopez et al., 2016). Finally,
a patient homozygous for the C9orf72 HRE was reported to have even lower C9orf72 transcript
levels than those seen in heterozygotes, but had similar clinical and neuropathological features
(Fratta et al., 2013). While additional HRE homozygotes are needed to establish whether this is a
reproducible pattern, these results suggest that loss-of-normal function of C9orf72 may not play a
significant role in FTLD-TDP pathogenesis.
In support of the toxic-gain-of-function model, various animal models have been generated
that express HREs of various lengths, usually >30 repeats to mimic disease and <10 repeats to
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mimic healthy individuals. For example, expression of 30 repeats in the Drosophila eye or motor
neurons results in neurodegeneration (Xu et al., 2013), and expression of 66 repeats in mouse
neurons results in TDP-43 inclusions in the brain, neurodegeneration, and behavioral deficits
(Chew et al., 2015). While some bacterial artificial chromosome (BAC) transgenic mouse models
expressing human C9orf72 with repeat expansions do not display TDP-43 pathology or
neurodegeneration (O'Rourke et al., 2015; Peters et al., 2015), others display neurodegeneration,
behavioral deficits, and in some cases, decreased lifespan (Jiang et al., 2016; Liu et al., 2016).
Since all of these studies use BACs containing similar genomic regions, the reason for the
discrepant results is unclear but raises the possibility that off-target effects might be causing some
of the phenotypes.
Various toxic-gain-of-function mechanisms for the C9orf72 HRE have been proposed, and
in many cases, validated. At the biochemical level, the HRE forms DNA and RNA G-quadruplexes
as a result of its G-rich sequence. One study demonstrated that nucleolin, a key nucleolar protein,
is sequestered by C9orf72 HRE RNA quadruplexes (Haeusler et al., 2014). Nucleolin localization
and nucleolar morphology is disrupted in patient cells and brain tissue, suggesting a role of
nucleolar stress in disease (Haeusler et al., 2014). In addition, HRE-expressing animals, patient
cells (typically fibroblasts from C9orf72+ FTLD-TDP patients that are differentiated into induced
pluripotent stem cell-derived neurons), and patient brains consistently display RNA foci consisting
of the transcribed HRE sequence (DeJesus-Hernandez et al., 2011; Donnelly et al., 2013; Gendron
et al., 2013; Lagier-Tourenne et al., 2013; Mizielinska et al., 2013; Renton et al., 2011; Zu et al.,
2013). Many studies have demonstrated that these foci sequester RNA-binding proteins (RBPs),
resulting in gene expression changes, as well as sensitivity to glutamate toxicity, although the
specific affected RBPs differ widely across studies (Cooper-Knock et al., 2014; Donnelly et al.,
2013; Haeusler et al., 2014; Lee et al., 2013; Mori et al., 2013; Sareen et al., 2013). However,
siRNA or shRNA-mediated knockdown of these foci have rescued cellular and organismal
phenotypes induced by the HRE, suggesting that they (or the dipeptide repeat proteins also
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produced from the HRE, see below) are toxic (Donnelly et al., 2013; Jiang et al., 2016; Sareen et
al., 2013).
The HRE transcript also produces dipeptide protein repeats (DPRs) through repeatassociated non-ATG (RAN) translation (Zu et al., 2011), which are seen in patient cells, patient
brain, and some animal models (Al-Sarraj et al., 2011; DeJesus-Hernandez et al., 2011; Mann et
al., 2013; Murray et al., 2011; Renton et al., 2011). Several studies have shown that these DPRs
are toxic when expressed in yeast, cultured neurons, Drosophila, and mice (Kwon et al., 2014;
Mizielinska et al., 2014; Tao et al., 2015; Wen et al., 2014; Yang et al., 2015; Zhang et al., 2016).
The pathogenicity of DPRs is further supported by genetic modifier screens performed in
Drosophila and yeast. These studies, using HRE models that produce RNA foci, DPRs, or both,
have identified proteins involved in nucleocytoplasmic transport as genetic modifiers of HRE toxicity
(Freibaum et al., 2015; Jovicic et al., 2015; Zhang et al., 2015). In general, the results suggest that
the HRE impairs the nuclear import, and possibly export, of mRNAs, resulting in the accumulation
of mRNAs in the nucleus (Freibaum et al., 2015; Jovicic et al., 2015; Zhang et al., 2015).
Finally, a toxic gain-of-function mechanism is also supported by the disease-modifying
effects of CpG methylation in the C9orf72 promoter. Hypermethylation of the promoter has been
shown to reduce C9orf72 levels and resulting RNA foci and DPRs, as well as protect against cellular
sensitivity to stress (Liu et al., 2014; Russ et al., 2015). Importantly, this hypermethylation also
appears to reduce neurodegeneration, delay age at death, and extend disease duration in human
patients (McMillan et al., 2015).
In summary, hexanucleotide repeat expansions in the C9orf72 gene are the most common
cause of FTLD, as well as ALS. C9orf72 appears to be involved in autophagy, although the function
of this protein is largely unknown. The HREs likely cause disease through a toxic gain-of-function
mechanism (driven by toxic RNA foci and DPRs), although loss of normal C9orf72 function may
play a role as well. The normal and disease-associated functions of C9orf72 are currently an area
of intense investigation.
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1.1.4.5 Rare mutations
As mentioned above, ~50% of familial FTLD cases are caused by mutations in the MAPT,
GRN and C9orf72 genes. These three genes appear to have quite different cellular functions,
although GRN and C9orf72, which both cause FTLD-TDP, have been implicated in autophagy,
suggesting that protein degradation pathways may play a role in FTLD pathogenesis. Intriguingly,
rarer FTLD-causing mutations also point to defects in autophagy, as well as the
ubiquitin/proteasome system, the other major protein clearance pathway in the cell (Cohen-Kaplan
et al., 2016). This genetic evidence that impaired protein degradation may play a role in FTLD is
strengthened by the fact that such impairments have been implicated in virtually all
neurodegenerative diseases (Martini-Stoica et al., 2016).
Some rare FTLD cases are caused by autosomal dominant mutations in the CHMP2B
gene, which is part of the endosomal sorting complex required for transport-III (ESCRT-III) complex
(Isaacs et al., 2011) (Figure 1.1B). This complex plays a role in protein degradation through the
endolysosomal and autophagic pathways. Two FTLD-causing mutations, one affecting splicing
and another introducing a premature stop codon, both result in a truncated protein lacking the Cterminal 36 or 49 amino acids, respectively (Isaacs et al., 2011). The mechanism by which the
mutation causes disease is unknown, but multiple studies have demonstrated an accumulation of
autophagic vesicles in cells expressing CHMP2B with FTLD-causing mutations (Isaacs et al.,
2011). In addition, mice expressing an FTLD mutant form of CHMP2B develop a lysosomal storage
disease (Clayton et al., 2015). Patients with these mutations have ubiquitin/p62-positive inclusions,
thus referred to as FTLD-UPS.
Other rare FTLD cases are caused by various missense mutations in the VCP gene
(Kimonis et al., 2008) (Figure 1.1B). VCP is an (AAA) ATPase and plays a critical role in the
ubiquitin/proteasome protein degradation pathway.

The disease-causing mutations cause a

distinct syndrome called inclusion body myopathy associated with Paget disease of the bone and
frontotemporal dementia (IBMPFD), which causes muscle weakness and bone disease in addition
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to FTLD (Mackenzie and Neumann, 2016). IBMPFD is characterized by TDP-43 pathology, and is
also inherited in an autosomal dominant manner (Erzurumlu et al., 2013; Kimonis et al., 2008).
Finally, rare mutations in TARDBP, the gene encoding TDP-43, have been reported to
cause ALS, and in even rarer cases, FTLD (Figure 1.1B), although the FTLD cases typically lack
neuropathological confirmation (Mackenzie and Neumann, 2016). Nonetheless, the important role
of TDP-43 in FTLD pathogenesis has been appreciated since 2006, when TDP-43 was reported to
be the main protein constituent of the neuronal cytoplasmic ubiquitinated inclusions seen in ~50%
of FTLD brains (originally referred to as FTLD-U, now referred to as FTLD-TDP) (Neumann et al.,
2006). TDP-43 is a heterogeneous ribonucleoprotein (hnRNP) that has widespread roles in RNA
processing, regulation, splicing, and stability (Ratti and Buratti, 2016). Experimental knockdown of
TDP-43 in mouse and human cells results in changes in expression levels and splicing patterns of
thousands of mRNAs (Polymenidou et al., 2011; Tollervey et al., 2011), and may also result in
widespread changes in other RNAs, such as microRNAs and long non coding RNAs (lncRNAs).
TDP-43 contains N- and C-terminal domains, which are thought to play a role in protein-protein
interactions, and two RNA recognition motifs (RRMs), which provide sequence specific RNAbinding properties (Ratti and Buratti, 2016). Over 50 disease-causing TDP-43 mutations have been
reported (the majority of which cause ALS, not FTLD), and occur mostly in the C-terminal region,
suggesting that they affect the interactions of TDP-43 with itself and/or other proteins. Many of
these mutations cause neuropathology or neurodegeneration when expressed in animal models,
and some enhance the ability of TDP-43 to form aggregates both in vitro and in vivo (Ratti and
Buratti, 2016). In general, however, TDP-43 animal models do not fully recapitulate the phenotypes
associated with ALS or FTLD, and the effects of the majority of disease-associated TDP-43
mutations are either unknown or contradicted in the literature (Buratti E., 2015).
In summary, known FTLD-causing mutations occur in six genes (Figure 1.1B). All but
MAPT have been implicated in protein degradation pathways; indeed, the primary cellular functions
of CHMP2B, VCP, and possibly C9orf72 may be directly related to protein degradation. TARDBP
has widespread roles in RNA processing, splicing, and metabolism, and thus likely plays a global
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(albeit indirect) role in regulating protein levels. Finally, accumulating evidence from cell-based
studies and animal models also implicate GRN in autophagy. Taken together, this genetic evidence
suggests that defects in protein homeostasis may play an important role in FTLD, making
autophagy and other processes related to protein degradation attractive therapeutic targets.
1.1.4.6 TMEM106B
While much progress has been made in understanding the genetic basis of FTLD, much
work remains to be done. As mentioned previously, known mutations account for only ~50% of
familial FTLD cases, and the mechanisms by which these mutations cause disease are not well
understood. Secondly, 80-90% of FTLD cases are not inherited in Mendelian patterns (Benussi et
al., 2015), suggesting that they are caused by combinations of genetic and environmental risk
factors – in other words, FTLD is a complex trait.

As is the case for many complex traits,

researchers have used the GWAS to identify genetic risk factors for FTLD, with the goal of
expanding our understanding of the pathways involved in disease, in order to help facilitate the
development of therapeutic interventions.
The first FTLD GWAS was performed on 515 FTLD-TDP cases and 2,509 controls of
Western European ancestry (Van Deerlin et al., 2010). Three SNPs in moderate to complete
linkage disequilibrium (LD) with each other (0.7<r2<1) were significantly associated with risk for
FTLD-TDP, with the major (more common) SNP alleles associating with increased disease risk
(P=1.08x10-11 and odds ratio=1.64 for the top SNP, rs1990622).

The SNPs are located on

chromosome 7p21; two are located in intronic regions of the previously uncharacterized gene
transmembrane protein 106B (TMEM106B), and the third, most significant (sentinel) SNP is located
~7kb downstream of TMEM106B (Van Deerlin et al., 2010).

Importantly, the association of

rs1990622 with FTLD was replicated both in the initial GWAS report, as well as in three independent
studies (Finch et al., 2011; Hernandez et al., 2015; van der Zee et al., 2011).
Supporting a more general role of TMEM106B genotype in neurodegeneration, the major
(risk) allele of rs1990622 and other linked SNPs have also been associated with hippocampal
sclerosis of aging (Nelson et al., 2015), cognitive impairment in ALS (Vass et al., 2011), increased
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TDP-43 pathology in Alzheimer’s disease and neurologically normal individuals (Rutherford et al.,
2012; Yu et al., 2015), decreased neuronal connectivity in asymptomatic GRN mutation carriers
(Premi et al., 2014), reduced plasma progranulin levels (Cruchaga et al., 2011; Finch et al., 2011),
and reduced temporal lobe gray matter and smaller anterior commissure cross-sectional area in
neurologically healthy individuals (Adams et al., 2014). While I discuss individual studies in greater
detail in Chapter 1.3, these results suggest that common genetic variation at the TMEM106B locus
affects risk for FTLD, as well as several other phenotypes associated with various
neurodegenerative diseases.
1.1.5

Summary
FTLD refers to a heterogeneous group of neurodegenerative diseases characterized by

progressive degeneration of the frontal and temporal lobes, behavioral changes, language
problems, executive function deficits, and oftentimes, motor neuron disease. Up until ~10 years
ago, there was very little understanding of the genetic causes, pathophysiology, and
neuropathology associated with FTLD; as a result, FTLD was (and still is) frequently misdiagnosed
as other types of dementia, psychiatric illness, and other conditions. The recent consolidation of
findings from the fields of genetics, neurology and neuropathology has refined our understanding
of the FTLD disease spectrum, and FTLD is now known to be a major neurodegenerative disease,
accounting for up to a quarter of all pre-senile dementia cases (Bang et al., 2015).
FTLD is a relatively heritable disease, with cases frequently presenting with a family history
of disease, making it unique among neurodegenerative diseases in general. The most common
disease-causing mutations are loss-of-function mutations in the GRN and MAPT genes and
hexanucleotide repeat expansion mutations in the C9orf72 gene, although these mutations are not
fully penetrant. In addition, most FTLD cases are of unknown cause, and the genes that harbor
disease-causing mutations have diverse and somewhat non-overlapping cellular roles. Thus, our
understanding of the mechanisms underlying FTLD is limited, necessitating further advances in
basic research that can be applied to nominate potential therapeutic targets. This is an especially
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important research goal, given that there are currently no disease-modifying treatments for this
fatal disease.
One approach that has been used to identify novel pathways and mechanisms involved in
FTLD is the GWAS, which has identified thousands of risk loci for hundreds of complex traits and
diseases (Welter et al., 2014). The first GWAS performed on FTLD identified an association of
SNPs on chromosome 7p21 with FTLD risk.

Interestingly, these SNPs fall in and near the

previously uncharacterized gene TMEM106B (Van Deerlin et al., 2010). However, the statistical
association alone does not demonstrate that TMEM106B itself is the causal gene, nor how genetic
variants at this locus might affect TMEM106B and/or other genes to influence disease risk. Thus,
it will be critical to identify how common genetic variation at this locus influences risk for FTLD.
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1.2 PART II: The role of common genetic variation in complex traits
1.2.1

Complex traits and genome-wide association studies
For many decades after the discovery of the structure of DNA and the genetic code, the

field of human genetics was largely focused on understanding the structure and function of proteincoding genes, and how mutations in these genes cause disease. The Central Dogma of molecular
biology posits that genes are first transcribed into messenger RNA (mRNA), after which the mRNA
is translated into protein (Crick, 1970). Because of the seemingly universal nature of the genetic
code, it was easy to predict how simple or complex alterations of the underlying DNA sequence
would change the amino acid composition of the resulting protein (Ghosh and Collins, 1996). In
addition, it was clear from Mendelian genetics that diseases that run in families in predictable
patterns are caused by mutations in a single gene. In the latter part of the 20 th century, the
causative mutations underlying many Mendelian diseases were elucidated by positional cloning
(Ghosh and Collins, 1996), and thus, an important hurdle was overcome in our understanding of
the genetic bases of human disease.
Today, the genetic lesions responsible for most of the common (and many of the rare)
Mendelian diseases are known, and in many cases researchers have determined how the mutation
in question affects protein function and human physiology (Ghosh and Collins, 1996). However,
many of the most common and deadly diseases, such as cardiovascular disease, cancer,
Alzheimer’s disease, Parkinson’s disease, and Type 2 diabetes, are typically not (or never) caused
by single mutations (Hirschhorn, 2005; Johnson and Todd, 2000). Such “complex traits” are
instead influenced by a combination of multiple genetic and environmental risk factors, and thus do
not follow Mendelian inheritance patterns (Ghosh and Collins, 1996). This situation poses a
formidable challenge to scientists trying to understand the causes of these diseases. While it may
not always be necessary to understand the cause of a disease in order to successfully treat it, such
a mechanistic understanding certainly increases the likelihood that a successful therapeutic
intervention will be achieved.
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For several reasons, elucidation of the genetic basis of a complex trait is a more daunting
task than identifying a disease-causing mutation (Ghosh and Collins, 1996). Family pedigrees are
of little use, and complex traits, by definition, are influenced by many genes (human height, for
example, appears to be affected by genetic variation at several hundred loci across the genome
(Wood et al., 2014)). Starting in 2005, researchers around the world have used the genome-wide
association study (GWAS) to identify loci that harbor genetic variants (typically single nucleotide
polymorphisms, or “SNPs”) that are associated with risk for complex diseases and traits (Edwards
et al., 2013). The GWAS era has been successful in the sense that thousands of loci have been
statistically associated with risk for hundreds of diseases and traits, and a notable number of these
loci are well-replicated, suggesting that they are true associations (Welter et al., 2014). However,
several factors have made it difficult to bridge the gap between statistical associations and a
functional understanding of how these variants influence disease risk. First, the association of a
locus with disease does not specify which variant at that locus is actually causing the association
(the “causal variant”), nor which gene is affected by the causal variant. The former problem is due
to the fact that there are often many co-inherited variants in strong linkage disequilibrium (LD) with
the most significant (sentinel) disease-associated variant, comprising a “haplotype” (Gabriel et al.,
2002); within the haplotype, SNPs and other genetic variants in strong LD often have statistically
indistinguishable associations with disease risk.

Therefore, only experimental validation can

determine which of the linked variants are functional (Edwards et al., 2013; Schaub et al., 2012).
The latter complication results from the fact that >90% of disease-associated variants (daVs) are
located in non-protein-coding regions of the genome, and many are far away from the nearest
known gene (Maurano et al., 2012; Schaub et al., 2012). What might these non-coding variants
be doing? One clue arises from the observation that daVs, as well as variants in strong LD with
them, are enriched in predicted transcriptional regulatory regions, called “cis-regulatory elements”
(CREs) (Maurano et al., 2012; Schaub et al., 2012). This suggests that many loci implicated by
GWAS to affect disease risk may do so by altering the genetic regulation of one or more target
genes. However, the complex nature of eukaryotic transcriptional regulation (Lelli et al., 2012) can
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make it difficult to assign putative CREs (and any disease-associated variants within them) to their
correct target genes (Edwards et al., 2013), necessitating the use of genomic data sets and
experimental approaches to help answer this question. Indeed, while several thousand GWAS
have been performed, and many thousands of loci have been confirmed as bona fide disease risk
factors (Welter et al., 2014), the number of studies that have investigated the mechanisms
underlying particular associations number only in the dozens (Figure 1.3), and the number of
studies that have functionally characterized all candidate causal variants at a given locus are even
fewer (Table 1.1 lists some recent examples, but is by no means exhaustive). The purpose of this
review is to present a general framework for the functional dissection of a disease-associated risk
locus, and to highlight individual studies as proof-of-principle examples for the various approaches
that have been used by researchers in mechanistic GWAS follow-up studies.
1.2.2

The role of gene expression in complex traits
As mentioned above, the vast majority of daVs reside in noncoding regions of the genome,

suggesting that these variants may affect gene expression through effects on transcription, splicing,
or mRNA stability. Consistently, several studies have shown that daVs are enriched in predicted
CREs, typically defined by chromatin accessibility (as determined by DNase-seq, FAIRE-seq,
ATAC-seq, or MNase-seq), transcription factor (TF) binding, and/or histone marks known to be
associated with transcriptional regulatory activity, such as H3K27ac, H3K4me1, and H3K4me3
(Maurano et al., 2012; Schaub et al., 2012). Intriguingly, daVs for a particular disease appear to
be specifically enriched in CREs that appear active in disease-relevant cell types. For example, a
study from Farh and colleagues (2015) examined the overlap of variants associated with 21
autoimmune diseases with six histone marks in multiple primary immune cell types and conditions
(Farh et al., 2015).

Importantly, the authors imputed the genotypes of variants not directly

genotyped in their respective GWAS, and determined which variants were most likely to be causal
using an algorithm that incorporates the LD structure and association pattern at each locus. The
authors found that candidate causal variants were enriched in predicted B and T cell enhancers
(consistent with the expected cellular origin of autoimmune diseases), and that this enrichment
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Figure 1.3. The mechanistic understanding of GWAS disease risk loci lags far behind the
total number of published GWAS and SNP-trait associations.
The number of total GWAS published as of the indicated year (according to the EBI GWAS
catalog (Welter et al., 2014)) are shown in blue, whereas the total number of published postGWAS functional studies as of each year are shown by the orange line. 2015 data does not
include studies published after 10/30/15. The number of published GWAS likely underestimates
the number of unique SNP-trait associations, since many individual GWAS identify multiple
disease or trait risk loci. Thus, a very small percentage of the thousands of SNP-trait associations
have been investigated mechanistically. Post-GWAS functional studies were identified
systematically by 1) reviewing the titles, and in some cases, abstracts, of all research articles
published in 23* of the highest impact biomedical research journals between 10/3/13 and
10/30/15, and 2) PubMed searches using the keywords “causal variant” and “functional variant”.
Occasional additional studies were identified through references provided in review or primary
research articles.
*American Journal of Human Genetics, Cancer Cell, Cell, Cell Reports, Cell Stem Cell, eLife,
Genome Biology, Genome Research, Human Molecular Genetics, Molecular Cell, Nature, Nature
Biotechnology, Nature Communications, Nature Genetics, Nature Medicine, Nature
Neuroscience, Nature Structural & Molecular Biology, Neuron, PLOS Genetics, PNAS, Science,
Science Translational Medicine, Stem Cell Reports
increases with the likelihood that the variant is causal (Farh et al., 2015). When expanding this
analysis to 18 additional traits and diseases and incorporating epigenetic data from additional cell
and tissue types, the authors observed an enrichment of variants associated with neurological
disease in predicted brain promoters and enhancers, whereas blood glucose risk variants were
enriched in regulatory regions predicted to be active in pancreatic islets (Farh et al., 2015).
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First Author

Locus

25865496

Lu,X

ETS1

25918370

He,H

26211971

Ogura,Y

26211970

Vicente,CT

26287746 Claussnitzer,M

Trait

Systemic lupus
erythematosus
FOXE1/PTCSC2
Papillary thyroid
carcinoma
BNC2
Adolescent idiopathic
scoliosis
8q21
Asthma and hay fever

Identify all
Variant prioritization
traitmethods
associated
variants
Epigenomic, in silico, chromatin
Y
interactions
Epigenomic, in silico
Y

Test all
putative
causal
variants
Y
Y

Y

Epigenomic

Y

Y

Epigenomic

Y

FTO

Obesity

PR

Epigenomic, in silico

N

Y

Epigenomic

Y

Y

Epigenomic

Y

Experimental approaches

EMSA, LC/MS, AS-ChIP-qPCR
AS-ChIP-qPCR, cellular reporter
assays, 3C
Cellular reporter assays, EMSA
AS-3C, cellular reporter assays,
ChIP-qPCR
Cellular reporter assays, genome
editing, EMSA
Cellular reporter assays, EMSA,
ChIP-qPCR

26637976

Roman,TS

GALNT2

26398868

Spisak,S

6q22.1

High density
lipoprotein cholesterol
levels
Prostate cancer

26560027

Oldridge,DA

LMO1

Neuroblastoma

Y

N/A

Y

26695686
26928228

Wang,M
Dunning,AM

3q28
ESR1

Bladder cancer
Breast cancer

Y
Y

in silico
Epigenomic

N
Y

27096366

Soldner,F

SNCA

Parkinson’s disease

PR

Epigenomic, in silico

N

27055116

Nakaoka,H

9p21

Endometriosis

Y

Epigenomic

Y

AS-ChIP-qPCR, epigenome
editing, genome editing
AS-ChIP-seq, cellular reporter
assays
Cellular reporter assays
AS-3C, EMSA, cellular reporter
assays, ChIP-qPCR
Genome editing, ChIP-qPCR,
EMSA
AS-3C, AS-ChIP-qPCR

27162171
27149122

Wang,X
Smith,JG

QT/QRS interval
Heart failure mortality

PR
Y

Cellular reporter assays, 4C
Cellular reporter assays

Vodo,D

Pemphigus vulgaris

Y

N

Cellular reporter assays

27213290

Zheng,J

LINC00673

Y

N

27259051

Painter,JN

14q32

Pancreatic ductal
adenocarcinoma
Endometrial cancer

Epigenomic
Epigenomic
Epigenomic, in silico,
conservation
in silico

Y
N

27148741

5q22
ST18

Y

Epigenomic

Y

27402876

Wyszynski,A

2q35

Breast cancer

PR

Experimental (3C)

N

Cellular reporter assays, isoform
overexpression
AS-3C, cellular reporter assays,
EMSA, ChIP-qPCR
3C, AS-ChIP-qPCR, epigenome
editing

N

Y

Epigenomic, in silico, chromatin
interactions, conservation
Tested all variants

Type 2 diabetes

PR

N/A

N

Y

Epigenomic, experimental (3C)

Y

5p12

Breast and ovarian
cancer
Breast cancer

Y

Epigenomic

Y

Powell,JE
Mika,KM

1p36.12
TAP2

Endometriosis
Fecundability

Y
N

Experimental (3C)
N/A

Y
N

27848966
27866707

Schmiedel,BJ
Ye,J

17q21
4q25

Asthma
Atrial fibrillation

PR
N

Epigenomic
Epigenomic, conservation

N
N

27817866

Vince,N

MHC

HLA-C levels

Y

in silico

N

27524613 Kandaswamy,R

15q15.1

Y

13q22.1

Chronic lymphocytic
leukemia
Pancreatic cancer

27580880

Hoskins,JW

27539148

Xia,Q

TCF7L2

27601076

Lawrenson,K

19p13

27640304

Ghoussaini,M

27655404
27745831

Y

Cellular reporter assays, EMSA,
4C
3C, cellular reporter assays,
EMSA, LC/MS
Capture-C, 4C, genome editing
Cellular reporter assays, 3C,
genome editing
3C, cellular reporter assays,
EMSA
3C, cellular reporter assays
Cellular reporter assays
ChIP-seq, ChIP-qPCR, 4C
Transgenic reporter assays,
cellular reporter assays, genome
editing, EMSA, ChIP-qPCR
EMSA, ChIP-qPCR

Table 1.1. Post-GWAS functional studies published in a recent 2 year period.
This list consists of studies published between March 1, 2015 and March 1, 2017, as identified by applying the methods described in Figure 1.3 to
the aforementioned 2 year time period. This approach identified 28 studies that investigated the mechanisms underlying a specific GWAS risk locus.
In order to maximize the relevance of the table to this chapter, studies that investigated causal protein-coding variants were not included. The
scientific rigor of each study is assessed in the last four columns, regarding 1) whether the study used statistical methods, such as imputation, to
identify all trait-associated variants (Y=yes; N=no; PR=previously reported), 2) the methods by which the study prioritized candidate causal variants
for experimental investigation, 3) whether the study experimentally tested all putative causal variants after prioritization for allele-specific function,
and 4) the experimental methods used to test variants for allele-specific function. Prioritization approaches include epigenomic annotation of
predicted transcriptional regulatory function, in silico prediction of transcription factor or microRNA binding sites, evolutionary conservation, and
chromatin interactions between regions harboring candidate causal variants and known active regions, such as gene promoters. PMID=PubMed ID;
AS=allele-specific, LC/MS=liquid chromatography/mass spectroscopy, which in all cases was used to identify peptides bound to a DNA probe in
EMSA experiments.
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Based on these results and other similar reports (Maurano et al., 2012), it has been
suggested that many GWAS causal variants may influence disease risk by altering the function of
cell type-specific regulatory elements, such as enhancers, with ensuing changes in target gene
expression.

This hypothesis is strongly supported by the overlap of daVs with expression

quantitative trait loci (eQTLs) – specifically, variants that are associated with the expression
(mRNA) levels of one or more genes are more likely to be daVs than would be expected by chance
(Fu et al., 2012; Nicolae et al., 2010; Schaub et al., 2012). Furthermore, the cell type in which the
eQTL effect is observed often matches cell types thought to be relevant to the disease in question,
consistent with the overlap of daVs with disease-relevant tissue-specific CREs. In a study by Raj
and colleagues (2014), a large-scale eQTL analysis in primary T cells and monocytes, representing
adaptive and innate immune processes, respectively, was performed (Raj et al., 2014). The
authors found a significant overlap between variants associated with expression in these cell types
and variants associated with autoimmune diseases. Moreover, some daVs were only associated
with gene expression levels in one of the two immune cell types. For example, daVs for Alzheimer’s
disease were associated with gene expression levels only in monocytes, which have been
implicated in Alzheimer’s pathogenesis and are related to the cellular precursors of brain microglia
(Raj et al., 2014). While these studies support a role of cell type-specific cis-regulatory variation in
complex disease pathogenesis, variants can also affect gene expression levels through posttranscriptional processes such as mRNA splicing and stability (Pai et al., 2015). Indeed, several
studies have characterized functional daVs that may influence disease risk through these types of
effects (Paraboschi et al., 2014; Richardson et al., 2013; Wang et al., 2014a; Zhang et al., 2011).
Other studies have associated genetic variants with altered levels of DNA methylation
(mQTLs) (Hannon et al., 2016; Kaplow et al., 2015), DNase hypersensitivity (dsQTLs) (Degner et
al., 2012), and TF binding (bQTLs) (Ding et al., 2014; Tehranchi et al., 2016), and some of these
reports show significant overlap of these variants with daVs as well (Hannon et al., 2016; Tehranchi
et al., 2016). Taken together, these observations suggest that many GWAS causal variants
influence disease risk by altering the function of a CRE (presumably by affecting the recruitment of
one or more trans-acting factor), which results in altered gene expression levels and disease-

relevant phenotypes. Notably, eQTL studies have consistently shown that most eQTL effects are
of relatively small magnitude (<2-fold change in expression) (Dimas et al., 2009; GTEx Consortium,
2015), agreeing with the results of large-scale experimental characterizations of putative regulatory
variants (Patwardhan et al., 2012; Tewhey et al., 2016). However, while much focus has been
applied to identifying and characterizing functional cis-regulatory variants and their effects on gene
expression, the mechanisms by which small changes in gene expression affect cellular or
organismal phenotypes to influence disease risk are not well understood.
1.2.3

Recent advances in functional genomics
As mentioned previously, the number of SNP-trait associations established by GWAS has

increased astronomically in the last decade. The number of SNP-trait associations that have been
functionally dissected in an unbiased and comprehensive manner, however, is still relatively low
(Table 1.1). Fortunately, this situation appears to be changing as a result of the advent of a series
of experimental techniques and large-scale databases.
In the mid/late 2000s, there was limited information regarding the specific genetic variants
that exist in human populations, and the functions of the noncoding regions of the genome were
largely unexplored. Some impressive early post-GWAS studies relied upon deep sequencing or
bacterial artificial chromosomes (BACs) to identify all the variants spanning a disease-associated
haplotype, and nominated causal variants based on biochemical assays or cell culture-based
experiments (Harismendy et al., 2011; Musunuru et al., 2010; Verlaan et al., 2009). For example,
Musunuru et al. (2010) used BACs to identify all the variants located in a haplotype that had been
associated with low density lipoprotein levels.

The authors then used reporter assays to

demonstrate haplotype-specific effects on gene expression, and, in combination with gel shift
assays, identified the causal variant responsible for this effect (Musunuru et al., 2010). However,
recent large-scale projects such as the International HapMap and 1000 Genomes projects (1000
Genomes Project Consortium et al., 2015; International HapMap 3 Consortium et al., 2010) have
extensively characterized genetic variation in numerous human populations, obviating the need for
sequencing (unless the causal variant is rare) and allowing for refinement and superior resolution
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of association signals (Edwards et al., 2013). Many early post-GWAS studies also performed
laborious epigenetic experiments in order to characterize potential CREs at their loci of interest
(Harismendy et al., 2011; Zhou et al., 2012). However, as a result of large-scale data sets
generated by The ENCODE Project (ENCODE Project Consortium et al., 2012), the NIH Roadmap
Epigenome Project (Roadmap Epigenomics Consortium et al., 2015), the FANTOM consortium
(Andersson et al., 2014; FANTOM Consortium and the RIKEN PMI and CLST (DGT) et al., 2014),
and others, there are now impressive annotations of putative CREs in hundreds of human cell types
and tissues; therefore, such in-house experiments are oftentimes unnecessary. In addition, a
wealth of eQTL data is now available for dozens of cell and tissue types (Albert and Kruglyak, 2015;
GTEx Consortium, 2015), such that the association of a daV with gene expression levels can easily
be queried, and potential causative genes can be identified. Finally, several new techniques have
been developed that show great potential for the interrogation of allele-specific transcriptional
processes, including genome and epigenome editing (Komor et al., 2016), chromosome
conformation capture (3C)-based assays (Denker and de Laat, 2016), massively parallel reporter
assays (MPRAs) (Inoue and Ahituv, 2015), and other allele-specific high-throughput sequencing
(HT-seq) analyses.
1.2.4

A general framework for the functional dissection of a genetic risk locus

1.2.4.1 Statistical approaches
How might one leverage the wealth of genomic data that exists today in order to derive
biological meaning from a GWAS-implicated disease risk locus?

Here, I propose a general

framework for translating a statistical association by GWAS to a functional understanding of the
causal genetic variant(s), which is outlined in Figure 1.4. First, the resolution of microarray-based
GWAS can be greatly increased by performing imputation of ungenotyped variants, using
population-based sequencing data, such as that from the 1000 Genomes Project (Edwards et al.,
2013). In this way, the significance of association of virtually all common (minor allele frequency >
1%) variants with disease risk can be estimated (1000 Genomes Project Consortium et al., 2012).
Conditional analyses can additionally be performed to determine if multiple weakly linked or
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unlinked causal variants are contributing to the association of the same locus with disease risk
(Edwards et al., 2013), as compared to a situation in which only one signal exists at the locus in
question. In one example of the former situation, Glubb and colleagues (2015) performed a metaanalysis of breast cancer GWAS, finding a complex pattern of association involving at least three
independent signals at and around the MAP3K1 locus (Glubb et al., 2015). In an example of the
latter situation, one study performed conditional analyses on seven loci associated with levels of
adiponectin, an adipocyte-secreted protein associated with cardiovascular and metabolic traits (Wu
et al., 2014). After conditioning on the sentinel GWAS SNP for each locus, six out of seven loci
showed no residual association at any other variants, suggesting that these associations are driven
by one or more strongly linked functional variants (Wu et al., 2014).
Next, most GWAS are performed initially in genetically similar groups of cases and
controls, leading to the association of traits with haplotypes as defined in these genetic groups. In
this context, trans-ethnic fine-mapping can be a useful approach to refine the region of association,
thereby reducing the number of candidate causal variants, due to the reduced LD and smaller
haplotype blocks in certain populations, particularly Africans (Campbell and Tishkoff, 2008;
Edwards et al., 2013). For example, Guthridge et al. (2014) used such an approach, combined
with re-sequencing of the candidate region, to reduce the number of candidate causal variants at
a lupus-associated locus from 30 to 3 (Guthridge et al., 2014).
In addition, due to the massive amount of eQTL data now available (Albert and Kruglyak,
2015), daVs can easily be investigated for association with gene expression levels in many cell and
tissue types. This is an important point, because if a daV is associated with the expression levels
of a gene, a testable hypothesis regarding the function of the causal variant can be formulated.
Importantly, conditional analyses can be performed using the sentinel GWAS and eQTL variants
to determine if both effects are likely driven by the same underlying mechanism.
While studies integrating GWAS and eQTL data have reported that nearly half of all daVs
are associated with gene mRNA levels in at least one cell type (Fu et al., 2012; Nicolae et al.,
2010), there are several other mechanisms by which a functional variant could influence disease
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risk. First, a variant could affect protein levels through effects on translation or protein stability
without an effect on mRNA levels; indeed, up to 1/3 of variants that associate with protein levels
(pQTLs) do not associate with the mRNA levels of the same gene (Battle et al., 2015), although
few studies have examined this overlap (Hause et al., 2014; Wu et al., 2013). In addition, a GWAS
causal variant may alter the amino acid sequence of a protein, thereby affecting protein function
rather than abundance (Cooper and Shendure, 2011). These possibilities can usually be excluded,
however, if there are no daVs in exonic regions. It is also increasingly being recognized that many
daVs are located at long non-coding RNA (lncRNA) loci, implying that some variants influence
disease risk through effects on lncRNA levels or function.

The annotation and functional

characterization of lncRNAs is a rapidly growing field, and there are already examples of functional
daVs that affect lncRNA function (Jendrzejewski et al., 2012; Zheng et al., 2016).
1.2.4.2 Incorporating public functional genomics data
Notwithstanding the caveats mentioned above, if a sentinel GWAS SNP and any strongly
linked variants (e.g. r2>0.8) are 1) associated with the mRNA levels of one or more genes in a
disease-relevant cell type, and 2) are all intronic or intergenic, then it is reasonably likely that the
causal variant influences disease risk by modulating the transcriptional regulation of the target
gene(s). Given the massive amount of publicly available epigenomic data mentioned previously,
researchers are increasingly using these data sets to prioritize candidate causal variants based on
overlap with accessible chromatin, TF binding, and/or histone marks associated with regulatory
activity (Figure 1.4). In addition, the pattern of histone modifications observed at a putative CRE
can help predict which type of regulatory element it may be (e.g. promoter, enhancer, insulator,
etc.), and therefore, how the region should be functionally tested. One study used such an
approach to identify functional variants underlying the association of the 8q21 locus with allergic
diseases (Vicente et al., 2015). The sentinel GWAS SNP was found to be associated with the
expression of the PAG1 gene in B lymphoblasts, and the authors used ENCODE data to identify
35 SNPs (out of a total of 118 that are in moderate LD (r 2>0.6) with the sentinel SNP) that overlap
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Figure 1.4. A framework for the functional dissection a GWAS-nominated disease risk
locus.
SNPs associated with disease risk by GWAS (tag SNPs) can be expanded upon with
imputation, and independent disease risk associations can be identified with conditional
analyses. Candidate causal variants can be prioritized through trans-ethnic fine-mapping, and,
if the variants are associated with gene expression levels, epigenomic prioritization. Various
experimental approaches can then be used to confirm which variants affect regulatory function.
While this pipeline will not identify exonic causal variants that might affect mRNA stability or
protein function, such variants likely do not underlie the majority of GWAS risk loci.
four distinct regions of DNase I hypersensitivity and enhancer-associated histone marks in this cell
type. These potential regulatory regions were further investigated using multiple approaches,
including chromosome conformation capture (3C) and reporter gene assays (Vicente et al., 2015).
In addition, epigenomic data sets have been used to investigate loci that are associated
with disease risk by GWAS, but do not reach statistical significance after correction for multiple
hypothesis testing (Wang et al., 2016). Indeed, GWAS typically employ the Bonferroni correction
method for multiple hypothesis testing, which is likely to be overly conservative due to LD between
nearby SNPs throughout the genome (Gao et al., 2010a; Johnson et al., 2010). Thus, some SNPs
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that do not reach the accepted genome-wide significance threshold (typically P<5x10-8) may
represent true disease risk loci. To investigate this hypothesis, a study by Wang et al. (2016)
examined the overlap of SNPs associated with cardiac QT interval with epigenetic enhancer marks
in cardiac and non-cardiac tissues. The authors found that both genome-wide significant SNPs
(P<5x10-8) and “sub-threshold” SNPs (5x10-8<P<1x10-4) were significantly enriched in predicted
cardiac enhancers, and >70% of enhancers harboring sub-threshold SNPs exhibit allele-specific
regulatory activity in induced pluripotent stem cell (iPSC)-derived cardiomyocyte luciferase reporter
assays (Wang et al., 2016). Furthermore, enhancer-associated sub-threshold SNPs were more
strongly associated with QT interval than non-enhancer-associated sub-threshold SNPs, and the
enhancer-associated SNPs were more likely to reach genome-wide significance in larger GWAS
meta-analyses (Wang et al., 2016).

Thus, prioritizing candidate causal variants based on

epigenomic annotations is a reasonable method for functionally characterizing candidate disease
risk loci.
Not long after these large-scale epigenomic data sets became available, many groups
developed online resources that combined these data with other useful data sets, including those
from eQTL studies, enhancer target gene predictions, phylogenetic conservation scores, and in
silico TF motif prediction tools. There are now a multitude of available web-based tools that are
useful for prioritizing candidate functional cis-regulatory variants at loci of interest, which have been
recently reviewed elsewhere (Tak and Farnham, 2015). Typically, a variant or list of variants can
be queried for overlap with potential CREs, disruption of TF binding motifs, association with gene
expression levels, and other features that can help predict the likelihood of that given variant being
functional.
1.2.4.3 Testing the function of a regulatory variant
Once a list of candidate CREs is identified, all containing one or more potential causal
variants, various experimental approaches can be used to test the functions of these regions. A
common approach involves in silico analysis to determine if a particular variant is predicted to
disrupt a TF binding motif (Heinemeyer et al., 1998; Mathelier et al., 2014), but evidence suggests
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that many causal variants that may in fact disrupt TF binding may not reside in known TF motifs.
For example, the Farh et al. study estimated that only 10-20% of autoimmune GWAS causal cisregulatory variants reside in known TF motifs (Farh et al., 2015). An alternative approach is to
functionally test all candidate CREs, using both the risk and protective alleles of the candidate
causal variants. Cell culture-based reporter assays have been widely used for these purposes: the
candidate CRE is cloned into a physiologically relevant position with respect to the reporter gene,
and transfected into a relevant cell type, and the activity of CREs containing alternate alleles (or
haplotypes) are compared. Since some CREs are not only cell type-specific, but signal-dependent
(Dickel et al., 2014; Shlyueva et al., 2014), it is necessary to determine the appropriate
experimental conditions in which to test the variant in order to avoid false positives and false
negatives.
Rather than testing reporter constructs one-by-one in cell culture contexts, several groups
have developed massively parallel reporter assays (MPRAs), in which thousands of variants can
be tested in a single experiment (Inoue and Ahituv, 2015; Melnikov et al., 2012; Patwardhan et al.,
2012; Shen et al., 2016; Smith et al., 2013; Ulirsch et al., 2016; Vockley et al., 2015).

These

approaches will surely be useful for researchers investigating large numbers of loci and variants at
once. For example, Tewhey and colleagues (2016) tested ~30,000 SNPs representing >3,500
eQTL signals (eSNPs), testing each eSNP and all variants in perfect LD with it for enhancer activity
in immortalized liver (HepG2) and B lymphoblast cell lines. Roughly 12% of the putative CREs
displayed enhancer function in one or both of the cell types tested, and of these, ~25% contained
SNPs that caused significant changes in reporter gene expression (Tewhey et al., 2016).
Importantly, ~80% of the expression differences caused by these variants agreed with the direction
of previously published eQTL effects in the same cell type (Tewhey et al., 2016). In addition, the
majority of functional variants identified in this study altered reporter gene levels by less than 2fold, consistent with eQTL effect sizes predicted by previous studies (Dimas et al., 2009; GTEx
Consortium, 2015; Patwardhan et al., 2012). These results reinforce current thinking that most
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causal gene regulatory variants underlying complex traits and diseases have modest effects on
target gene expression.
While reporter assays are often a useful first step in determining the function of a potential
regulatory variant, they have several limitations: first, reporter assays can display a significant
amount of transcriptional noise, and thus are not always reproducible (Brown et al., 2013). Second,
small differences in reporter activity can result from small differences in the molar amounts of each
plasmid that is transfected into cells, which is unavoidable even with the most accurate DNA
concentration measurements. These issues can make small differences in expression difficult to
distinguish statistically. Perhaps most importantly, reporter assays test the transcriptional function
of a variant in the context of plasmid DNA, rather than the native genomic context in which the
variant actually exists (Inoue and Ahituv, 2015). This situation can produce false negative and false
positive results, due to the intricate relationships between DNA, histones, transcription factors, and
long-range chromatin interactions (Inoue and Ahituv, 2015).
In light of these issues and others, a more physiologically-relevant method to confirm the
function of a regulatory variant may be genome editing (Engel et al., 2016). There are currently
three available genome-editing technologies: the protein-based zinc finger nucleases (ZFNs) and
transcription activator-like effector nucleases (TALENs), and the nucleic acid-based clustered
regularly interspaced short palindromic repeat (CRISPR)-based systems (Gaj et al., 2016). Due to
its simple, cheap, and rapidly scalable utility, CRISPR has become the most widely used genome
editing method. With genome editing, a researcher can theoretically make any change he/she
wants to any region of the genome, and then use well-established molecular assays to determine
if changes in regulatory function and gene expression have occurred. In one of the first applications
of genome editing to a GWAS-nominated locus, Bauer and colleagues (2013) used TALENs to
delete a 10kb intronic region in the mouse ortholog of BCL11A. The orthologous region in humans
harbors the top SNPs associated with fetal hemoglobin levels, for which BCL11A is a known
repressor (Bauer et al., 2013). Thus, the causal variant may function by regulating BCL11A, which
might in turn affect levels of fetal and embryonic β-globin – and indeed, manipulating this pathway
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is an attractive prospect for treating β-hemoglobinopathies (Lettre and Bauer, 2016). The authors
demonstrate that some of these top SNPs fall within three distinct regions of open chromatin and
enhancer-associated histone marks that are specific to human erythroid cells, consistent with the
erythroid-specific expression patterns of the globin genes. The SNP most significantly associated
with fetal hemoglobin, located in one of these three candidate CREs, disrupts a DNA motif known
to bind the erythroid TFs GATA1 and TAL1, and the authors demonstrate that the motif-disrupting
allele indeed reduces binding of these factors in multiple primary human erythroid samples. (Bauer
et al., 2013). Next, the authors used TALENs to delete the 10kb interval containing the three
candidate CREs (including the putative causal variant) in mature murine erythroid cells. This
resulted in drastically reduced Bcl11a expression levels and drastically increased embryonic βglobin levels, thus establishing the region as a functional Bcl11a enhancer that is required for
repression of embryonic β-globin (Bauer et al., 2013).
In the example above, a large genomic region was deleted to demonstrate the importance
of that region to gene regulatory function. However, genome editing can also be used to make
more precise changes, such as mutating an individual SNP from one allele to the other. In Spisák
et al. (2015), the authors used TALEN-mediated homology directed repair (HDR) to confirm the
functional role of a SNP previously reported to influence prostate cancer risk by modulating the
expression of the RFX6 gene (Huang et al., 2014). Specifically, they compared edited and unedited
prostate cancer cell line clones, and demonstrated that this candidate causal variant altered RFX6
expression levels by ~2-fold (Spisak et al., 2015).

Moreover, the authors characterized the

regulatory potential of the region harboring the SNP by fusing a catalytically-inactive TALE array
with either a VP64 transcriptional activation domain, or LSD1, a histone lysine-specific demethylase
known to remove H3K4 methylation enhancer marks and decrease enhancer activity (Mendenhall
et al., 2013). As expected, site-specific recruitment of VP64 and LSD1 to the putative causal SNP
increased and decreased RFX6 levels, respectively, establishing the region harboring the causal
variant as a bona fide regulatory element (Spisak et al., 2015). Thus, genome editing technologies
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can also be used to validate potential CREs by altering their epigenetic state (referred to as
“epigenome editing”) (Dominguez et al., 2016).
A more recent study used CRISPR/Cas9 gene editing to investigate candidate causal
variants at the SNCA locus (Soldner et al., 2016), which is associated with risk for Parkinson’s
disease (PD) (Nalls et al., 2014), and which encodes α-synuclein, the protein that accumulates in
the characteristic Lewy Body inclusions of PD (Toulorge et al., 2016). The authors demonstrate
that the SNCA risk haplotype is associated with increased SNCA brain expression, which has
previously been associated with PD pathogenesis, since families with duplications or triplications
of the SNCA locus (resulting in increased SNCA levels) exhibit Mendelian forms of PD (Singleton
et al., 2003). After prioritizing candidate causal variants based on epigenetic signatures and in
silico TF motif predictions, the authors deleted a 500bp putative enhancer at this locus containing
two SNPs in human embryonic stem (ES) cells (Soldner et al., 2016). They reinserted the 500bp
region using HDR with either the risk or protective alleles of the two SNPs, and differentiated the
ES cells into neural precursors and mixed neuronal cultures (Soldner et al., 2016). Cell clones
bearing the risk-associated alleles of the enhancer SNPs demonstrated significantly higher SNCA
levels than clones bearing the protective alleles, and this effect was driven entirely by the variant
predicted to be functional by in silico and experimental analyses (Soldner et al., 2016).
Analogous to the high-throughput reporter assays (MPRAs) mentioned above, several
groups have also developed high-throughput CRISPR screens to identify essential genes (Wang
et al., 2014b), potential drug targets (Shi et al., 2015) or noncoding regulatory regions (Diao et al.,
2016; Fulco et al., 2016; Korkmaz et al., 2016; Rajagopal et al., 2016; Sanjana et al., 2016). As
with MPRAs, high-throughput gene editing screens will facilitate efficient testing of many candidate
cis-regulatory regions and their associated variants in a single experiment, with the additional
benefit of testing variants in their endogenous genomic context.
1.2.4.4 Determining the target gene(s) of a regulatory variant
While genome editing can confirm the allele-specific functions of a distal CRE, editing
experiments alone cannot determine the mechanisms by which these elements affect transcription
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of their target genes. The last few years have seen an explosion in the number of studies
investigating how the genome is organized in the nucleus, both at small and large scales, and there
is now abundant evidence that chromosomes can bend and form loops at kilobase and megabase
scales, and that these loops play an important role in transcriptional regulation and disease
(Merkenschlager and Nora, 2016; Pombo and Dillon, 2015; Wang and Dostie, 2016). While the
transcription of a gene occurs at the promoter, enhancers and other distal regulatory elements
appear to affect transcription by physically interacting with their target promoters, and oftentimes
with each other, through chromatin looping (Merkenschlager and Nora, 2016; Pombo and Dillon,
2015; Wang and Dostie, 2016). Thus, physical contact between a distal regulatory element and a
promoter may be considered evidence for a regulatory function of that element. The marriage of
chromosome conformation capture (3C) with high-throughput sequencing has allowed for the
investigation of all long-range contacts in the genome (Hi-C, an “all-versus-all” approach), or, with
superior depth and resolution, all long-range contacts involving a region of interest, such as a gene
promoter (4C, Capture-C, or Capture Hi-C; “one-versus-all” approaches) (Denker and de Laat,
2016).
The value that these approaches possess for post-GWAS functional studies (and for the
study of eukaryotic transcriptional regulation in general) cannot be overstated. Even in cases in
which the likely causal variant is already known based on statistical association, allele-specific
effects on reporter genes and TF binding, etc., it can be extremely difficult to know a priori what the
target gene(s) of the CRE harboring the variant might be (Edwards et al., 2013). “One-versus-all”
approaches – in which a specific genomic region is captured or selectively amplified in conjunction
with all interacting regions – are well-suited to identify the target promoters of enhancers and other
distal elements, or conversely, all distal regulatory elements that interact with a given promoter,
such that the regulatory effects of a variant can be linked to the correct gene(s).
A striking example of the importance of considering the three-dimensional organization of
chromatin concerns the association of intronic genetic variants at the FTO locus with obesity
(Smemo et al., 2014). The FTO locus is the strongest known risk factor for obesity, with an odds
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ratio of >1.4 for the sentinel SNP located on chromosome 16q12.2 (Berndt et al., 2013).
Furthermore, FTO expression levels have been reported to affect body mass and composition in
mice; thus, FTO was considered by many to be the gene responsible for conferring risk for obesity
at this locus (Church et al., 2010; Fischer et al., 2009; Gao et al., 2010b). However, while the top
obesity-associated SNPs at this locus are all intronic, suggesting a regulatory effect for the causal
variant, none of the SNPs have been associated with FTO expression (Smemo et al., 2014). To
resolve this conundrum, Smemo and colleagues (2014) performed 4C in mouse embryos and brain
to determine if the obesity-associated interval interacts with any genes other than FTO. This
analysis demonstrated strong interactions between the obesity-associated region and the Irx3
promoter, located several hundred kilobases away. As the obesity-associated region displays
enhancer-associated histone marks, the authors then demonstrated enhancer activity for this
region using transgenic mouse assays (Smemo et al., 2014). Importantly, they also demonstrate
an association between the obesity-associated SNPs and IRX3 expression in a large set of human
brain samples, confirming IRX3 as a likely target gene of the FTO enhancer region. These results
were then corroborated by mouse models demonstrating a role for lrx3 in body weight maintenance
(Smemo et al., 2014). An impressive follow-up investigation by Claussnitzer et al. (2015) identified
the likely causal variant at this locus, using precise genome editing and several other approaches
(Claussnitzer et al., 2015). This work identified an additional target gene of the obesity-associated
region, IRX5, which also appears to affect obesity-related cellular phenotypes. Thus, 3C-based
approaches were essential in identifying the genes responsible for conferring obesity risk through
long-range regulatory effects of obesity-associated variants at the FTO locus.
It has been suggested that if the activity of a distal regulatory region is modified by a
functional variant, and regulation of the target gene(s) by such a region involves long-range
interactions, then regulatory variants might influence the long-range interactions themselves (Dixon
et al., 2015). Accordingly, 3C-based approaches have been used to identify allele-specific longrange interactions, typically using cell lines or tissues that are heterozygous for the diseaseassociated haplotype. It is worth emphasizing that allele-specific effects in general may be best
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investigated within multiple heterozygous samples, rather than between samples of different
genotypes, due to significant inter-individual phenotypic variation. In line with this, even robust
allele-specific effects in heterozygous cell lines have been reported to be highly variable, and not
well reproducible, across individuals (GTEx Consortium, 2015).
Allele-specific long-range interactions can be detected by using SNP-specific primers or
probes for PCR-based approaches (e.g., 3C or 4C) (Holwerda et al., 2013), or, for approaches
involving HT-seq (e.g. 4C or Hi-C), designing the experiment such that haplotype marker SNPs are
present in the sequenced ligation products (Dixon et al., 2015; Stadhouders et al., 2014; Tang et
al., 2015). In an example of the former approach, Stadhouders et al. (2014) used K562 cells to
investigate long-range interactions involving a putative enhancer region that harbors variants
associated with fetal hemoglobin levels (Stadhouders et al., 2014). The authors performed 3C with
a SNP-specific primer in order to demonstrate allele-specific chromatin looping between the
putative enhancer and the promoter of the MYB gene, which is a key hematopoietic and
erythropoietic TF (Stadhouders et al., 2014). With regards to the latter approach, several groups
have attempted to identify allele-specific interactions by sequencing the 3C ligation products and
determining whether SNPs contained in the ligated fragments deviate from either a 50/50 allelic
ratio, or the allelic ratio present in a control sample or condition (Dunning et al., 2016; Ghoussaini
et al., 2014; Vicente et al., 2015). However, such marker SNPs are oftentimes not available, and,
depending on the approach used and the experimental design, well-placed SNPs may lack
sufficient sequencing depth to distinguish modest allele-specific interactions (Dixon et al., 2015).
Furthermore, the relationship between allele-specific expression and allele-specific long-range
interactions is not well understood, so further studies are needed to investigate these phenomena.
Notably, while daV-containing CREs have been reported to engage in allele-specific long-range
interactions, such as enhancer/promoter interactions (Dunning et al., 2016; Nakaoka et al., 2016;
Painter et al., 2016; Stadhouders et al., 2014; Vicente et al., 2015), the potential involvement of
causal GWAS variants in altering higher-order chromatin architecture is unknown.
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One important caveat with respect to 3C-based approaches is that although distal CREs
appear to engage in long-range interactions to influence transcription, these interactions may not
always be necessary, nor sufficient, for gene regulation (Ghavi-Helm et al., 2014). Thus, 3C-based
approaches should complement other experimental approaches to demonstrate the functionality of
a candidate causal variant. In summary, 3C-based approaches are increasingly being used to
complement post-GWAS functional studies, and the combination of genome editing with 3C and
high-throughput sequencing is a powerful tool for dissecting the functions of cis-regulatory variants.
1.2.4.5 Determining the molecular function of a regulatory variant
If one or more of the approaches mentioned above succeed in identifying a functional cisregulatory variant, the question remains as to how the variant affects the function of the CRE at the
molecular level. Given the overwhelming evidence supporting the critical role of TFs and chromatin
remodelers in transcriptional regulation (Lelli et al., 2012), coupled with the significant overlap of
daVs with mQTLs and bQTLs (Hannon et al., 2016; Tehranchi et al., 2016), one may hypothesize
that a causal cis-regulatory variant enhances or represses the ability of one or more trans-acting
factors to bind the CRE. This effect may be direct (e.g., directly affecting binding of one or more
TFs or chromatin-modifying enzymes) or indirect (e.g., affecting DNA methylation). Some variants
may be located in confirmed TF binding sites from resources such as ENCODE, which in
combination with motif analysis, can help predict which TFs may be affected by the variant. The
effect of a variant on TF binding can be confirmed by chromatin immunoprecipitation quantitative
polymerase chain reaction (ChIP-qPCR) using allele-specific probes or primers, such that allelic
differences in TF binding can be determined at the variant of interest in a heterozygous cell line or
tissue.

This approach was used to confirm allele-specific binding of the transcription factor

HOXB13 at a putative causal variant at the RFX6 locus (Huang et al., 2014). Alternatively, ChIPseq experiments can be performed to investigate potential allele-specific TF binding. In samples
heterozygous for the candidate functional variant, sequencing reads covering the variant (or a
nearby linked variant) are expected to be present in equal allelic ratios if the variant does not affect
binding of that particular factor; conversely, deviations from a 50/50 allelic ratio have been used to
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infer function of candidate causal variants both at pre-determined loci (Bauer et al., 2013) and in
genome-wide analyses (Maurano et al., 2015). These ratios are often normalized to the allelic
ratios present in the input DNA, in order to correctly interpret results.
Electrophoretic mobility shift assays (EMSAs, or “gel shift assays”) are another method of
determining whether a variant affects recruitment of a nuclear factor in vitro, although these assays
can be difficult to interpret and lack biological context (Hellman and Fried, 2007). Antibodies raised
against candidate TFs can be added to the reaction to confirm their binding to the variant;
alternatively, purified recombinant protein can be used instead of nuclear extract to assess binding
of specific TFs (Hellman and Fried, 2007). In many cases it may be difficult to predict which TFs
or other types of nuclear proteins are affected by the variant, in which case unbiased approaches
such as EMSA followed by mass spectrometry can be helpful (Stead et al., 2006). For example, a
study by Fogarty and colleagues (2014) combined these approaches to investigate a putative
causal variant at the CDC123/CAMK1D Type 2 diabetes risk locus (Fogarty et al., 2014). After
prioritizing candidate causal variants based on epigenomic annotations and identifying a variant
that affects enhancer activity in cell-based reporter assays, the authors performed EMSAs to
determine which trans-acting factors might be affected by the variant. Twenty-one base pair probes
containing either the risk or protective allele of rs11257655, the candidate causal variant, were
incubated with nuclear extract from HepG2 immortalized liver cells and two rodent insulinoma cell
lines. In all three extract types, the authors observed one or more risk allele-specific probe/protein
complexes that could be supershifted with antibodies raised against the enhancer-binding proteins
FOXA1 and FOXA2 (Fogarty et al., 2014). Consistently, rs11257655 is located within a predicted
FOXA1/2 motif, and the protective allele alters a highly conserved “T” base pair within the motif.
The authors further confirmed risk allele-specific binding of FOXA2 by performing a DNA affinity
capture assay followed by mass spectroscopy (Fogarty et al., 2014).
1.2.4.6 Linking gene expression changes to complex traits
While determining the molecular mechanism by which a disease-associated variant affects
gene expression is an intriguing line of inquiry, perhaps a more physiologically- and disease-
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relevant question is to ask how small changes in a gene’s expression levels affect cellular and
organismal phenotypes in order to influence disease risk. Indeed, while many studies have
reported genetic variants that alter cis-regulatory function, the mechanisms by which the resulting
alterations in gene expression influence disease risk are often not investigated, or are unknown
(Deplacnke et al., 2016). Some studies have functionally linked expression levels of the causative
gene to disease-relevant phenotypes, but many of these studies relied upon imprecisely-controlled
overexpression, strong knockdown, or knockout approaches (Huang et al., 2014; Kapoor et al.,
2014; Musunuru et al., 2010; Smemo et al., 2014). Recapitulating the gene expression differences
relevant to a disease risk locus is difficult for at least two reasons: first, eQTL effect sizes are, in
terms of fold expression change, typically unknown, not reported, or small; second, it is technically
difficult to finely titrate the overexpression or knockdown of a gene. To overcome this issue, some
studies have looked for correlations between the expression levels of the gene of interest and
disease-relevant phenotypes, across samples or individuals. For example, Huang et al. (2014)
characterized a functional variant at the RFX6 locus, which appears to increase prostate cancer
risk by increasing enhancer-mediated RFX6 regulation. Knockdown of RFX6 impaired prostate
cancer cell migration and invasion, and consistently, RFX6 expression levels were positively
correlated with tumor aggressiveness and relapse across 128 prostate cancer samples (Huang et
al., 2014). Some studies have also reported trait-relevant phenotypes that are distinguishable
between cell lines of different genotypes, such as pigmentation in melanocytes (Visser et al., 2012),
although this may not be a common phenomenon among complex traits.
The limitation of the approaches discussed above is that they are correlational. Thus, to
determine the phenotypic effects of allele-specific changes in gene expression, genome editing
may again be the best approach. By mutating the causal variant from one allele to the other, the
resulting changes in gene expression are 1) more likely to be physiologically relevant than those
seen in overexpression or knockdown experiments, and 2) can be causally linked to the variant.
By using HDR to mutate the RFX6 causal variant, Spisák et al. (2015) demonstrate a 2-fold
expression difference between risk and protective allele homozygote clones (Spisak et al., 2015).
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Intriguingly, protective allele homozygote clones displayed notably different cellular morphology
and impaired cellular adhesion compared with risk allele homozygotes. However, no effects on
cell migration or invasion were seen, presumably because of the smaller changes in RFX6
expression than in the Huang et al. study (Spisak et al., 2015). In Claussnitzer et al. (2015), precise
editing of the FTO obesity causal variant in adipocytes not only caused the expected changes in
target gene expression, but also affected metabolic rate, oxygen consumption, and thermogenesis,
all pathways that are associated with obesity (Claussnitzer et al., 2015). While these initial results
are promising, a more complete understanding of the mechanistic link between allele-specific
changes in gene expression and risk for complex diseases and traits is needed.
1.2.5

Summary
As mentioned previously, GWAS have identified thousands of SNP-trait associations

throughout the genome, linking common genetic variation to hundreds of complex diseases and
traits.

However, only a small fraction of these statistical associations have been thoroughly

investigated to determine 1) which variant or variants are causal, 2) what the molecular functions
of the causal variants are, 3) which genes are affected by the causal variants, and 4) how changes
in the function or regulation of the causal genes lead to altered disease risk. This is also the case,
specifically, for neurodegenerative disease. GWAS have identified ~200 loci associated with the
four major neurodegenerative diseases (AD, PD, ALS, and FTLD) and related phenotypes (Welter
et al., 2014), yet only one of these loci, the SNCA locus, which has been known to be involved in
PD risk for decades (Polymeropoulos et al., 1997; Spillantini et al., 1997), has been mechanistically
investigated in detail. Thus, to date, GWAS approaches have not significantly improved our
understanding of the pathogenesis of neurodegenerative disease.
Given the emergence of the new tools, technologies, and experimental techniques mentioned
in this section, researchers studying neurodegenerative disease are in a better position than ever
to translate statistical associations by GWAS into a functional understanding of disease
mechanisms. In the case of FTLD, a fatal and untreatable neurodegenerative disease that affects
patients as early as the 5th decade of life, common variants at the TMEM106B locus have been
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associated with risk for FTLD-TDP, hippocampal sclerosis, TDP-43 pathology in Alzheimer’s
disease, and other neurological phenotypes (Nelson et al., 2015; Rutherford et al., 2012; Vass et
al., 2011; Yu et al., 2015). In addition, TMEM106B genotype affects age at death and/or age at
onset of disease in FTLD-TDP cases caused by mutations in the GRN and C9orf72 genes
(Cruchaga et al., 2011; Finch et al., 2011; Gallagher et al., 2014). Thus, TMEM106B is not only a
risk factor for FTLD, but a genetic modifier that can affect disease manifestation. Understanding
how genetic variation at TMEM106B affects risk and prognosis of FTLD-TDP could provide critical
insights into the pathogenesis of FTLD, and possibly other neurodegenerative diseases.
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1.3

PART III: TMEM106B is a genetic risk factor for frontotemporal lobar

degeneration
As mentioned in Chapter 1.2, many human diseases, including diseases of aging, are
complex traits. FTLD is no exception, with up to ~90% of cases not attributable to Mendelian
mutations (Benussi et al., 2015). Like any complex trait, the majority of FTLD cases are likely
caused by a combination of genetic and environmental risk factors. However, compared to other
neurodegenerative diseases, FTLD has a relatively high heritability (30-50% of patients have a
family history of dementia (Bang et al., 2015; Tan et al., 2017)), making it an attractive disease to
study various types of genetic effects. In addition, FTLD is currently untreatable and fatal, so the
identification of pathways involved in the pathogenesis of the disease is urgently needed.
In this section, I will review the discovery and subsequent investigations of a locus on
chromosome 7p21 first associated with FTLD by GWAS, thus setting the stage for the work
described in this dissertation.
1.3.1

Discovery of TMEM106B as a risk locus for neurodegeneration

1.3.1.1 Association of the TMEM106B locus with frontotemporal lobar degeneration
The first FTLD GWAS included 515 FTLD-TDP cases of Western European ancestry, 499
of which had autopsy-confirmed TDP-43 pathology, and 16 of which were living patients with GRN
mutations, who are known to develop TDP-43 pathology (Van Deerlin et al., 2010). The authors
hypothesized that increasing the neuropathological homogeneity of cases (all cases exhibited TDP43 pathology) would compensate for the small sample size (GWAS typically consist of many
thousands of cases and controls). Of the 515 cases, a total of 89 had GRN mutations (16 living
GRN+ FTLD-TDP individuals and 73 with neuropathologically-confirmed TDP-43 pathology), 80
had C9orf72 mutations (this was unknown at the time of the GWAS since C9orf72 was not identified
as an FTLD-causing gene until 2011), and the remaining cases tested negative for MAPT and
TARDBP mutations, the former of which causes non-TDP-43 pathology. The cases were amassed
from 45 institutions in 11 countries (United States, Canada, United Kingdom, Netherlands, Belgium,
Spain, Germany, Australia, Finland, France and Sweden). The ethnically-matched control cohort
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consisted of 1,297 children from the Children’s Hospital of Philadelphia, and 1,212 adults from the
Wellcome Trust Case Control Consortium. The inclusion of children and the lack of neurological
confirmation of normal brain function in the adults was justified by the fact that FTLD is relatively
rare (~10-20 per 100,000 individuals in the 45-64 age group), such that the genotype frequencies
in any ethnically-matched control group would very likely be representative of the population in
general.
Out of a total of >500,000 genotyped SNPs, the GWAS identified three SNPs on
chromosome 7p21 that reached a genome-wide statistically significant (P<5x10-8) association with
FTLD-TDP (Figure 1.5). The most significant (sentinel) SNP was rs1990622 (P=1.08x10-11), which
is located ~7kb downstream of the gene TMEM106B. A second SNP, rs6966915 (P=1.63x10-11),
is in complete linkage disequilibrium (LD) (r2=1) with rs1990622 and is located in the 5th intron of
TMEM106B. The third SNP, rs1020004 (P=5.00x10-11), is in moderate LD (r2=0.7) with both
rs1990622 and rs6966915 and is located in the 3rd intron of TMEM106B (Figure 1.5). The major
alleles of all three SNPs were associated with increased risk of FTLD-TDP, with an odds ratio of
1.64 for the risk allele of rs1990622, and have ~60% allele frequencies in populations of Western
European ancestry (1000 Genomes Project Consortium et al., 2015). Interestingly, the association
was stronger in individuals with GRN mutations (GRN+ FTLD-TDP) (P=1.34x10-9 for rs1990622)
than in individuals without GRN mutations (GRN- FTLD-TDP) (P=6.90x10-7 for rs1990622), despite
the much smaller number of GRN+ individuals (n=80 GRN+ FTLD-TDP versus 435 GRN- FTLDTDP). Thus, genetic variation at the TMEM106B locus may affect FTLD pathogenesis even in the
presence of a highly penetrant mutation (Van Deerlin et al., 2010).
The association of rs1990622 and rs1020004 with FTLD-TDP was replicated in an
independent cohort of 89 FTLD-TDP cases and 553 self-identified European-descended controls
(P=0.002 for rs1990622 and P=0.0004 for rs1020004; rs6966915 genotyping was not performed
due to technical issues) in the original GWAS study (Van Deerlin et al., 2010). The replication
cohorts consisted of cases and controls not included in the GWAS, but that came from the same
sources and met the same criteria as the GWAS cohorts. In addition, when using the combined

43

Figure 1.5. Association of common variants at the 7p21 locus with FTLD (from Van Deerlin et al.,
2010, Nature Genetics).
(A) Manhattan plot of −log10(observed P-value) for all genotyped SNPs across genome demonstrating
region of genome-wide significant association on chromosome 7.
(B) Regional plot of the TMEM106B locus. Foreground plot: Scatter plot of the SNP −log10 P-values
plotted against physical position (NCBI build 36). Background Plot: Estimated recombination rates (from
phase 2 of the HapMap) plotted to reflect the local LD structure. The color of the dots represent the
strength of LD between the top SNP rs1990622, and its proxies (red: r 2≥0.8; orange 0.8>r2≥0.4; blue
<0.4). Gene annotations were obtained from assembly 18 of the UCSC genome browser.
(C) Location of the 3 most strongly associated SNPs (green arrows) relative to the gene structure of
TMEM106B (blue bars, 3′ and 5′-untranslated regions; larger red bars, coding exons; thick gray line,
intronic regions; gray dashed line, downstream chromosome sequence) and chromosome 7 location.
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GWAS cohort, the risk allele of rs1020004 was associated with shorter duration of (i.e., more
severe) disease. Importantly, an additional replication using 192 cases of non-specific FTLD
(neuropathology not known) found no association between any of the three SNPs and FTLD,
highlighting the importance of the authors’ initial decision to control for neuropathological subtype
(Van Deerlin et al., 2010).
Three studies in 2011 attempted to independently replicate the 7p21 association with FTLD
in individuals of Western European ancestry. The first study, Finch et al. (2011), confirmed a
significant association of rs1990622 (P=0.036) and rs6966915 (P=0.038) with FTLD in a clinicallydefined cohort of 640 cases and 822 age- and sex-matched neurologically normal controls (Finch
et al., 2011). As with Van Deerlin et al., the major alleles of these SNPs were associated with
increased FTLD-TDP risk. The case cohort included 78 GRN+ FTLD-TDP individuals and 80
additional patients with confirmed TDP-43 pathology, and individuals with mutations associated
with non-TDP-43 pathology were excluded. As was seen in Van Deerlin et al., the associations
were more significant when analyzing only GRN mutation carriers (P=0.00003 for rs1990622),
despite the much smaller sample size (n=78 GRN+ individuals). In particular, the percentage of
minor (protective) allele homozygotes was drastically lower in GRN+ FTLD-TDP (2.6%) than in
controls (19.1%) (P=0.003). The authors also showed that among the GRN+ individuals, minor
allele homozygotes developed FTLD-TDP ~13 years later than major allele homozygotes and
heterozygotes (P=0.018) (Finch et al., 2011). This genetic modifier effect was also reported by an
independent study in the same year, using a cohort of 50 GRN+ FTLD-TDP individuals from four
families (Cruchaga et al., 2011). Thus, the minor allele of rs1990622, or a linked variant, appears
to protect against developing both GRN+ FTLD-TDP and non-Mendelian forms of FTLD-TDP.
The second replication study, van der Zee et al. (2011), replicated the association of
rs1990622 with FTLD in cohort of 288 clinically diagnosed FTLD cases who tested negative for
MAPT or CHMP2B mutations, or had autopsy-confirmed TDP-43 pathology (van der Zee et al.,
2011). Again, the direction of association matched Van Deerlin et al (2010). This cohort included
13 GRN+ FTLD-TDP cases, two individuals with VCP mutations, and 14 individuals with autopsy-
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confirmed FTLD-TDP. The control cohort consisted of 595 age-matched individuals without family
history of neurodegenerative disease and with normal neurological exam function.
A third study attempting to replicate this association was published in 2011 by Rollinson
and colleagues (2011). This study used a case cohort of 312 clinically defined FTLD cases,
although GRN mutation carriers in addition to MAPT mutation carriers were excluded, which, based
on the results of the previous studies, would likely weaken any association with the TMEM106B
risk variants (Rollinson et al., 2011a). The control cohort consisted of 248 neurologically normal
adults. No significant differences in allele frequencies of rs1990622, rs6966915 or rs1020004 were
identified between cases and controls (Rollinson et al., 2011a), although the small sample size,
lack of neuropathological homogeneity, and lack of GRN+ individuals make a comparison with the
other studies difficult.
Finally, a meta-analysis of all four studies, including an additional case-control study from
the meta-analysis authors, was published in 2015 (Hernandez et al., 2015). The case-control
cohort in this study included 146 clinically-defined FTLD cases and 234 neurologically normal
controls from Spain. Individuals with FTLD-causing mutations were not excluded, but only one
MAPT mutation carrier was present in the cohort. The authors observed a non-significant trend of
association (P=0.092) of the major (risk) allele of rs1990622 with increased risk for FTLD in their
cohort (Hernandez et al., 2015). By combining their results with the previous four studies, a
statistically significant association was seen (P=0.0067), with all studies showing the same
direction of effect (Hernandez et al., 2015).

However, considerable heterogeneity was seen

between studies (P=0.00014), likely due in part to neuropathological heterogeneity present in the
clinical cohorts.
Taken together, these data suggest a true association between the TMEM106B locus first
identified by Van Deerlin et al. (2010) with the neuropathological form of FTLD characterized by
TDP-43 inclusions (FTLD-TDP), but not necessarily with other neuropathological forms of FTLD
that may be clinically indistinguishable from FTLD-TDP. Moreover, they highlight the importance
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of clearly defining a particular trait on the best biological grounds possible (which may not be clinical
presentation) when performing association studies.
1.3.1.2 Association of the TMEM106B locus with other neurodegenerative phenotypes
Given that many SNP-trait associations identified by GWAS are not replicated in
independent studies, the replication of the 7p21 association with FTLD by multiple groups reduces
the likelihood that the association is spurious. The extremely high significance (P=1.08x10-11 for
rs1990622) and effect size (odds ratio=1.64 for rs1990622) of this association further support that
this is a true signal. Intriguingly, the importance of genetic variation at 7p21 in neurodegeneration
has been further confirmed by several studies that investigated other neurodegenerative and/or
neuropathological phenotypes. One study published shortly after the GWAS demonstrated that
the allele of rs1990622 associated with increased FTLD-TDP risk also associated with cognitive
impairment in amyotrophic lateral sclerosis (ALS) (Vass et al., 2011).

Given the clinical,

neuropathological, and genetic overlap between FTLD-TDP and ALS (see Chapter 1.1.4.3), this
result is intriguing. Furthermore, this result establishes TMEM106B genotype as a modifier of
clinical presentation in ALS, in addition to FTLD (Cruchaga et al., 2011; Finch et al., 2011; Gallagher
et al., 2014).
Additional studies have demonstrated an association of the rs1990622 FTLD-TDP risk
allele with increased risk for hippocampal sclerosis of aging, a neurodegenerative condition that
presents with similar clinical symptoms as Alzheimer’s disease (AD) (Nelson et al., 2015), as well
as increased TDP-43 pathology in AD and in neurologically normal individuals (Rutherford et al.,
2012; Yu et al., 2015). Two studies reported an association between the rs1990622 risk allele and
decreased plasma PGRN levels (Cruchaga et al., 2011; Finch et al., 2011), suggesting that genetic
variation at TMEM106B may influence disease risk at least partly through an effect on PGRN
production and/or secretion. This intriguing possibility has a plausible mechanistic basis, given that
loss-of-function GRN mutations cause FTLD-TDP (Cruts et al., 2006), and that impaired secretion
of PGRN by microglia (which are closely related to peripheral leukocytes) is toxic to neurons
(Martens et al., 2012) (see Chapter 1.1.4.2).

Finally, the risk allele of rs1990622 has been
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associated with decreased neuronal connectivity in the brains of asymptomatic GRN mutation
carriers (Premi et al., 2014), and reduced temporal lobe gray matter and interhemispheric
structures in neurologically normal adults (Adams et al., 2014).
In conclusion, the GWAS sentinel SNP, rs1990622, not only associates with risk of
developing FTLD, but also the clinical presentation of FTLD-TDP and ALS, and several phenotypes
related to normal and/or pathological brain function. Moreover, although the disease (and nondiseased) states vary across the previously-mentioned studies, one unifying theme may be the
presence of TDP-43 pathology, which characterizes FTLD-TDP (both with and without GRN
mutations) and ALS, and was specifically investigated in the studies of AD and neurologically
normal individuals. Thus, genetic variation at the 7p21 locus may specifically influence risk for
TDP-43-mediated disease processes.
1.3.2

Increased levels of TMEM106B are implicated in disease
While the association of genetic variants at the TMEM106B locus with FTLD-TDP and

related phenotypes does not prove that TMEM106B is the “causal” gene, this was considered likely
to be the case, given that the closest gene 5’ of TMEM106B, THSD7A, is ~380kb away, and the
closest gene 3’ of TMEM106B, VWDE, is ~85kb away (Hinrichs et al., 2016). In order to answer
this question definitively, however, one would need to functionally dissect the mechanisms
underlying the association of TMEM106B SNPs with FTLD-TDP risk.

This question will be

addressed in detail in Chapter 4, in which an unbiased and comprehensive characterization of all
candidate causal variants at the TMEM106B locus is described, but one result published in the
FTLD-TDP GWAS provides a plausible working hypothesis. As discussed in Chapter 1.2, many
loci associated with disease by GWAS are also associated with the expression levels of one or
more genes (an expression quantitative trait locus (eQTL) effect) (Edwards et al., 2013), and the
variants in question are significantly enriched in predicted cis-regulatory elements (CREs)
(Maurano et al., 2012; Schaub et al., 2012). In Van Deerlin et al. (2010), the FTLD-TDP-associated
SNPs were queried for association with gene expression levels using a publicly available eQTL
study performed in Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines (LCLs) (Dixon
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et al., 2007; Van Deerlin et al., 2010). Interestingly, the risk alleles of all three GWAS SNPs were
significantly associated with increased mRNA levels of TMEM106B in LCLs (P=6.9x10-8 for
rs1990622), and importantly, these SNPs were not associated with the expression levels of any
other genes in the genome (Dixon et al., 2007; Van Deerlin et al., 2010). This result suggests that
one or more variants at the TMEM106B locus may influence risk for FTLD-TDP by altering
TMEM106B expression. Additionally, rs1020004, which is in only moderately strong LD with
rs1990622 and rs6969915 (r2=0.7), and which was least strongly associated with FTLD-TDP risk
in the GWAS and subsequent replication studies, also showed the weakest association with
TMEM106B expression levels in this eQTL study (P=1.1x10-6) (Dixon et al., 2007; Van Deerlin et
al., 2010). Thus, the association of TMEM106B variants with FTLD-TDP risk (and perhaps the
other neurodegenerative phenotypes discussed earlier) may be driven by the same functional
causal variant(s) underlying the association with TMEM106B expression levels. Moreover, these
association patterns between TMEM106B variants and TMEM106B mRNA levels have been
replicated in more recent large-scale LCL eQTL studies (Lappalainen et al., 2013; Liang et al.,
2013; Stranger et al., 2012), as well as in eQTL studies of T cells, neutrophils, and inflammatorystimulated monocytes (Fairfax et al., 2014; Peters et al., 2016; Raj et al., 2014).
Since brain is the tissue relevant to FTLD, Van Deerlin and colleagues extracted RNA from
25 prefrontal cortex samples (n=8 GRN+ FTLD-TDP, n=10 GRN- FTLD-TDP, and n=7 normal) and
quantified TMEM106B levels using reverse transcription quantitative polymerase chain reaction
(RT-qPCR). They then asked whether genotype at rs1990622 associated with TMEM106B levels
in human brain, and observed that risk allele homozygotes displayed the highest expression levels,
heterozygotes displayed intermediate expression levels, and protective allele homozygotes
displayed the lowest expression levels (P=0.027) (Van Deerlin et al., 2010). However, the presence
of disease was also reported to affect TMEM106B levels in this study (see below), and controlling
for disease status (GRN+ FTLD-TDP, GRN- FTLD-TDP or normal) eliminated the association
(unpublished data).

Subsequent studies also failed to detect genotype-dependent effects on

TMEM106B levels in brain (Cruchaga et al., 2011; van der Zee et al., 2011). However, these
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studies, which consisted of only 23-40 samples, were likely underpowered to detect small effects
on expression, as eQTL effects often require hundreds or even thousands of individuals with mixed
genotypes in order to be detected (Albert and Kruglyak, 2015). Consistent with this explanation
based on sample size, a study of 325 dorsolateral prefrontal cortex samples from aged but
neurologically normal individuals revealed a significant association between the rs1990622 risk
allele and increased TMEM106B mRNA levels (Yu et al., 2015). Thus, TMEM106B genotype may
increase FTLD risk by increasing TMEM106B levels in the brain.
Interestingly, an independent line of evidence suggests that increased TMEM106B levels
may be involved in FTLD pathogenesis. Van Deerlin and colleagues (2010) also demonstrated
that when grouping the same 25 individuals by disease status, individuals with FTLD-TDP had
significantly increased TMEM106B levels (P=0.045). This effect was driven mostly by the GRN+
individuals, who exhibited the highest expression levels (Van Deerlin et al., 2010). This was
confirmed in a follow-up study using additional brain regions (temporal cortex and occipital cortex),
and increased TMEM106B expression was also confirmed at the protein level in GRN+ FTLD-TDP
frontal cortex samples (Chen-Plotkin et al., 2012). Importantly, this effect appears to be at least
partially independent from the effect of TMEM106B genotype on TMEM106B levels (Van Deerlin
et al., 2010), implicating additional regulatory processes that may affect FTLD-TDP pathogenesis
by upregulating TMEM106B.
Finally, an unrelated study reported that a nonsynonymous protein-coding variant,
rs3173615, which is in complete LD with rs1990622, results in altered TMEM106B protein levels,
but has no effect at the mRNA level (Nicholson et al., 2013). Indeed, since the reporting of the
7p21 locus association with FTLD-TDP, many papers and reviews have mentioned rs3173615 as
a potential causal variant, since it is the only amino acid-altering variant that is in strong LD with
the GWAS sentinel SNP (Cruchaga et al., 2011; van der Zee et al., 2011; van der Zee and Van
Broeckhoven, 2011). The risk allele of rs3173615 is predicted to change a serine residue to a
threonine, which only differ in molecular composition by a single carbon atom. Nicholson and
colleagues (2013) cloned the TMEM106B open reading frame with either the risk or protective allele
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of rs3173615 into an expression construct and transfected these constructs into HeLa and HEK293
cells. They observed no effect of rs3173615 on TMEM106B mRNA levels, but observed a ~40%
reduction in TMEM106B protein levels in cells transfected with the protective allele construct, in
both cell lines (Nicholson et al., 2013). They further show that the protective allele of rs3173615
reduces TMEM106B protein stability, thus explaining the reduced steady-state levels (Nicholson et
al., 2013).
While it is possible that rs317615 has a phenotypic effect that is relevant to FTLD risk,
there are four concerns regarding this study. First, the TMEM106B eQTL effect reported in many
studies in different cell and tissue types exists at the mRNA level, and is not addressed in the
Nicholson study. Second, other groups have investigated the functional effects of rs3173615 and
have failed to detect reproducible effects on cellular phenotypes, including TMEM106B sub-cellular
localization, TMEM106B dimerization, and effects on PGRN levels (Brady et al., 2013; Nicholson
et al., 2013; Stagi et al., 2014). Finally, and most importantly, this study suffers from a critical
technical limitation, in that the antibody used to detect TMEM106B only detects the TMEM106B
monomer species in brain. Because of this, the authors assume that TMEM106B dimers, which
have been verified in human cell lines and brain by multiple other antibodies (Brady et al., 2013;
Chen-Plotkin et al., 2012), do not exist or are not important. I have attempted to replicate these
results using our well characterized antibody that detects TMEM106B monomers and dimers
(Chen-Plotkin et al., 2012), and have shown that when expressing either TMEM106B isoform under
the control of the endogenous TMEM106B promoter in HEK293 cells, the decrease in monomer
seen in cells expressing the protective allele is compensated for by an increase in the amount of
dimer, with no change in total TMEM106B levels (unpublished data). Consistently, a recent study
also failed to reproduce an effect of rs3173615 genotype on steady-state TMEM106B levels (Jun
et al., 2015). Thus, rs3173615 may affect TMEM106B dimerization kinetics rather than total protein
levels. However, further studies are needed to determine whether this variant affects TMEM106B
function.
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In conclusion, two independent lines of evidence suggest that increased expression of
TMEM106B may be involved in FTLD pathogenesis. Of particular interest, the association of the
FTLD-TDP risk SNPs with TMEM106B levels in human cell lines and brain suggests a plausible
mechanism by which genetic variation at TMEM106B influences risk for FTLD-TDP and other
neurodegenerative phenotypes. One variant in complete LD with rs1990622 is predicted to cause
a serine (protective allele) to threonine (risk allele) amino acid change, although this variant has
not consistently altered any biochemical or cellular phenotypes under investigation.
1.3.3

TMEM106B is involved in the autophagosomal/endolysosomal pathway
At the time of the discovery of the association between the TMEM106B SNPs and risk for

FTLD-TDP, nothing was known about TMEM106B, the sole gene within ~85kb of the FTLD risk
SNPs. Within 3 years of the GWAS report, several studies reported initial biochemical and cellular
characterizations of TMEM106B.

TMEM106B was determined to be a Type II integral

transmembrane protein that localizes to late endosomes and lysosomes, as defined by colocalization with the late endosomal/lysosomal markers LAMP-1, Rab7 and Rab9 (Brady et al.,
2013; Chen-Plotkin et al., 2012; Lang et al., 2012). This localization pattern has been observed in
various murine, non-human primate, and human cell types, including neurons and glia, and has
been confirmed in additional studies (Busch et al., 2016; Schwenk et al., 2014; Stagi et al., 2014).
In addition, TMEM106B expression has been confirmed in neurons and glia by performing
immunohistochemistry on human brain samples from individuals both with and without FTLD-TDP
(Busch et al., 2013; Chen-Plotkin et al., 2012).
In light of the fact that TMEM106B levels have been implicated in FTLD pathogenesis (see
Chapter 1.3.2), many of these studies have overexpressed and/or knocked down TMEM106B.
Several studies have shown that TMEM106B overexpression in various cell types increases
lysosomal size, and in some cases affects lysosomal trafficking, although the effects of knockdown
are less clear (Brady et al., 2013; Chen-Plotkin et al., 2012; Schwenk et al., 2014; Stagi et al.,
2014).

Some studies have also reported that overexpression results in impaired lysosomal

acidification and protein degradation, as well as cell death, which may be the result of caspase-

52

and/or lysosome-dependent cell death pathways (Brady et al., 2013; Busch et al., 2016; ChenPlotkin et al., 2012; Suzuki and Matsuoka, 2016). TMEM106B levels have also been shown to
affect neuronal dendritic branching, lysosomal stress responses, and the sensitivity of lysosomes
to oxidative damage (Schwenk et al., 2014; Stagi et al., 2014). Importantly, these phenotypes do
not seem to be significantly affected by the rs3173615 protein-coding variant, although more
rigorous studies are required to definitively rule out potential functions of this SNP (Brady et al.,
2013; Stagi et al., 2014). Given that most of the genes known to harbor FTLD-causing mutations
have roles in either endolysosomal pathways, which are critical for autophagy (Lamb et al., 2013),
or the ubiquitin/proteasome system, the apparent lysosomal function of TMEM106B and its effects
on protein degradation are intriguing.
Furthermore, the localization and overexpression phenotypes of TMEM106B have been
linked to both GRN and C9orf72, the two most common genes that contain FTLD-causing
mutations. First, TMEM106B and PGRN co-localize extensively at LAMP-1+ organelles, and
TMEM106B overexpression causes increases in intracellular PGRN levels (Brady et al., 2013;
Chen-Plotkin et al., 2012; Nicholson et al., 2013). As PGRN has recently been implicated in
lysosomal function (Petkau and Leavitt, 2014), TMEM106B may thus act as an FTLD risk factor
and modifier at least partly through GRN-dependent effects on lysosomes. The FTLD-TDP risk
allele of TMEM106B has also been associated with reduced plasma PGRN levels, and TMEM106B
and PGRN levels appear to be negatively correlated in immortalized lymphoblasts and brain
(Cruchaga et al., 2011; Finch et al., 2011; Yu et al., 2015). In addition, recent work in my lab has
demonstrated that the cellular phenotypes associated with TMEM106B overexpression can be
rescued or exacerbated by C9orf72 knockdown and overexpression, respectively (Busch et al.,
2016). Consistently, C9orf72 has recently been implicated in lysosomal processes (Farg et al.,
2014; Sellier et al., 2016; Ugolino et al., 2016; Webster et al., 2016; Yang et al., 2016) (see Chapter
1.1.4.3). Thus, the role of TMEM106B in FTLD-TDP risk and in modifying FTLD-TDP clinical
prognosis in the presence of GRN and C9orf72 mutations may involve interactions between these
proteins in lysosomal pathways.
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1.3.4

Summary
In summary, common genetic variants at the TMEM106B locus have been associated with

risk for FTLD-TDP, and this association has been replicated by independent groups. In addition,
the risk variants at TMEM106B also appear to modify age at death and/or age at onset in FTLDTDP patients with disease-causing GRN or C9orf72 mutations. Finally, TMEM106B risk variants
influence risk for hippocampal sclerosis of aging, TDP-43 pathology, cognitive impairment in ALS,
PGRN levels, temporal lobe gray matter volume, brain interhemispheric structure volume, and
functional network connectivity in asymptomatic GRN mutation carriers. Thus, genetic variation at
TMEM106B appears to play an important role in many phenotypes related to neurodegeneration,
and possibly normal brain function, many of which are associated with TDP-43 pathology.
Two independent lines of evidence suggest that TMEM106B may be the causal gene that
affects these phenotypes in a genotype-dependent manner. First, genome-wide eQTL studies
performed in several white blood cell types have revealed a significant association between the
TMEM106B risk SNP alleles and increased TMEM106B expression levels, and this association has
been confirmed to exist in human prefrontal cortex. Importantly, these genome-wide studies fail to
show a significant association between FTLD-TDP-associated SNPs and the expression levels of
any other genes. In addition, TMEM106B levels are increased in FTLD-TDP brains compared to
healthy controls, irrespective of TMEM106B genotype. Consistent with a potentially pathogenic
role of increased TMEM106B levels, cell-based studies have repeatedly shown that TMEM106B
overexpression results in enlarged, poorly acidified lysosomes, impaired protein degradation, and
cell death. Finally, several lines of evidence suggest that TMEM106B function may be linked to
those of GRN and C9orf72 in lysosomal pathways, potentially explaining the ability of TMEM106B
genotype to modify disease course in FTLD patients with disease-causing mutations in these
genes.
Taken together, these results implicate TMEM106B as an important genetic risk factor for
FTLD and other neurodegenerative phenotypes. Given our poor current understanding of the
pathogenesis of FTLD and related conditions, and the lack of effective treatments for these
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devastating diseases, TMEM106B provides a unique opportunity to improve our understanding of
the mechanisms underlying this disease.
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CHAPTER 2: TMEM106B, THE RISK GENE FOR FRONTOTEMPORAL DEMENTIA, IS
REGULATED BY THE MICRORNA-132/212 CLUSTER AND AFFECTS
PROGRANULIN PATHWAYS

by

Alice S. Chen-Plotkin, Travis L. Unger, Michael D. Gallagher, Emily Bill, Linda K. Kwong,
Laura Volpicelli-Daley, Johanna I. Busch, Sebastian Akle, Murray Grossman, Vivianna
Van Deerlin, John Q. Trojanowski, and Virginia M.-Y. Lee

This chapter was written by Alice Chen-Plotkin, with input from Michael Gallagher and
other authors, and originally published in the Journal of Neuroscience (August 15, 2012,
Volume 32, Issue 33, Pages 11213-27). The majority of the microRNA work, shown in
Figures 2.3 and 2.4, was performed by Michael Gallagher, and relates to the rest of the
dissertation by implicating increased TMEM106B levels in FTLD pathogenesis.
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2.1

ABSTRACT
Frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) is a fatal

neurodegenerative disease with no available treatments. Mutations in the progranulin gene (GRN)
causing impaired production or secretion of progranulin are a common Mendelian cause of FTLDTDP; additionally, common variants at chromosome 7p21 in the uncharacterized gene TMEM106B
were recently linked by genome-wide association to FTLD-TDP with and without GRN mutations.
Here we show that TMEM106B is neuronally-expressed in postmortem human brain tissue, and
that expression levels are increased in FTLD-TDP brain.

Furthermore, using an unbiased,

microarray-based screen of over 800 microRNAs, we identify microRNA-132 as the top microRNA
differentiating FTLD-TDP and control brains, with <50% normal expression levels of three members
of the microRNA-132 cluster (microRNA-132, microRNA-132*, and microRNA-212) in disease.
Computational analyses, corroborated empirically, demonstrate that the top mRNA target of both
microRNA-132 and microRNA-212 is TMEM106B; both microRNAs repress TMEM106B
expression through shared microRNA-132/212 binding sites in the TMEM106B 3’UTR. Increasing
TMEM106B expression to model disease results in enlargement and poor acidification of endolysosomes, as well as impairment of mannose-6-phosphate-receptor trafficking.

Finally,

endogenous neuronal TMEM106B co-localizes with progranulin in late endo-lysosomes, and
TMEM106B over-expression increases intracellular levels of progranulin. Thus, TMEM106B is an
FTLD-TDP risk gene, with microRNA-132/212 depression as an event which can lead to aberrant
over-expression of TMEM106B, which in turn alters progranulin pathways. Evidence for this
pathogenic cascade includes the striking convergence of two independent, genomic-scale screens
on a microRNA:mRNA regulatory pair. Our findings open novel directions for elucidating miRNAbased therapies in FTLD-TDP.
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2.2

INTRODUCTION
The neurodegenerative dementia FTLD-TDP is a sporadic and familial neurodegenerative

disease causing progressive impairment in language, behavioral control, or both (Baker et al.,
2006; McKhann et al., 2001). One of the major forms of presenile dementia (Ratnavalli et al.,
2002), FTLD-TDP is characterized by ubiquitinated inclusions comprised primarily of the HIV TARDNA binding protein of 43kD, or TDP-43 (Arai et al., 2006; Neumann et al., 2006). These TDP-43
inclusions are also found in the motor neuron disease amyotrophic lateral sclerosis (ALS) (Arai et
al., 2006; Neumann et al., 2006). Mutations in the TDP-43 gene (TARDBP) are rare genetic causes
of both FTLD-TDP (Benajiba et al., 2009) and ALS (Gitcho et al., 2008), suggesting that FTLD-TDP
and ALS might be two phenotypic ends of one disease spectrum (Chen-Plotkin et al., 2010a).
Additionally, mutations in the progranulin gene (GRN) – a secreted growth factor (He and Bateman,
2003) – are a major Mendelian cause of FTLD-TDP (Baker et al., 2006; Cruts et al., 2006) and
account for ~10% of all cases (Gass et al., 2006). Deficiency of progranulin production (Baker et
al., 2006; Cruts et al., 2006) or secretion (Mukherjee et al., 2008; Shankaran et al., 2008) appears
to be the disease mechanism in these autosomal dominant FTLD-TDP cases (Cruts and Van
Broeckhoven, 2008).
To identify additional risk factors for FTLD-TDP, we previously conducted a genome-wide
association study (GWAS) and showed that chromosome 7p21 variants within the gene
TMEM106B confer increased risk of FTLD-TDP, with an odds ratio of 1.6 (Van Deerlin et al., 2010),
and this association has been replicated (van der Zee et al., 2011). Intriguingly, decreased plasma
progranulin levels correlate with TMEM106B risk genotypes (Finch et al., 2011), and, in ALS
patients, TMEM106B genotypes associated with FTLD-TDP increase the risk of developing
dementia (Vass et al., 2011). While these observations correlate with TMEM106B genotype, they
do not provide mechanistic evidence that TMEM106B is the causative 7p21 genetic signal
observed in the GWAS. Furthermore, very little is known about TMEM106B, a 274 amino-acid,
predicted single transmembrane domain protein, with no yeast orthologue and homology only to
two other uncharacterized members of the TMEM106 family.
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Here, we investigate the genetic regulation and pathophysiological function of TMEM106B,
both of which were previously unknown. We demonstrate that TMEM106B is elevated in FTLDTDP brains. We further show that TMEM106B is normally repressed by microRNA-132 and
microRNA-212, which are significantly decreased in FTLD-TDP. Finally, we demonstrate that
TMEM106B over-expression in turn disrupts endosomal-lysosomal pathways, sequesters
progranulin in TMEM106B positive late endosomes or lysosomes, and increases intracellular levels
of progranulin. We thus establish TMEM106B mechanistically as the 7p21 genetic risk factor for
FTLD-TDP and elucidate pathophysiological steps which may be amenable to targeted intervention
in an otherwise fatal disease.
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2.3

RESULTS

2.3.1

TMEM106B shows increased expression in FTLD-TDP brain
TMEM106B is a minimally characterized protein. Thus, we first sought to investigate its

expression in normal and FTLD-TDP brain tissue. We thus raised an affinity-purified polyclonal
antibody, N2077, which specifically recognizes an N-terminus peptide sequence unique to
TMEM106B.
In both HEK293 cells (Figure 2.1A) and murine primary cortical neurons (Figure 2.1B)
transfected with a FLAG-tagged TMEM106B construct, staining patterns for N2077 and anti-FLAG
antibody showed nearly perfect overlap.

Similarly, immunoblots performed on sequentially-

extracted HEK293 cell lysates transfected with FLAG-tagged TMEM106B constructs showed the
same band when probed with N2077 or antibodies against the tag (Figure 2.1C), again
demonstrating that the N2077 antibody recognizes TMEM106B. Furthermore, both N2077 and the
anti-FLAG antibodies recognize TMEM106B in RIPA-extracted samples, consistent with the
predicted transmembrane character of TMEM106B. Finally, preabsorption of N2077 with the
peptide immunogen resulted in the disappearance of TMEM106B immunobands on immunoblotting
(Figure 2.1D), as well as the disappearance of TMEM106B staining within cellular structures on
immunofluorescence (data not shown). Taken together, these results demonstrate the specificity
of the N2077 antibody for TMEM106B in both biochemical and cell biological contexts.
Unexpectedly, however, the molecular weight of the main species recognized by both
N2077 and antibodies directed against the FLAG tag was approximately 75kD, with a fainter band
occasionally seen at 40kD, while the predicted molecular weight of TMEM106B is 31kD. We
accordingly tested other commercially available antibodies against TMEM106B; only one
recognized immunobands that increased with over-expression of TMEM106B, and this antibody
demonstrated the same 75kD and 40kD bands (Figure 2.1D), with possibly greater affinity for the
40kD band than N2077. To investigate the apparent discrepancy between predicted and observed
molecular weights of TMEM106B, we manipulated the protein in various ways. Dephosphorylating
or reducing cell lysates with DTT did not change the molecular weight (Figure 2.1E). Incubating
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the protein at 37°C or above, however, demonstrated that the 75kD species recognized by both
N2077 and antibodies against the TMEM106B construct tag was very sensitive to heat, even in the
presence of protease inhibitors. Specifically, when cell lysates containing TMEM106B were kept
at 37°C for 30 minutes, several changes were observed in the immunoblot pattern (Figure 2.1F).
First, more than 50% of the protein was lost. Second, the 40kD band became more prominent.
Third, when cell lysates containing TMEM106B were heated to 56°C or above, both the 75kD and
40kD bands were lost, and a high-molecular weight species was seen at the top of the gel, again
consistent with the transmembrane character of TMEM106B. Human brain homogenates behaved
similarly, with the exception that the 40kD band was much less prominent (Figure 2.1G).
Finally, TMEM106B has recently been reported to be glycosylated, with at least five
glycosylation sites C-terminal to the predicted transmembrane domain (Lang et al., 2012). We
confirmed this finding and extended it to brain tissue by deglycosylating cell lysates and human
brain homogenates. Specifically, we found that if we combined treatment with N-glycosidase F
with short pre-treatment with heat, the 40kD band (prominent in cell lysates and visible although
less prominent in human brain homogenates) collapsed to the expected 31kD weight of
TMEM106B, while the 75kD band collapsed to ~60kD (Figure 2.1H). Taken together, these data
suggest that TMEM106B is glycosylated, detergent-soluble, and exists primarily in a heat-sensitive
protein complex migrating at an apparent molecular weight of 75kD. Accordingly, all subsequent
biochemical experiments performed for quantitation were done with the samples kept at 4 oC.
Having demonstrated the specificity of our N2077 antibody, we used it to evaluate the
expression of TMEM106B in human frontal cortex brain tissue (n=5 each of normal cases. FTLDTDP without GRN mutations, FTLD-TDP with GRN mutations). TMEM106B was abundantly
expressed in human brain tissue, with a cytoplasmic perikaryal localization in neurons from normal
individuals (Figure 2.2A), reminiscent of TMEM106B’s expression pattern in murine primary
cortical neurons (Figure 2.1B). Intriguingly, TMEM106B appeared more widely distributed in the
cytoplasm of neurons from individuals with FTLD-TDP, and particularly FTLD-TDP with GRN
mutations (GRN(+) FTLD-TDP, Figure 2.2A). In these individuals, TMEM106B expression
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Figure 2.1. TMEM106B antibody and protein characterization.
We raised a novel polyclonal antibody (N2077) recognizing amino acids 4-19 of TMEM106B.
(A,B) HEK293 cells (Panel A) or murine primary cortical neurons (Panel B) were transfected with
FLAG-tagged TMEM106B. Double label immunofluorescence microscopy demonstrates that antiFLAG antibody recognizes the same cellular structures as anti-TMEM106B antibody (N2077),
demonstrating the specificity of our antibody in a cell biological context.
(C) HEK293 cells transfected with FLAG-tagged TMEM106B were sequential extracted into highsalt (HS), RIPA, and 2% SDS (SDS) buffers. A RIPA-soluble 75kD band was recognized by both
anti-FLAG antibody and anti-TMEM106B antibody (N2077), demonstrating the specificity of our
antibody in a biochemical context.
(D) TMEM106B over-expression in HEK293 cells resulted in the appearance of bands at 75kD and
40kD, detected by both N2077 (first two columns) and a commercially available N-terminus
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antibody (Bethyl, middle two columns). Both bands disappeared when N2077 was preabsorbed
with immunizing peptide (last two columns). O/E indicates whether TMEM106B was overexpressed (+) or not (-). Peptide indicates whether the antibody was preabsorbed with peptide
immunogen (+) or not (-).
(E) Neither dephosphorylation with lambda phosphatase, nor treatment with the reducing agent
DTT changed the electrophoretic mobility of TMEM106B. Dephos = dephosphorylated, DTT = DTT
treated; (-) indicates control, (+) indicates treated condition.
(F,G) TMEM106B shows unusual heat sensitivity at temperatures above 4°C, even in the presence
of protease inhibitors. In cell lysates from HEK293 cells transfected with FLAG-tagged TMEM106B
(Panel F), TMEM106B appeared primarily as a 75kD band when samples were kept on ice (4).
When heated at 37°C for 30 minutes (37S) or 45 minutes (37L), the 75kD band faded, and a 40kD
species began to appear. At higher temperatures (e.g. 56°C for 15min, lane labeled 56), both the
40kD and 75kD bands were lost and a >150kD aggregate appeared at the top of the gel.
Overexpression (O/E) indicates whether TMEM106B was over-expressed (+) or not (-). Blots were
probed with both anti-FLAG and N2077 antibodies, demonstrating the specificity of the bands.
Similar heat-sensitivity was seen for TMEM106B extracted from human brain tissue from normal
individuals (Panel G). In contrast to HEK293 cell lysates, however, the 40kD band was never
prominent in human brain samples. For all panels, samples were extracted into RIPA buffer, and
equal amounts of protein were loaded into all lanes.
(H) TMEM106B from human brain samples (left), or over-expressed in HEK293 cells (right) was
deglycosylated with PNGase F after short pre-treatment at 37°C. The 75kD and 40kD bands
observed prior to deglycosylation (-) collapsed to lower molecular weight species of ~60kD and
31kD, respectively, after PNGase F treatment (+). Note that the predicted molecular weight of
TMEM106B is 31kD. Blots probed with the Bethyl TMEM106B antibody.
All immunoblots: Arrowheads indicate TMEM106B species. *non-specific band.

extended beyond the cell body into neuronal processes, filling the cytoplasm of the cells. Of note,
none of the commercially available TMEM106B antibodies produced a clear staining pattern in
human brain tissue (data not shown), whereas N2077's perikaryal neuronal staining was robust
and disappeared upon preabsorption of the antibody with the peptide immunogen (Figure 2.2B).
These immunohistochemical findings, as well as preliminary data reported in our prior
GWAS (Van Deerlin et al., 2010), suggested that TMEM106B expression is increased in FTLDTDP. We therefore quantified TMEM106B expression in FTLD-TDP brain.
At the mRNA level, quantitative reverse-transcription PCR (QRT-PCR) demonstrated that
TMEM106B brain expression was lowest in normal individuals (n=6), higher in FTLD-TDP patients
without GRN mutations (GRN(-) FTLD-TDP, n=7) and highest in GRN(+) FTLD-TDP (n=5, see
Table 2.1 for patient and control characteristics). These trends were observed in multiple areas of
the brain (Figure 2.2C), with the most striking differences seen in frontal cortex, corroborating our
previously published report (Van Deerlin et al., 2010) with a wider range of samples. For a subset
of patients, never-thawed frontal cortex samples were available for protein quantitation, and
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quantitation of immunoblots performed on these frontal cortex samples corroborated the mRNA
finding that TMEM106B expression is increased in GRN(+) FTLD-TDP (Figure 2.2D). It is worth
noting that human brain TMEM106B expression appears to be much higher than in HEK293 cells,
which show negligible expression by immunoblot in the absence of over-expression. In addition,
we have previously shown that the GRN(+) FTLD-TDP brains used in this study do not have more
severe TDP-43 pathology than the GRN(-) FTLD-TDP brains (Chen-Plotkin et al., 2010b),
suggesting that general mechanisms of TDP-43 mediated pathology and/or neurodegeneration
cannot account for the observed differences in TMEM106B expression.
Thus, TMEM106B appears to be abundantly expressed in human brain tissue, with
particularly high levels of expression in GRN(+) FTLD-TDP brain, and possible modest increases
in GRN(-) FTLD-TDP brain as well.
2.3.2

The microRNA-132 cluster is decreased in FTLD-TDP brain
We next sought to identify genetic modifiers of TMEM106B expression which might be

responsible for the observed increase in expression in FTLD-TDP.

To do this, and to

simultaneously pursue effectors of a distinct mRNA expression signature previously demonstrated
in FTLD-TDP (Chen-Plotkin et al., 2008), we performed global microRNA (miRNA) expression
profiling. MiRNAs – small noncoding RNAs of ~22bp – have emerged in recent years as major
regulators of gene expression, binding to complementary sequences in the 3’ untranslated region
(3’UTR) of specific mRNAs and repressing expression by targeting mRNAs for degradation or
blocking translation (Filipowicz et al., 2008). In addition, miRNA dysfunction has been implicated
in a growing number of diseases, including the neurodegenerative disorders Alzheimer’s disease
(Hebert et al., 2008; Wang et al., 2008), Parkinson’s disease (Kim et al., 2007a), and
spinocerebellar ataxia (Lee et al., 2008).
Utilizing a microarray platform testing all known human miRNAs (n=836), we compared
frontal cortex tissue from FTLD-TDP patients (n=12) and controls (n=6, see Table 2.1 for patient
and control characteristics). Three miRNAs in the miR-132 cluster – miR-132, miR-132*, and miR212 – all emerged within the 11 miRNAs showing significantly dysregulated expression in FTLD-
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Figure 2.2. TMEM106B expression is increased in FTLD-TDP.
(A) Immunohistochemical staining was performed with N2077 anti-TMEM106B antibody on frontal
cortex brain sections from age-matched controls (Normal), GRN(-) FTLD-TDP and GRN(+) FTLDTDP). GRN(+) FTLD-TDP patients had more diffuse TMEM106B staining, extending throughout
the cell body and into neuronal processes. Representative lower-magnification images (top) and
higher-magnification images of typical neurons from the same field (bottom) are shown. Scale bar
represents 100µm.
(B) Neuronal staining (top) was abolished with preabsorption of N2077 with the immunizing peptide
(bottom). Scale bar represents 200µm.
(C) Total mRNA was isolated from neurologically normal controls (n=6), GRN(-) FTLD-TDP (n=7),
and GRN(+) FTLD-TDP (n=5), and TMEM106B transcript expression was measured by QRT-PCR
in multiple brain regions. Compared to both normal controls and to GRN(-) FTLD-TDP, GRN(+)

65

FTLD-TDP had significantly higher levels of TMEM106B expression. Means +/- SEM shown.
*p<0.05, **p<0.01
(D) Frontal cortex protein was RIPA-extracted. Equal amounts of total protein from neurologically
normal controls (n=4), GRN(-) FTLD-TDP (n=3), and GRN(+) FTLD-TDP (n=4) were loaded, and
immunoblots were probed for TMEM106B. Corroborating our mRNA findings, GRN(+) FTLD-TDP
brain showed higher levels of TMEM106B protein expression. Quantification (means +/- SEM)
includes all available samples; representative subset immunoblot is also shown.

Group

N

Gender

FTLD-TDP with GRN mutations
c.26C>A (A9D)
c.911G>A (W304X)
c.1252C>T (R418X) – 2
cases
c.1477C>T (R493X)

5

2M/3F

Age at death
Median
(IQR)
68 (65-76)

7
6

3M/4F
4M/2F

68 (56-73)
71 (60-75)

FTLD-TDP without GRN
mutations
Neurologically normal controls

Table 2.1. Human brain samples.
Characteristics of postmortem brain samples used for this study. All GRN genetic variants
used in this study are believed to be pathogenic (http://www.molgen.ua.ac.be/admutations/).
M=Male, F=Female
Nomenclature follows cDNA sequence NM_002087.2.

TDP (Figure 2.3A). A fourth putative member of the miR-132 cluster – miR-212* – is not in the
microRNA database miRBase 17 (http://www.mirbase.org/index.shtml) and was not represented
on the microarray.
The top miRNA thus identified was miR-132 (p=0.0001, Figure 2.3A), a CREB-activated
miRNA previously reported to play diverse roles in neuronal differentiation (Magill et al., 2010; Vo
et al., 2005). In addition, by corroborative QRT-PCR, miR-132, miR-132*, and miR-212 all showed
<50% expression in both GRN(-) FTLD-TDP and GRN(+) FTLD-TDP compared to normal controls
(QRT-PCR, Figure 2.3B). This decreased expression relative to normal controls persisted in both
GRN(-) FTLD-TDP and GRN(+) FTLD-TDP subgroups, removing the possibility that one subgroup
is driving the effect; a significant difference also persisted when quantitation was normalized to the
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brain-expressed miRNA miR-124, removing the possibility that neuronal loss associated with
FTLD-TDP is driving the effect (data not shown). However, absolute levels of miR-132 were ~100
times higher than miR-132* and miR-212 in all groups (Figure 2.3B).
MiR-132, miR-132*, and miR-212 are all generated from a shared primary miRNA
transcript (pri-miRNA) on chromosome 17; this pri-miRNA is then processed into 2 pre-miRNAs,
which in turn become the three mature miRNAs (Figure 2.3C). Interestingly, miR-132, miR-132*,
and miR-212 levels were highly correlated on an individual-to-individual basis (R2 values > 90%,
Figure 2.3D), suggesting that the observed decrease of all three miRNAs may result from
decreased expression of the pri-miRNA transcript in FTLD-TDP.
2.3.3

MiR-132 and miR-212 are dual repressors of TMEM106B through shared binding

sites in the 3’UTR
Having identified the miR-132 cluster by genomic-scale screening for FTLD-TDPdysregulated miRNAs, we next performed computational analyses of miR-132 cluster targets using
the program TargetScan (Lewis et al., 2003) (release 5.1, http://www.targetscan.org). Strikingly,
the top computationally-predicted target of both miRNA-132 and miR-212 was TMEM106B, ranked
1 of 283 predicted mRNA targets (Table 2.2). Specifically, miR-132 and miR-212 share one
recognition sequence, and two sites within the TMEM106B 3’UTR contain this “seed match”
(Figure 2.4A, nucleotides in red). Indeed, on an individual-by-individual basis, irrespective of
disease status, frontal cortex levels of both miR-132 and miR-212 showed significant inverse
associations with frontal cortex levels of TMEM106B (linear regression one-tailed p-value = 0.03
for miR-132, 0.05 for miR-212).
To determine if the computationally predicted relationship between miR-132/212 and
TMEM106B could be demonstrated experimentally, we transfected each miRNA into HEK293 cells.
Transfection of either miR-132 or miR-212 resulted in a 40% decrease of endogenous mRNA levels
of TMEM106B, suggesting that these miRNAs are bona fide negative regulators of TMEM106B
(Figure 2.4B).

67

Figure 2.3. The microRNA 132/212 cluster is decreased in FTLD-TDP.
(A) Frontal cortex samples from normal controls (n=6) and patients with FTLD-TDP (n=12)
were evaluated by microarray for differentially expressed microRNAs. Eleven microRNAs
demonstrated nominally significant differences in FTLD-TDP compared to controls, with
microRNA-132 (miR-132) demonstrating the most significant association (p=0.0001), and a
decrease of ~50% in FTLD-TDP.
(B) Confirmation of microarray screening results by QRT-PCR showed significant 65-75%
reductions in miR-132, miR-132*, and miR-212 for FTLD-TDP frontal cortex samples from
patients with (GRN+, n=5) and without (GRN-, n=7) progranulin mutations, compared to
neurologically normal controls (n=6). Absolute levels of miR-132, however, were 50-100 times
higher than levels of either miR-132* or miR-212. Relative expression (means +/- SEM) of
microRNAs are shown on a log2 scale, calibrated to one normal sample’s miR-132 expression
value. *p<0.05, **p<0.01.
(C) Three of the 11 microRNAs with differential expression in FTLD-TDP are known to arise
from processing of the same CREB-responsive primary transcript. Specifically, a primary
transcript on chromosome 17 gives rise to pre-microRNA (pre-miRNA) 132 and pre-miR-212.
Pre-miR-132 is then further processed to yield mature miR-132 and miR-132*, while pre-miR212 yields mature mir-212.
(D) MiR-132 (x-axis), miR-132* (y-axis, red), and miR-212 (y-axis, blue) show highly correlated
expression levels across all 18 human samples, suggesting that the observed decrease of all
3 microRNAs may be due to decreased expression of the shared primary transcript. For each
miRNA, values are normalized to one sample within that group to account for the much higher
expression levels of mir-132.

68

Rank

Target
Gene

Gene Name

Total context
score

1

TMEM106B

transmembrane protein 106B

-0.96

2

ZNF516

zinc finger protein 516

-0.89

3

LEMD3

LEM domain containing 3

-0.81

4

CDC2L6

cell division cycle 2-like 6 (CDK8-like)

-0.81

5

GMFB

glia maturation factor, beta

-0.79

6

ETNK1

ethanolamine kinase 1

-0.79

7

TIMM9

translocase of inner mitochondrial membrane 9 homolog

-0.75

8

SLC26A7

solute carrier family 26, member 7

-0.71

9

CCDC88A

coiled-coil domain containing 88A

-0.69

MIA3

melanoma inhibitory activity family, member 3

-0.68

10

Table 2.2. Top ten mRNA targets of miR-132/212, as predicted by TargetScan.
The total context score reflects the likelihood of true targeting and is related to the number of
predicted binding sites, the quality of each binding site, and the genomic context. A more
negative value suggests a stronger probability of true targeting. Of note, miR-132 and miR-212
have the same target binding sequence, thus accounting for the shared mRNA targets.
We next evaluated the site-specific contributions of the two predicted miR-132/212 binding
sites within the TMEM106B 3’UTR (Sites 1 and 2 in Figure 2.4A) on miR-132/212 regulation of
TMEM106B. First, we used a “subtraction” strategy – removing miR-132/212 binding sites from
the native TMEM106B 3’UTR by truncations and by site-directed deletions (Figure 2.4A). We
expressed these TMEM106B 3’UTR mutants in HEK293 cells and assayed their expression levels
under the regulation of endogenous miR-132/212.
Expression of a TMEM106B construct lacking the predicted 3’UTR miR-132/212 binding
sites resulted in high TMEM106B protein expression (Figure 2.4C). Inclusion of the 3’ end of the
’UTR in the full 3’UTR-containing TMEM106B construct resulted in a 65% decrease of TMEM106B
protein (Figure 2.4C) and mRNA levels (Figure 2.4D), compared to the construct without miR132/212 binding sites – demonstrating the repressive function of this portion of the 3’UTR.
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Moreover, a targeted deletion eliminating only the seed region of miR-132/212 Site 1 from the full
3’UTR construct resulted in significant restorations of TMEM106B protein (Figure 2.4C) and
mRNA (Figure 2.4D) levels, while a targeted deletion eliminating only the seed region of miR132/212 Site 2 resulted in negligible change in TMEM106B levels. Finally, a construct containing
targeted deletions of both miR-132/212 Site 1 and miR-132/212 Site 2 seed regions resulted in the
largest restorations (>50%) of TMEM106B expression at the protein (Figure 2.4C) and mRNA
(Figure 2.4D) levels. Thus, miR-132/212 Site 1 and miR-132/212 Site 2 are necessary in mediating
the repression of TMEM106B by endogenous microRNAs, with greater repressor activity from Site
1.
Second, we employed an “addition” strategy – selectively adding the full miR-132/212
binding Site 1 or 2 to luciferase reporter constructs in the 3’ regulatory region. Co-transfection of
luciferase reporter constructs with miR-132 or miR-212 into HEK293 cells resulted in a significant
reduction in luciferase reporter activity for both the Site 1 construct (Figure 2.4E) and the Site 2
construct (Figure 2.4F). This reduction was not seen when cells were treated with an irrelevant
microRNA or with no microRNAs, or when mir-132/212-site-containing reporters were substituted
with either empty vector (Figures 2.4E and 2.4F, grey bars) or a luciferase reporter construct
inserting the same base pairs in a scrambled order that would abolish microRNA binding (Figures
2.4E and 2.4F, black bars). Thus, either miR-132/212 Binding Site 1 or miR-132/212 Binding Site
2 of the TMEM106B 3’UTR is sufficient to confer regulatory activity by miR-132 and miR-212.
We next evaluated whether miR-132/212 activation by a physiologic stimulus in a neuronal
cell would demonstrate the same regulatory effect of miR-132/212 on TMEM106B. Previous
studies have shown that in neurons, miR-132 and miR-212 are CREB-activated miRNAs (Impey et
al., 2004; Magill et al., 2010) and that treatment with BDNF, which activates CREB-mediated
transcription, also increases miR-132 and miR-212 expression. Because the miR-132/212 binding
sites in the TMEM106B 3’UTR are not conserved beyond primates, we used retinoic acid induced
neuronally-differentiated human SHSY5Y cells. BDNF treatment in SHSY5Y cells resulted in a
rapid (1-2hr) increase in both the known CREB-responsive gene fos and precursor forms of miR-
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Figure 2.4. TMEM106B is regulated by miR-132 and miR-212.
(A) MiR-132 and miR-212 are predicted to target the same mRNAs through a common seed region
(nucleotides in red). The TMEM106B 3’UTR has two 8mer miR-132/miR-212 target sites at
positions 5084 and 5662 (NM_001134232.1). Bolded, underlined nucleotides indicate regions of
perfect complementarity between the TMEM106B 3'UTR and miR-132, which may have greater
affinity than miR-212 for Site 2 of the TMEM106B 3'UTR through a stretch of complementarity
outside the seed region. Constructs containing TMEM106B with the intact 3’UTR (Full 3’UTR), or
truncations or targeted deletions removing one or both miR-132/212 sites, were used for
experiments shown in C and D.
(B) Endogenous TMEM106B mRNA transcript is significantly reduced with addition of miR-132 or
miR-212 mimics (means±SEM from 4 independent transfections).
(C) Compared with the truncated construct (Part 3’UTR), protein levels of the TMEM106B construct
containing both miR-132/212 binding sites (Full 3’UTR) was decreased by 65%. Deletion of miR132/212 Site 1 restored TMEM106B protein levels by ~40%, while deletion of miR-132/212 Site 2
had minimal effect. Targeted deletions of both miR-132/212 binding sites (Site1and2Mut) resulted
in even greater restoration of TMEM106B expression. Representative immunoblot (top) and
quantitation (means±SEM of 5 independent replicates) are shown. For TMEM106B constructs,
only the 75kD band was apparent for cell lysates, which were always kept on ice.
(D) Corresponding TMEM106B mRNA levels (means±SEM of 5 independent replicates) for the
same constructs.
(E,F) Luciferase reporters were generated containing TMEM106B 3’UTR miR-132/212 binding Site
1 (Panel E) or Site 2 (Panel F) with 5-10 flanking base pairs. Transfection of MiR-132 or miR-212
resulted in significant decreases in reporter activity (means±SEM from 3 independent replicates)
when either site was intact. No change was seen for reporters containing scrambled versions of
the miR-132/miR-212 binding sites (Site1Mut and Site2Mut) or for reporters without miR-132
binding sites (Vector). Luminescence ratio is the ratio between the firefly luciferase reporter under
3’UTR control and the constitutively active renilla luciferase reporter, controlling for differences in
transfection efficiency.
(G,H) BDNF was applied to neuronally-differentiated SHSY5Y cells to induce CREB-responsive
genes. Pre-miR-132 and pre-miR-212, as well as the canonical CREB-responsive gene fos, were
induced by BDNF within 1-2 hours (Panel G). Mature miR-132 was maximally induced 24 hours
after BDNF treatment (Panel H). Expression of the known miR-132 target gene p250GAP, as well
as TMEM106B, decreased with BDNF treatment, with maximal repression at 48 hours for
TMEM106B. MiR-132 levels had a significant effect on both TMEM106B (p=0.009) and p250GAP
(p=0.006) expression.
Ratios of BDNF-treated to non-treated conditions are shown for a minimum of 4 separate
transfections.
All panels: *p<0.05, **p<0.01, ***p<0.001

132 and miR-212, consistent with CREB-activated transcription of these two miRNAs (Figure
2.4G).
We observed a subsequent rise in mature forms of miR-132 and miR-212, peaking at 24
hours after BDNF treatment. Concomitant with the rise in miR-132, TMEM106B transcript levels
fell, with a maximum effect 48 hours after BDNF treatment (Figure 2.4H). Reduction in TMEM106B
expression was significantly associated with rise in miR-132, and similar in magnitude to observed
reduction in the known miR-132 target gene p250GAP (Remenyi et al., 2010; Wayman et al., 2008),
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consistent with miR-132 repression of TMEM106B in a neuronal setting (Figure 2.4H). Similar
trends were seen for miR-212, but total levels were 5-10 times lower than miR-132 in SHSY5Y
cells and negative correlation with TMEM106B and p250GAP expression was not significant for
miR-212 (data not shown). Taken together, these results provide empirical confirmation of the
computationally predicted regulation of TMEM106B by miR-132 and miR-212.
2.3.4

Neuronal TMEM106B is localized to late endosomes or lysosomes
Having established that the miR-132 cluster is decreased in FTLD-TDP, that TMEM106B

is increased in FTLD-TDP, and that miR-132 and miR-212 can both repress TMEM106B
expression, we turned our attention to the biology of this previously uncharacterized protein. Using
immunofluorescence microscopy, we first evaluated the subcellular localization of TMEM106B
using the N2077 antibody. Of note, the commercially available antibodies against TMEM106B did
not show co-localization with antibodies against various tags upon expression of tagged constructs,
so we did not use them for cell biological experiments. FLAG-tagged TMEM106B in HEK293 cells
(Figure 2.5A) co-localized with the late endosomal/lysosomal marker LAMP-1, supporting previous
reports using immortalized cell lines that TMEM106B may be localized to lysosomes (Lang et al.,
2012).

We extended these findings by demonstrating that endogenous TMEM106B in non-

transfected murine primary cortical neurons (Figure 2.5B) also co-localized with LAMP-1, as well
as Lysotracker, an indicator of acidic organelles (Figure 2.5C). In contrast, there was little overlap
in staining between TMEM106B and Golgi markers (Figure 2.5D) or between TMEM106B and
TDP-43 (Figure 2.5E). Similar late endosomal/lysosomal staining patterns were seen for murine
primary hippocampal neurons, and for primary hippocampal and primary cortical neurons from rats
(data not shown).

Thus, neuronal TMEM106B is localized primarily in late endosomes or

lysosomes.
2.3.5

Over-expression of TMEM106B results in abnormalities in the endosomal-lysosomal

pathway
Having established the late endosomal/lysosomal subcellular localization of TMEM106B,
we next evaluated the effect of over-expression of TMEM106B on the endosomal-lysosomal

73

74

Figure 2.5. TMEM106B is associated with late endosomes/lysosomes in neurons.
TMEM106b antibody N2077 was used for immunofluorescence microscopy. Scale bars represent
10µm.
(A) Structures staining with TMEM106B antibody (green) also expressed the late
endosomal/lysosomal marker LAMP-1 (red) in HEK293 cells transiently transfected with
TMEM106B.
(B) In non-transfected primary murine cortical neurons, endogenous TMEM106B (green) colocalized with LAMP-1 (red) in cell processes, and in the cell body (inset).
(C) In non-transfected primary murine cortical neurons, TMEM106B (green) co-localized with a
marker for acidic organelles, Lysotracker (red), corroborating the association of TMEM106B with
late endosomes/lysosomes.
(D) TMEM106B did not co-localize with the cis-Golgi marker GM130.
(E) TMEM106B did not co-localize with TDP-43.

pathway. To do this, we transiently over-expressed TMEM106B and performed double-label
immunofluorescence for TMEM106B and LAMP-1. As shown in Figure 2.6A, HeLA cells overexpressing TMEM106B (arrowhead) demonstrated enlargement of LAMP-1+/TMEM106B+
organelles, while neighboring cells with normal levels of TMEM106B did not. We observed this
general enlargement of LAMP-1+ organelles upon TMEM106B over-expression in multiple cell
lines, including HEK293 cells, HeLA cells, and the mouse neuronal cell line Neuro2A, with virtually
no "normal-sized" LAMP-1+ organelles (Figure 2.6B) seen. Additionally, we occasionally observed
the formation of very large cytoplasmic vacuolar structures ~5µm in diameter; these structures
showed LAMP-1 and TMEM106B staining co-localized at the limiting membrane (Figure 2.6A,
bottom).
Since large vacuolar structures have been described upon treatment of cells with alkalizing
agents such as the lysosomotropic drug chloroquine (Brown et al., 1984), we sought to determine
whether these large LAMP-1+/TMEM106B+ organelles were acidified. To do this, we used the pHsensitive dyes Lysotracker and Lysosensor, both weak bases that fluoresce intensely at low pH
and weakly (or not at all) at higher pH. As shown in Figure 2.6C, HeLA cells over-expressing
TMEM106B (arrowhead) contained large LAMP-1+/TMEM106B+ organelles which were not as
acidic as the LAMP-1+ organelles in neighboring cells with normal levels of TMEM106B expression.
Indeed, the Lysotracker mean fluorescence intensity of the cytoplasmic compartment of cells overexpressing TMEM106B was significantly lower than that of cells expressing normal levels of
TMEM106B, indicating a general failure to acidify organelles (Figure 2.6D).
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The effect of

TMEM106B over-expression was reminiscent of the cellular alkalization induced by bafilomycin A1
(BafA1), a selective inhibitor of the vacuolar ATPase that acidifies lysosomes (Figures 2.6C
(bottom) and 2.6D). Similar results were obtained in HEK293 cells, and in both HeLAs and HEK293
cells live-imaged with the Lysosensor dye (data not shown).
Alkalization of cells with BafA1 was recently reported to result in increased TMEM106B
expression (Lang et al., 2012). We confirmed this finding in HeLA cells (Figure 2.6E) and HEK293
cells (data not shown).

Thus, not only can TMEM106B over-expression impair endosomal-

lysosomal acidification, but impairing the acidification of these organelles can in turn result in
increased expression of TMEM106B.
We sought to determine whether these enlarged, poorly acidified LAMP-1+ organelles
were improperly acidified lysosomes, or late endosomes unable to mature into lysosomes. To do
so, we performed double-label immunofluorescence for LAMP-1 and the cation-independent
mannose-6-phosphate-receptor (M6PR), which is not present on lysosomes, under conditions of
TMEM106B over-expression. In HeLA cells at steady state, the M6PR was found primarily in the
trans-Golgi network (TGN) and did not colocalize extensively with LAMP-1 (Figure 2.6F, top).
However, in cells over-expressing TMEM106B, LAMP-1 and the M6PR co-localized extensively in
enlarged organelles (Figure 2.6F, bottom), suggesting that there may be a block in endosomallysosomal fusion, and, further, that retrograde transport from the late endosome to the TGN is
affected.

Taken together, our data suggest that over-expression of TMEM106B results in

endosomal-lysosomal dysfunction as demonstrated by dramatic abnormalities in late endosomelysosome morphology and acidification, and M6PR trafficking. Moreover, blocking endosomallysosomal function could itself prevent TMEM106B degradation, causing its levels to increase,
further exacerbating these defects.
2.3.6

Over-expression of TMEM106B alters the appearance and compartmentalization of

progranulin
Since progranulin has been previously linked to lysosomes through proteomic identification
of lysosomal contents (Kollmann et al., 2005), we investigated whether TMEM106B and progranulin
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Figure 2.6. Over-expression of TMEM106B results in abnormalities in the endosomallysosomal pathway.
(A) In HeLa cells over-expressing TMEM106B (arrowhead), LAMP-1+ organelles demonstrate a
general increase in size, compared with neighboring cells not over-expressing TMEM106B. In
addition, over-expression of TMEM106B also results in occasional formation of large vacuolar
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structures ~5µm in diameter (asterisks indicate two vacuolar structures in top panel, also pictured
throughout the cytoplasm of cell in bottom panel). While these large vacuolar structures occur only
occasionally with TMEM106B over-expression (the more typical finding is enlarged ~1.5µm LAMP1+ organelles), they are not seen in the absence of TMEM106B over-expression.
(B) Similar results were obtained in HeLas, HEK293 cells, and in the neuronal cell line Neuro2A.
Size quantitation (means +/- SEM) was performed by measuring LAMP-1+ organelle diameter on
>10 40X fields containing a mixture of cells with and without TMEM106B over-expression. Because
the large vacuolar structures are only occasionally seen, they were not included in the quantitation.
(C) HeLa cells over-expressing TMEM106B (arrowhead) showed less intense staining with
Lysotracker, a dye which demonstrates greater fluorescence at lower pH, than neighboring cells
not over-expressing TMEM106B (top). This effect was abrogated by treatment of cells with
bafilomycin A1, an inhibitor of the vacuolar ATPase, which resulted in diminished Lysotracker
fluorescence for all cells (bottom).
(D) Quantitation of mean fluorescence intensity for cells over-expressing TMEM106B
demonstrated that Lysotracker staining was significantly less intense than in neighboring cells with
normal levels of TMEM106B expression. Quantitation (means +/- SEM) was performed on >10
40X fields containing a mixture of cells with and without TMEM106B over-expression.
(E) Immunoblot analysis of HeLa cells treated with the vacuolar ATPase inhibitor bafilomycin A1
(Baf) showed increased intracellular levels of TMEM106B and progranulin. Treatment with the
lysosomal protease inhibitor leupeptin (Leu) increased levels of TMEM106B but did not affect levels
of progranulin. Treatment with the lysosomal protease inhibitor pepstatin A (Pep) did not affect
either protein, while treatment with the proteasome inhibitor MG132 decreased TMEM106B levels.
Representative immunoblot (top) and quantitation of five replicate immunoblots (means +/- SEM,
bottom) are shown. Asterisk indicates TMEM106B 40kD band only seen with leupeptin treatment.
(F) Under normal conditions, the cation-independent mannose-6-phosphate receptor (M6PR) does
not co-localize with LAMP-1. In cells over-expressing TMEM106B, M6PR co-localizes with LAMP1 at the limiting membrane of enlarged LAMP-1+ organelles.
*p<0.05, **p<0.01, ***p<0.001.
All immunofluorescence panels: TMEM106B staining performed with N2077. Scale bar represents
10µm.

are found together in lysosomes.

Indeed, double label immunofluorescence showed that

TMEM106B partially colocalized with progranulin in murine primary cortical neurons (Figure 2.7A).
Moreover, endogenous neuronal TMEM106B and progranulin appeared most co-localized in
neuronal processes, within LAMP-1+ organelles (Figure 2.7B).
Defects in the production or secretion of progranulin are known to cause FTLD-TDP and
among the cases with progranulin mutations, we observed increased mRNA and protein expression
of TMEM106B (Figure 2.2).

Furthermore, progranulin has been reported to internalize via

endocytosis to lysosomes using sortilin-1 as a plasma membrane receptor (Hu et al., 2010), and
our data suggested that TMEM106B over-expression may impair the endosomal-lysosomal
pathway.

Finally, impairment of endosomal-lysosomal acidification, shown here to be an effect of

TMEM106B over-expression, has been reported by others (Capell et al., 2011) to result in
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increased progranulin levels, a finding we confirmed (Figure 2.6E). Thus, we asked what impact
increased TMEM106B expression might have on progranulin.
Intriguingly, over-expression of TMEM106B in HEK293 cells (Figure 2.7C, arrowhead) and
HeLA cells resulted in striking changes in the appearance of progranulin (Figure 2.7C), in addition
to the enlargement of LAMP-1+ organelles. Indeed, ~60% of cells over-expressing TMEM106B
contained intense puncta that colocalized with progranulin, while less than 5% of cells with normal
levels of TMEM106B expression showed this pattern (Figure 2.7D).

In neighboring, non-

transfected cells with normal levels of TMEM106B expression (Figure 2.7C, arrows), progranulin
intracellular staining was much less intense, exhibiting the more diffuse pattern previously reported
in the literature (Shankaran et al., 2008).
These observations suggested that increased expression of TMEM106B might alter the
trafficking of progranulin. We therefore tested the hypothesis that TMEM106B over-expression
would affect levels of intracellular or extracellular progranulin.

As shown in Figure 2.7E,

intracellular progranulin levels significantly increased by ~30% with over-expression of TMEM106B
in HEK293 cells.

In contrast, extracellular progranulin measured in the conditioned medium

remained relatively constant, showing a non-significant slight decrease in the setting of TMEM106B
over-expression. Normalization of progranulin measurements to those of another secreted protein,
IGFBP-2, did not alter these results and in fact increased the apparent differences. Thus, overexpression of TMEM106B increases levels of intracellular progranulin.
Taken together, these data demonstrate that aberrant over-expression of TMEM106B
affects the distribution and intracellular levels of progranulin, suggesting that the two proteins may
act in the same pathogenic pathway in FTLD-TDP.
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Figure 2.7. Over-expression of TMEM106B alters the compartmentalization of progranulin.
Immunofluorescence microscopy (panels A-C) performed on cells stained for TMEM106B (N2077
antibody) and progranulin. Scale bar represents 10µm.
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(A,B) Endogenous TMEM106B (green) in non-transfected primary murine cortical neurons colocalized with progranulin (GRN, red) in the cell body (A, arrowheads), and in processes (B,
arrowheads). TMEM106B and GRN co-localized within late endosomes or lysosomes, as indicated
by LAMP-1 staining (blue, panel B).
(C) Progranulin (GRN, red) appearance changed under conditions of TMEM106B over-expression.
Progranulin formed intensely stained cytoplasmic puncta variably co-localizing with TMEM106B
(green) only in HEK293 cells over-expressing FLAG-tagged TMEM106B (arrowhead). In the
absence of TMEM106B over-expression, progranulin staining was much less intense (arrows).
(D) More than 60% of cells over-expressing TMEM106B showed intense cytoplasmic puncta of
progranulin, compared with <5% of cells with normal levels of TMEM106B expression. Assessment
of progranulin staining pattern performed on six 20X fields of HEK293 cells containing a mixture of
cells with and without TMEM106B over-expression.
(E) Intracellular (left) and extracellular/secreted (right) pools of progranulin were measured by
ELISA under conditions of TMEM106B over-expression (TMEM, white bars) vs. vector transfection
in HEK293 cells. Progranulin measurements (means ±SEM for 5 experiments) were normalized to
total protein in the cell lysate, to account for differential rates of cell growth. Over-expression of
TMEM106B resulted in a 30% increase in intracellular progranulin, with a trend towards decreased
extracellular progranulin. Intracellular progranulin is shown measured at 48 hours after transfection
of TMEM106B. Extracellular progranulin is shown at baseline and indicated time periods after
transfection of TMEM106B. **p<0.01

81

2.4

DISCUSSION
Following our recent GWAS reporting the uncharacterized gene TMEM106B as a risk

factor for FTLD-TDP, here we describe TMEM106B’s genetic regulation and relationship to
progranulin. Specifically, we show that TMEM106B is highly expressed in human brain tissue, with
particularly increased expression in GRN(+) FTLD-TDP. We further demonstrate that FTLD-TDP
(with and without GRN mutations) shows <50% normal expression of three members of the miR132 cluster: miR-132, miR-132*, and miR-212.

Strikingly, miR-132 and miR-212 repress

TMEM106B through two specific sites in the TMEM106B 3’UTR. Having observed increased
TMEM106B expression in FTLD-TDP, and uncovered a possible upstream cause in miR-132/212,
we then explored the consequences of TMEM106B over-expression.

Over-expression of

TMEM106B, which shows steady-state neuronal localization to late endo-lysosomes and colocalizes in these organelles with progranulin, disrupts late endo-lysosome function and
consequently, both the appearance and compartmentalization of progranulin. Taken together, the
data presented in the current study are compatible with a model (Figure 2.8) which illustrates how
decreased levels of miR-132/212 lead to increased TMEM106B expression, perturbation of
progranulin pathways, and increased risk of developing FTLD TDP.
There have been conflicting data regarding the levels of TMEM106B expression in FTLDTDP. In our initial paper (Van Deerlin et al., 2010), we reported that FTLD-TDP patients show
increased expression of TMEM106B mRNA in frontal cortex. Others, however, have not found
significant differences in TMEM106B mRNA expression in FTLD-TDP patients vs. controls (van der
Zee et al., 2011). In the present study, we demonstrate again that TMEM106B expression is
increased in disease states. First, we directly measure human brain TMEM106B at the mRNA and
protein levels, quantifying transcript levels in multiple brain regions; we consistently observe higher
levels of TMEM106B in GRN(+) FTLD-TDP. In addition, we present a second, independent line of
evidence suggesting that TMEM106B expression is aberrantly elevated in FTLD-TDP. Specifically,
we find that miR-132 and miR-212, both computationally predicted and experimentally shown to
negatively regulate TMEM106B, are significantly reduced in GRN(-) and GRN(+) FTLD-TDP brain.
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Figure 2.8. Hypothetical model of causes and effects of TMEM106B over-expression in
FTLD-TDP.
Our data are compatible with a model whereby decreased levels of miR-132/212 result in
increased TMEM106B expression. As a result, increased TMEM106B expression leads to (1)
endosomal-lysosomal dysfunction, which may in turn further increase levels of TMEM106B,
and also to (2) perturbation of progranulin pathways, thereby increasing the risk of developing
FTLD-TDP. Black arrows indicate steps evidenced by the current study, grey arrows indicate
steps reported in the literature, and yellow arrows indicate hypothetical steps.
The expected effect of a reduction in these miRNAs would be de-repression, or over-expression,
of their target mRNA TMEM106B.
In terms of miR-132/212 regulation of TMEM106B, while both miRNAs can decrease
TMEM106B expression, miR-132 may be the dominant miRNA. Specifically, miR-132 levels are
orders of magnitude higher than miR-212 levels in human brain tissue, and only miR-132 elevation
was significantly associated with decrease of TMEM106B in neuronal cells.
The miR-132 cluster – comprised of miR-132, miR-132*, miR-212, and a fourth potential
member, miR-212* – has been previously shown to be important in neuronal development and in
the neurobiology of addictive behavior. Much of the literature has focused on miR-132 and miR212, which are also the only two miRNAs in the cluster that show potential binding to TMEM106B.
Specifically, introduction of miR-132 in primary neuronal cultures has been reported to stimulate
neurite outgrowth through specific effector mRNAs (Vo et al., 2005), and knockdown of the miR132 cluster in newborn hippocampal neurons decreases the length and arborization of dendrites
(Magill et al., 2010). Increasing striatal expression of miR-212 through lentiviral delivery, on the
other hand, has been reported to decrease addictive cocaine-ingestion behavior in rats, while
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inhibition of miR-212 has an opposing effect (Hollander et al., 2010). Both miR-132 and miR-212
appear to be regulated by the transcription factor CREB (Impey et al., 2004), but the connection, if
any, between the neuronal phenotypes observed with miR-132 manipulation and the whole
organism behaviors observed with miR-212 manipulation are unclear. In any case, miR-132 and
miR-212 have been postulated to be the downstream effectors of the phenotypes – including
increased neuronal survival – associated with CREB activation (Magill et al., 2010; Wayman et al.,
2008). Thus, the greatly decreased levels of miR-132 cluster expression observed in FTLD-TDP
may have deleterious effects on neurons beyond the de-repression of TMEM106B.
In addition to demonstrating the miR-132/212 regulation of TMEM106B, our study adds to
a growing body of evidence that TMEM106B and progranulin may be mechanistically related. That
is, TMEM106B genotype has been reported to correlate with plasma levels of progranulin in normal
controls (Finch et al., 2011), and with age at onset in GRN(+) FTLD-TDP (Cruchaga et al., 2011).
Evidence from the current study to support a link between TMEM106B and progranulin includes:
1) increased protein and mRNA expression of TMEM106B in GRN(+) FTLD-TDP cases; 2)
abnormal localization of TMEM106B in neuronal processes in GRN(+) FTLD-TDP cases; 3) colocalization of TMEM106B and progranulin in late endo-lysosomes; and 4) increased accumulation
of intracellular progranulin when TMEM106B is overexpressed.

Indeed, we provide the first

demonstration of a relationship between TMEM106B and progranulin in a model system which can
be directly manipulated. Of note, a prior study (Lang et al., 2012) reported no change in progranulin
levels with over-expression of TMEM106B, a result that contradicts our present result. Various
methodological differences, such as our use of ELISA to measure progranulin, may explain the
discrepancy.
At a more general level, the data presented here strongly support TMEM106B as a risk
gene for FTLD-TDP and the source of the 7p21 signal found by GWAS. First, there is the striking
fact that both miR-132 and TMEM106B emerged as single-best hits from independent, genomicscale screens in FTLD-TDP. Their convergence as a microRNA:mRNA regulatory pair greatly adds
to our confidence that both are real signals and also argues for the centrality of the miR-132/212:
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TMEM106B pathway in this disease. Second, we link TMEM106B to effects on progranulin –
haploinsufficiency of which is a known pathogenic mechanism in FTLD-TDP. In doing so, our data
suggest a clear direction for further mechanistic studies of TMEM106B. It is worth noting that
establishment of whether a GWAS signal is “true” and, additionally, what the causative gene behind
a signal might be, is not always straightforward. Indeed, while additional cohorts of clinical FTLD
(van der Zee et al., 2011) and clinical-pathologic FTLD/FTLD-TDP cases (Finch et al., 2011) have
replicated the association of FTLD with rs1990622 genotype, some clinical cohorts have not
demonstrated this association (Rollinson et al., 2011a), possibly because only ~50% of FTLD
clinical cases have underlying FTLD-TDP.
Future directions suggested by the data presented here include a detailed analysis of the
biochemistry of TMEM106B. Specifically, we have shown that TMEM106B is glycosylated and
heat-sensitive, with both 75kD and 40kD species -- collapsing to ~60kD and 31kD, respectively,
after deglycosylation -- apparent by immunoblotting. However, it is presently unclear whether
TMEM106B, with a predicted molecular weight of 31kD, migrates at the higher molecular weight
because it self-associates into a dimer or because it is complexed to another unknown protein.
Understanding the native complex in which TMEM106B occurs may be important in determining its
molecular function in normal and disease states.
Additionally, the exact molecular mechanisms by which increased expression of
TMEM106B affects progranulin are at present unclear and would be an important direction for
future studies. Several hypotheses are compatible with our data. First, increased TMEM106B
might cause intracellular retention of progranulin, an intriguing possibility since decreased secretion
of progranulin is a known mechanism of FTLD-TDP pathogenesis (Mukherjee et al., 2008;
Shankaran et al., 2008). We note here that while we did not see a significant drop in secreted
progranulin with TMEM106B over-expression, the trend towards decreased extracellular
progranulin was present at every timepoint, and technical limitations such as the high turnover rate
in culture medium may have precluded our ability to see a significant change in levels of secreted
progranulin. Second, increased TMEM106B might increase the internalization of progranulin from
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the extracellular space, in the same way that sortilin-1 over-expression increases progranulin’s
internalization and sorting into lysosomes (Hu et al., 2010). Third, increased TMEM106B may
impair the maturation of lysosomes, as suggested by our observation of enlarged, poorly acidified
organelles expressing both LAMP-1 and the M6PR upon TMEM106B over-expression. This defect
may in turn alter the dynamics of progranulin internalization and turnover, as others have shown
(Capell et al., 2011), and we have confirmed, that blocking lysosomal acidification can increase
levels of progranulin.
In conclusion, we demonstrate here the microRNA regulation of TMEM106B and its effects
on the endosomal-lysosomal pathway and the FTLD-TDP-associated protein progranulin. Our
findings thus open up novel directions for elucidating miRNA-based mechanisms of
neurodegeneration in FTLD-TDP and related TDP-43 proteinopathies that could become targets
for drug discovery in these currently untreatable diseases.
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2.5

METHODS

Human brain samples
Frontal cortex samples from 12 FTLD-TDP cases (5 with GRN mutations and 7 without
GRN mutations) and 6 neurologically normal controls of either sex (see Table 2.1 for details) were
obtained from the University of Pennsylvania Center for Neurodegenerative Disease Research
Brain Bank. Total RNA was isolated and evaluated for quality control parameters as previously
described (Chen-Plotkin et al., 2008), with the exception that a column purification step was not
used, in order to retain small RNAs. Protein was sequentially extracted from a subset of frontal
cortex samples. Informed consent was obtained for postmortem studies.
Of note, some of the frontal cortex samples used for mRNA quantitation were previously
reported in our GWAS study (Van Deerlin et al., 2010); these data were included here so that sets
of data from multiple brain regions included the same samples.
MicroRNA screening and QRT-PCR validation.
1µg of total RNA from each individual brain sample, as well as 1µg of a pooled reference
sample, was hybridized to the miRCURY LNA array version 11.0 (Exiqon, Copenhagen) for
microRNA quantitation. No microRNA enrichment was needed, as concentrations of miRNAs were
high. Statistical analyses of miRNA expression were performed using open source R software
packages available from Bioconductor and specifically the limma package for two-color arrays.
Microarray QC was performed as previously described (Chen-Plotkin et al., 2008); no outlier chips
were identified for elimination. Raw data were RMA normalized (Wettenhall and Smyth, 2004), and
median values for each microRNA were used to compare groups using pairwise contrasts within
an ANOVA (Analysis of Variance) model correcting for gender and age. R-scripts for these
analyses are available on request. Promising candidate microRNAs found by array screening to
differ in disease were evaluated using QRT-PCR with TaqMan microRNA assays from Applied
Biosystems (AB Assay ID 000457, AB Assay ID 002132, AB Assay ID 000515); microRNAs were
normalized to either the geometric mean of two housekeeping small RNAs (human let-7a, AB
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Assay ID 000377; human RNU38b, AB Assay ID 001004) or a neuron-specific microRNA (human
miR-124a, AB Assay ID 000446).
QRT-PCR was also used for transcript quantitation for TMEM106B and other mRNAs of
interest as previously described (Chen-Plotkin et al., 2008). Relative quantification was performed
(delta-delta method) using ß-actin and/or PPIA as our reference housekeeping gene after
verification that these transcripts remain constant in the experimental conditions used.
SNP genotyping
DNA was extracted from brain samples and genotyping was performed using TaqMan
chemistry-based allelic discrimination assays as previously described (Van Deerlin et al., 2010).
MicroRNA target prediction and verification
The TargetScan program (release 5.1, http://www.targetscan.org) was used to predict
targets of specific microRNAs and specific microRNA regulators of TMEM106B. To verify the
predicted regulation of TMEM106B by miR-132 or miR-212, we performed three types of assays.
First, in an endogenous TMEM106B assay, HEK293 cells were plated one day before
transfection at 2 x 105 per well in 12-well plates. The following day, 75pmoles of miRNA mimic
(miR-132, Applied Biosystems PM10166; miR-212, Applied Biosystems PM10340; miR-124
Applied Biosystems PM 10691) were transfected using Lipofectamine 2000 (Invitrogen) according
to manufacturer’s instructions in serum-free conditions. Medium was replaced after 4-6 hours to
standard 10% FBS-containing medium.

Appropriate amounts of microRNA mimics were

determined empirically by testing a range of concentrations. 48 hours after transfection, cells were
harvested, and total RNA was isolated using the miRNeasy kit (Qiagen) before quantitation by
QRT-PCR.
Second, TMEM106B constructs containing the full 3’UTR, or lacking various portions of the
3’UTR were cloned into a commercially available construct (TMEM106B construct, Origene
SC113580). For miR-132/212 Site 1 and 2 deletions, the seed match region (red nucleotides on
the 3’ end of sequences shown in Figure 4A) was deleted. 4µg of the relevant TMEM106B
construct was transfected into each well of a 6-well plate. RNA and protein were harvested at 48
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hours after transfection. For protein studies, cells were lysed in RIPA buffer with protease inhibitors
and PMSF on ice, and lysates were centrifuged (16,000xg, 4°C, 15min) to remove debris, before
downstream immunoblotting.
Third, luciferase reporter constructs were created adding 35-40bp of TMEM106B 3’UTR
sequence including and flanking the relevant miR-132/212 binding sites to the 3’UTR regulatory
region of a commercially available dual-luciferase reporter (pmiRGLO Vector, Promega).

In

addition, mutated versions of these same constructs, containing the same 35-40bp in a scrambled
order to abrogate miR-132/212 binding, were also cloned into the luciferase reporters in a similar
manner. For miR-132/212 Site 1, the following sequence (flanking regions plus miRNA binding
sites,

with

miRNA

binding

site

in

bold)

was

inserted:

CTAGTGAGATGGTGGAGTAAAAAGACTGTTAAACATTGCA. For miR-132/212 Site 1 mutated
sequence, the following sequence (flanking regions plus scrambled miRNA binding sites, with
scrambled

miRNA

binding

site

in

bold)

CTAGTGAGATAGGGGTGAATACAATGAGCTTAACATTGCA.

was

inserted:

For miR-132/212 Site 2, the

following sequence (flanking regions plus miRNA binding sites, with miRNA binding site in bold)
was inserted: CTAGTATTACTACCATGTAGACTGTTATAGTTTGCA.

For miR-132/212 Site 2

mutated sequence, the following sequence (flanking regions plus scrambled miRNA binding sites,
with

scrambled

miRNA

binding

site

in

CTAGTATTAGTACTACGTACAGGTATTTAGTTTGCA.

bold)

was

inserted:

These constructs were then co-

transfected into HEK293 cells with microRNA mimics as described above. 50ng of the relevant
luciferase reporter construct was co-transfected. 24 hours after transfection, lysates were prepared
according to instructions from the Dual Luciferase Assay kit (ProMega) and read on a Berthold
LB941 TriStar vTI Multimode Reader.
TMEM106B antibodies
An

N-terminus

peptide

corresponding

to

amino

acid

residues

4-19

(SLSHLPLHSSKEDAYDC) was synthesized and used to immunize rabbits, and site-specific IgG
was affinity-purified with an N-terminus peptide column. The resulting antibody was named N2077.
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Antibody specificity was verified with immunoblots and immunofluorescence microscopy (Figure
1). Peptide preabsorption was performed with a 5:1 (by weight) ratio of immunizing peptide to
N2077 antibody, incubated overnight at 4°C, with rotation.
In addition, we tested commercially available antibodies against TMEM106B raised against
N-terminus amino acids 1-50 (Bethyl Laboratories, Montgomery, TX) and against the C-terminus
of the protein (Proteintech, Chicago, IL).

Neither antibody demonstrated specificity in

immunocytochemical experiments (data not shown), but the N-terminus antibody recognized the
same bands as N2077 on immunoblot (Figure 2.1D) and was used to confirm key biochemical
findings.
Cell culture and transfection
Primary cortical and hippocampal neurons were prepared from embryonic day 18 (E18) to
E20 C57BL/6 mice, plated, and maintained as previously described (Tseng et al., 2006). In
addition, HEK293 and SHSY5Y cells were maintained and used for experiments. Where indicated,
cells were transfected with the respective construct(s) using Lipofectamine-2000 (Invitrogen) one
day after plating (50-70% confluency) according to manufacturer instructions; transfections were
performed under serum-free conditions. SHSY5Y cells were neuronally differentiated prior to their
use in experiments as previously described (Remenyi et al., 2010). Neuro2A cells were neuronally
differentiated directly after transfection for 48 hours prior to their use by incubation in neurobasal
media (Gibco catalog # 1208) with B27 (Gibco catalog #1209) together with complete DMEM in a
1:1 ratio in an adaption of a previously described protocol (Ishikura et al., 2005).
Treatment of cells with lysosomal and proteosomal inhibitors
Cells were treated with the vacuolar ATPase inhibitor bafilomycin A1, lysosomal protease
inhibitors Pepstatin A or Leupeptin, proteosomal inhibitor MG132, or control DMSO as previously
described (Capell et al., 2011), with the exception that Leupeptin was not used in a mix but rather
alone at a concentration of 1µM.
Immunofluorescence microscopy
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Cells were fixed (2% paraformaldehyde, 15min, RT), washed five times with PBS, and then
blocked for 60 minutes at room temperature in blocking buffer (3% BSA, 0.05% saponin, in PBS).
Primary antibodies were diluted in blocking buffer, and coverslips were incubated overnight at 4°C.
The next day, coverslips were washed four times with blocking buffer before incubation with
secondary antibody. Secondary antibodies were diluted in blocking buffer, and coverslips were
incubated for 1 hour at room temperature protected from light. Following this incubation, coverslips
were washed five times with blocking buffer, once with PBS, and then mounted on slides (ProLong
Gold, Invitrogen).
The following antibodies and conditions were used. TMEM106B: N2077 antibody (see
“TMEM106B antibodies”) was used at 1μg/mL. FLAG: M2 antibody (Sigma) was used at 1 µg/mL.
Progranulin: goat anti-human GRN (R&D Systems) was used at 1 µg/mL, and sheep anti-mouse
GRN (R&D Systems) was used at 1 µg/mL. TDP-43: N171 antibody (mouse monoclonal antibody
generated at University of Pennsylvania (Lippa et al., 2009)) was used at 1 µg/mL. Mannose-6phosphate receptor (M6PR, cation-independent): mouse anti-human M6PR (Catalog number
ab2733, Abcam, Cambridge, MA) was used at 2 µg/mL. LAMP-1: mouse anti-human H4A3 (DSHB,
Iowa City, IA) and mouse anti-human CD107A (Catalog number 555798, BD Biosciences, San
Jose, CA) were used at 1 µg/mL; rat anti-mouse 1D4B (DSHB, Iowa City, IA) was used at 1 µg/mL.
GM130: mouse GM130 antibody recognizing human, mouse, and rat GM130 (BD Biosciences, San
Jose, CA) was used at 1.25 µg/mL.

All secondary antibodies were Alexa Fluor antibodies

(Invitrogen, Carlsbad, CA) used at 1:1000, with the exception of an AMCA anti-mouse IgG (Vector
Labs, Burlingame, CA) used at 1:100.
Lysosensor and Lysotracker staining
The weak base dyes Lysosensor DND-189 (Invitrogen, Carslbad, CA) and Lysotracker
DND-99 (Invitrogen, Carlsbad, CA) were used to assess the acidity of intracellular organelles, since
they both fluoresce intensely at low pH, and more weakly or not at all at higher pH. Live cells were
incubated with Lysosensor (1µM, 30 minutes, 37ºC) or with Lysotracker (100nM, 2 hours, 37ºC).
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Lysosensor-stained cells were imaged live immediately in 4ºC PBS. Lysotracker-stained cells were
imaged live in 4ºC PBS or fixed and stained for immunofluorescence microscopy as above.
Quantification of LAMP-1+ organelle size, Lysosensor/Lysotracker mean fluorescence
intensity, and progranulin staining appearance
LAMP-1+ organelle size: An average of twelve fields containing a representative
heterogenous mixture of cells with and without TMEM106B over-expression after transient
transfection were captured at 40X magnification after staining for LAMP-1 and TMEM106B. The
diameter of LAMP-1+ organelles was measured for an average of three TMEM106B overexpressing and three TMEM106B non-over-expressing cells per field, and average diameters (+/SEM) were calculated for cells with and without TMEM106B over-expression. TMEM106B overexpressing cells occasionally contained very large vacuolar LAMP-1+ organelles; these were not
included in the quantitation.
Lysosensor/Lysotracker mean fluorescence intensity: An average of eleven fields
containing a representative heterogeneous mixture of cells with and without TMEM106B overexpression after transient transfection were captured at 40X magnification after staining for
TMEM106B and the indicated pH-sensitive dye. The cytoplasmic compartment was outlined as a
region of interest for measures of mean fluorescence intensity (MFI) in the Lysosensor or
Lysotracker channel. An average of two TMEM106B over-expressing and three TMEM106B nonover-expressing cells per field were quantitated for MFI, and average MFIs (+/- SEM) were
calculated for cells with and without TMEM106B over-expression.
Progranulin staining appearance: Six fields containing a representative heterogeneous
mixture of cells with and without TMEM106B over-expression after transient transfection were
imaged at 20X magnification after staining for TMEM106B and progranulin. The presence or
absence of intense puncta of progranulin staining was then scored for an average of 14
TMEM106B-over-expressing cells and >50 TMEM106B-non-over-expressing cells per field.
Protein preparation and immunoblotting
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Where indicated, sequential biochemical fractionation of cell lysates or postmortem human
brain samples was performed. Samples were sequentially extracted in buffers of increasing
strength: High-salt (10 mM Tris, 500 mM NaCl, 2 mM EDTA, 1mM DTT, 10% sucrose, pH 7.5),
RIPA (50 mM Tris, 150 mM NaCl, 5mM EDTA, 0.5% sodium deoxycholate, 1% NP-40, 0.1%
sodium dodecyl sulfate [SDS], pH 8.0), and 2% SDS. Since most TMEM106B is extractable in
RIPA with a small fraction in High-salt, we extracted directly into RIPA for routine biochemical
experiments unless otherwise indicated. Immunoblotting was performed as previously described
(Neumann et al., 2006).
Enzyme-linked immunosorbent assay (ELISA)
Sandwich ELISAs were used for measurement of progranulin and the control secreted
protein IGFBP-2 from cell culture lysates and conditioned medium.

Specifically, progranulin

quantification was performed using a commercially available ELISA (Human progranulin ELISA kit,
AdipoGen, Korea). IGFBP-2 quantification was also performed using a commercially available
ELISA (Human IGFBP-2 ELISA kit, RayBiotech, Inc, USA).
For the progranulin secretion assay, 50µL samples of conditioned medium were removed
from each cell culture well (containing a total of 1mL of medium) at designated time intervals after
transfection. At the last time point (48 hours), a 50µL conditioned medium sample was collected,
the remaining medium was removed, cells were washed once with PBS, and cell lysates were then
extracted in RIPA buffer as described in the preceding section.
Statistical tests
Two-tailed t-tests were used, unless confirming a specific directionality of change (e.g.
QRT-PCR verification of microarray results), in which case one-tailed t-tests were used. Statistical
analysis of microarray data was performed as described in “MicroRNA screening and QRT-PCR
validation” section. For BDNF treatment experiments in SHSY5Y cells, linear regressions were
used to evaluate the correlation of miRNA levels with target mRNA levels, adjusting for time point
of measurements and the interaction of miRNA effect with time. For repeated measurements of
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extracellular progranulin over time, repeated measures two-way ANOVA was used to evaluate the
effect of increased TMEM106B expression.
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CHAPTER 3: TMEM106B IS A GENETIC MODIFIER OF FRONTOTEMPORAL
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by
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Analyses for genetic modifier effects and progranulin assays were completed by Michael
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95

3.1

ABSTRACT
Hexanucleotide repeat expansions in chromosome 9 open reading frame 72 (C9orf72)

have recently been linked to frontotemporal lobar degeneration (FTLD) and amyotrophic lateral
sclerosis (ALS), and may be the most common genetic cause of both neurodegenerative diseases.
Genetic variants at TMEM106B influence risk for the most common neuropathological subtype of
FTLD, characterized by inclusions of TAR DNA binding protein of 43kDa (FTLD-TDP). Previous
reports have shown that TMEM106B is a genetic modifier of FTLD-TDP caused by progranulin
(GRN) mutations, with the major (risk) allele of rs1990622 associating with earlier age at onset of
disease. Here we report that rs1990622 genotype affects age at death in a single-site discovery
cohort of FTLD patients with C9orf72 expansions (n=14), with the minor allele correlated with earlier
age at death (p=0.024). We replicate this modifier effect in a 30-site international neuropathological
cohort of FTLD-TDP patients with C9orf72 expansions (n=75), again finding that the minor allele
associates with earlier age at death (p=0.016), as well as earlier age at onset (p=0.019). In
contrast, TMEM106B genotype does not affect age at onset or death in 241 FTLD-TDP cases
negative for GRN mutations or C9orf72 expansions. Thus, TMEM106B is a genetic modifier of
FTLD with C9orf72 expansions.

Intriguingly, the genotype that confers decreased risk for

developing FTLD-TDP (minor, or C, allele of rs1990622) is associated with earlier age at onset and
death in C9orf72 expansion carriers, providing an example of sign epistasis in human
neurodegenerative disease.
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3.2

INTRODUCTION
Frontotemporal lobar degeneration (FTLD) is the second most common dementia in

individuals under 65 years of age (Seelaar et al., 2011). The most common neuropathological
subtype is frontotemporal lobar degeneration with TAR DNA-binding protein of 43kDa (TDP-43)
inclusions (FTLD-TDP) (Seelaar et al., 2011). We previously reported the minimally characterized
gene, TMEM106B, as a risk factor for FTLD-TDP by genome-wide association study (GWAS) (Van
Deerlin et al., 2010), and this association has been verified independently (Finch et al., 2011; van
der Zee et al., 2011). In our GWAS, three SNPs reached genome-wide significance for association
with FTLD-TDP (Van Deerlin et al., 2010); all are located within a 36kb haplotype block that
contains TMEM106B and no other genes. The major alleles of all three SNPs are associated with
increased risk of FTLD-TDP (P=1.08x10-11, odds ratio=1.64 for rs1990622, the top GWAS SNP)
(Van Deerlin et al., 2010).
Several studies have begun to elucidate the role TMEM106B plays in FTLD-TDP.
TMEM106B levels have been shown to be increased in FTLD-TDP brains (Chen-Plotkin et al.,
2012; Van Deerlin et al., 2010), and risk-associated alleles resulting in amino acid variation in the
TMEM106B protein have been reported to result in higher steady-state levels of TMEM106B
through slower protein degradation (Nicholson et al., 2013).

In addition, the major allele of

rs1990622 has been associated with reduced plasma progranulin (PGRN) levels in both healthy
individuals and in individuals with FTLD-TDP caused by mutations in the gene encoding
progranulin, GRN (Cruchaga et al., 2011; Finch et al., 2011). Mutations in GRN are a major cause
of familial FTLD-TDP (Gass et al., 2006), and are thought to cause disease via haploinsufficiency
of the progranulin protein (Gass et al., 2006; Shankaran et al., 2008). Interestingly, among GRN
mutation carriers with FTLD (GRN+ FTLD), TMEM106B risk alleles have been reported to
associate with earlier age at disease onset (Cruchaga et al., 2011). Experiments in cell culture
systems have also demonstrated that TMEM106B and PGRN co-localize in several cell types,
including neurons, and that overexpression of TMEM106B alters intra- and extracellular levels of
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PGRN (Brady et al., 2013; Chen-Plotkin et al., 2012; Nicholson et al., 2013). Therefore, increased
expression of TMEM106B may confer risk for FTLD-TDP by altering PGRN levels.
While GRN mutations account for ~5% of clinical FTLD cases (Gass et al., 2006), and other
rarer, monogenic causes of FTLD are known (including mutations in MAPT, CHMB2B and VCP)
(Hutton et al., 1998; Skibinski et al., 2005; Watts et al., 2004), the majority of familial cases were
until recently of unknown cause. This changed in late 2011 when two groups reported that
hexanucleotide repeat expansions in the C9orf72 gene are perhaps the most common cause of
familial FTLD, familial amyotrophic lateral sclerosis (ALS), and familial FTLD with motor neuron
disease (FTLD-MND) (DeJesus-Hernandez et al., 2011; Renton et al., 2011). Although these
mutations display an autosomal dominant mode of inheritance, 3-6% of apparently sporadic cases
of FTLD and ALS harbor C9orf72 expansions as well (DeJesus-Hernandez et al., 2011; Renton et
al., 2011).
The function(s) of C9orf72 and its role in disease are currently areas of ongoing research
(Cruts et al., 2013), with evidence for both loss-of-function (Ciura et al., 2013; DeJesus-Hernandez
et al., 2011; Gijselinck et al., 2012; Renton et al., 2011) and gain-of-toxic-function (Ash et al., 2013;
Fratta et al., 2012; Mori et al., 2013) mechanisms. At a neuropathological level, C9orf72 expansion
positive FTLD (C9orf72+ FTLD) and ALS (C9orf72+ ALS) cases exhibit TDP-43 pathology
reminiscent of GRN+ FTLD, as well as mutation-negative ALS and FTLD, although C9orf72+ FTLD
and ALS cases show unique pathological features as well (Boxer et al., 2011; Snowden et al., 2012;
Stewart et al., 2012).
Here, we assess whether TMEM106B risk genotypes exert a genetic modifier effect in
C9orf72+ FTLD and ALS, GRN+ FTLD, and FTLD cases without either mutation.

We also

investigate whether these genotypes are associated with disease status in C9orf72+ FTLD and
with plasma progranulin levels in C9orf72+ expansion carriers.
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3.3

RESULTS

3.3.1

TMEM106B genotype at rs1990622 influences age at death in a discovery cohort of

C9orf72+ FTLD
TMEM106B genotype has been shown to demonstrate a genetic modifier effect in FTLDTDP caused by autosomal dominant mutations in the progranulin gene (GRN) (Cruchaga et al.,
2011). We therefore asked whether genetic variation at TMEM106B influences age at death or
age at onset in C9orf72+ FTLD or ALS disease cases. We assumed a codominant model for these
initial analyses.
In C9orf72+ FTLD (n=14), age at death was significantly correlated with TMEM106B
genotype at rs1990622, the SNP previously found in our GWAS to associate most strongly with
FTLD-TDP risk (P=0.024, Table 3.1). Adjusting for sex and presence/absence of co-existing MND
did not affect this association. Moreover, the direction of association was surprising; specifically,
the minor allele of rs1990622 (C) was associated with earlier age at death in C9orf72+ FTLD. In
our prior GWAS, the minor allele of rs1990622 was found to be protective against the development
of FTLD.
In contrast, rs1990622 genotype did not affect age at death in C9orf72+ ALS (n=39, Table
3.1).

In this discovery cohort, rs1990622 genotype did not affect age at onset for C9orf72

expansion carriers who presented with either ALS (n=47) or FTLD (n=26). However, a statistically
significant association emerged when we performed a multivariate analysis controlling for gender
and presence of FTD in the clinical ALS cases, with the major allele associating with earlier age at
onset (n=47, Table 3.1).
3.3.2

TMEM106B genotype at rs1990622 influences age at onset and age at death in a

replication cohort of C9orf72+ FTLD
We sought to replicate the genetic modifier effect of TMEM106B in C9orf72+ FTLD in an
independent cohort of patients. Since the majority of cases from our prior FTLD-TDP GWAS had
been screened for the presence of C9orf72 expansions, these cases provided an ideal replication
cohort to evaluate the effect of TMEM106B rs1990622 genotype on age at death in C9orf72+ FTLD
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Disease

Outcome

Predictors

FTLD and
FTLD-TDP

Age at Death
(n=14)

rs1990622
rs1990622,
Sex, MND
rs1990622
rs1990622,
Sex, MND
rs1990622
rs1990622,
Sex, FTD
rs1990622
rs1990622,
Sex, FTD

Age at Onset
(n=26)
Age at Death
(n=39)

ALS

Age at Onset
(n=47)

Beta
(rs1990622,
each minor
allele)
-6.278
-5.297

R2 for
model

P-value
(rs1990622)

0.303
0.393

0.024 *
0.049 *

n.s.
n.s.
n.s.
n.s.
4.264
4.900

0.044
0.075

0.085 n.s.
0.048 *

Table 3.1. TMEM106B genotype affects age at death in C9orf72 expansion carriers with
FTLD or FTLD-TDP in a discovery cohort.
Linear regressions were used to evaluate the effect of TMEM106B genotype at rs1990622 on the
age at death or age at onset in C9orf72 expansion carriers from a discovery cohort. In individuals
who presented with clinical FTLD or FTLD-TDP, rs1990622 genotype was significantly associated
with age at death in both univariate models and models adjusting for age and presence/absence
of motor neuron disease (MND). In individuals who presented with ALS, rs1990622 genotype was
not significantly associated with age at death, with a trend towards association with age at onset.
Asterisks denote significance.

for three key reasons. First, since the FTLD-TDP GWAS predated the discovery of C9orf72
expansions as a cause of FTLD, this large, international cohort was unbiased in enrollment with
respect to C9orf72 status. Second, all cases were neuropathologically confirmed to have FTLDTDP, ensuring neuropathological homogeneity. Third, because all cases had undergone genomewide genotyping, we could be certain that cases did not have cryptic familial relationships with one
another.
As shown in Table 3.2, rs1990622 genotype was again correlated with age at death in this
cohort (n=75), in both univariate analyses (P=0.016) and linear regression models adjusting for sex
and the presence or absence of MND (P=0.019). Moreover, in this larger replication cohort,
rs1990622 genotype was also correlated with age at onset (n=68 with age at onset data, P=0.019
for univariate analyses and P=0.032 for multivariate analyses adjusting for sex and presence or
absence of MND). Consistent with the results from our discovery cohort, the minor allele (C) of
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Disease

Outcome

Predictors

FTLD-TDP

Age at Death
(n=75)

rs1990622
rs1990622,
Sex, MND
rs1990622
rs1990622,
Sex, MND

Age at Onset
(n=68)

Beta
(rs1990622,
each minor
allele)
-3.342
-3.413

R2 for
model

0.048
0.032

P-value
(rs1990622)

0.016 *
0.019 *

-3.473
-3.198

Table 3.2. TMEM106B genotype affects age at death and age at onset in C9orf72 expansion
carriers in a multi-site FTLD-TDP replication cohort.
Linear regressions were used to evaluate the effect of TMEM106B genotype at rs1990622 on the
age at death or age at onset in C9orf72+ FTLD from a multi-site replication cohort of FTLD-TDP
cases. Rs1990622 genotype was significantly associated with both age at death and age at onset,
in both univariate models and models adjusting for age and presence/absence of motor neuron
disease (MND). Asterisks denote significance.

rs1990622 was associated with earlier age at death, as well as earlier age at onset. Indeed,
patients showed earlier disease onset and earlier death by more than three years for each
additional minor allele at rs1990622 carried.
We further examined this genetic modifier effect using Kaplan-Meier survival analyses
performed on the combined cohort (discovery plus replication, n=89 for age at death analysis, n=94
for age at onset analysis) of C9orf72+ FTLD cases.

As shown in Figure 3.1, TMEM106B

genotypes at rs1990622 were significantly associated with age at death (Figure 3.1A, P=0.046,
log rank test for trend), with a trend towards association for age at onset (Figure 3.1C, P=0.064) in
this combined cohort. In addition, we observed that the curve separation between rs1990622 minor
allele homozygotes (CC) and heterozygotes (TC) was greater than the separation between
heterozygotes (TC) and major allele homozygotes (TT). We therefore re-analyzed our data under
a major-allele dominant model for rs1990622 and observed a stronger effect of TMEM106B
genotype on age at death (p=0.041, log rank test for trend) and age at onset (P=0.037, log rank
test for trend) in C9orf72+ FTLD. Indeed, at any given age, CC homozygotes at rs1990622 had
more than twice the risk of manifesting disease (Figure 3.1D, HR 2.022, 95% CI 1.042-3.925), and
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Figure 3.1. TMEM106B genotype influences age at death and age at onset in C9orf72+
FTLD.
All survival analyses were performed in 104 total C9orf72+ FTLD cases, from the combined
discovery and replication cohorts. Of these 104 total cases, 89 had available age-at-death
data, and 94 had age-at-onset data.
(A) Age at death was significantly associated with TMEM106B genotype at rs1990622, the top
SNP associated with FTLD-TDP in our prior GWAS. Log rank test for trend two-tailed p=0.046,
assuming a codominant model.
(B) Under a major-allele-dominant model, TMEM106B rs1990622 genotype was even more
significantly associated with age at death, with more than twice the risk of death at any given
age for CC carriers compared to carriers of one or more T alleles (two-tailed P=0.041,
HR=2.039, 95% CI 1.031-4.033).
(C) Age at onset showed a trend towards association with TMEM106B genotype at rs1990622.
Log rank test for trend two-tailed P=0.064, assuming a codominant model.
(D) Under a major-allele-dominant model, TMEM106B rs1990622 genotype showed a
significant association with age at disease onset, with more than twice the risk of disease onset
at any given age for CC carriers compared to carriers of one or more T alleles (two-tailed
P=0.037, HR=2.022, 95% CI 1.042-3.925).
more than twice the risk of death (Figure 3.1B, HR 2.039, 95% CI 1.031-4.033), compared to other
genotypes.
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3.3.3

TMEM106B genotype does not exert a genetic modifier effect in C9orf72 expansion

negative FTLD-TDP cases
We next asked whether the TMEM106B genetic modifier effect observed for C9orf72+
FTLD extended to FTLD-TDP cases without C9orf72 expansions, again using FTLD-TDP cases
from the FTLD-TDP GWAS for which C9orf72 and/or GRN mutation status was known. We
considered cases with and without GRN mutations separately.
As shown in Figure 3.2A, TMEM106B rs1990622 genotype did not affect age at death in
FTLD-TDP cases without C9orf72 expansions or GRN mutations (n=241). In the subset of GRNrelated FTLD-TDP (n=116, Figure 3.2B), only one rs1990622 CC individual had age at death
information available, so we could only compare TT and TC individuals, who did not differ
significantly in age at death. Similar results were obtained for age-at-onset analyses (data not
shown).
3.3.4

TMEM106B genotype is associated with FTLD-TDP in C9orf72 expansion carriers
The observed genetic modifier effect for TMEM106B in C9orf72+ FTLD is surprising in its

direction. Specifically, the rs1990622 minor allele associated with decreased risk of FTLD-TDP by
GWAS is correlated with younger age at onset and death among C9orf72+ FTLD cases, implying
a deleterious effect in this mutation subgroup. We therefore examined TMEM106B rs1990622
allele frequencies in 116 GRN+ FTLD cases, 80 C9orf72+ FTLD cases, and 241 FTLD-TDP cases
in which mutations in GRN and expansions in C9orf72 had been excluded. As with the age-atonset and age-at-death analyses, FTLD-TDP cases were from our prior FTLD-TDP GWAS,
although numbers in each group are slightly higher because individuals with genotypes but lacking
age-at-death or age-at-onset data could be included.

As shown in Table 3.3, TMEM106B

rs1990622 genotype was significantly associated with FTLD-TDP in all three subgroups, with the
same direction of association. In each case, the major allele of rs1990622 was enriched in disease.
3.3.5

TMEM106B genotype is not associated with plasma progranulin levels in C9orf72

expansion carriers
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Figure 3.2 TMEM106B genotype does not affect age at death or age at onset for FTLDTDP without C9orf72 expansions.
(A) In 241 FTLD-TDP cases negative for GRN mutations or C9orf72 expansions, TMEM106B
genotype at rs1990622 did not affect age at death.
(B) In 116 FTLD-TDP cases with GRN mutations, we found no significant difference in age at
death comparing TT and TC carriers at rs1990622. In this cohort, only one individual had the
CC genotype, precluding our ability to evaluate the influence of this genotype.
(C) Plasma progranulin levels were measured in a convenience subset of 24 C9orf72
expansion carriers by ELISA. Progranulin levels did not differ significantly by TMEM106B
rs1990622 genotype, although the TT carriers exhibited significantly less variance in their
progranulin levels. Black dots indicate individuals who presented with ALS, while red dots
indicate individuals who presented with FTLD.
TMEM106B genotype has been reported to influence plasma progranulin levels in healthy
individuals and GRN+ FTLD, with the rs1990622 minor allele associated with increased progranulin
expression. We evaluated whether this relationship was also true in C9orf72 expansion carriers.
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Disease status

N

rs1990622
Major allele
T

rs1990622
Minor allele
C

P-value

Normal

2509

0.564

0.436

-

GRN+ FTLD-TDP

116

0.776

0.224

<0.0001

C9orf72+ FTLD-TDP

80

0.669

0.331

0.008

FTLD-TDP (no mutation)

241

0.640

0.360

0.001

Table 3.3. TMEM106B rs1990622 genotype is associated with FTLD-TDP in all genetic
subgroups.
Chi-square tests were performed to evaluate for association between disease and rs1990622
genotype for FTLD-TDP subgroups defined by the presence of GRN mutations (GRN+ FTLD-TDP),
presence of C9orf72 expansions (C9orf72+ FTLD-TDP), or the absence of both genetic mutations
(FTLD-TDP (no mutation)). The major allele was significantly associated with disease in all three
subgroups. Allele frequencies for normal controls provided here are from our previously published
GWAS.

In a convenience subset of 24 C9orf72 expansion carriers (20 with C9orf72+ ALS and 4
with C9orf72+ FTLD) from the UPenn discovery cohort for whom we had plasma samples, we
measured progranulin levels using an enzyme-linked immunosorbent assay (ELISA). As shown in
Figure 3.2C, there were no significant differences in plasma progranulin levels comparing C9orf72
expansion carriers with TT, TC, and CC genotypes at rs1990622. Adjusting for sex and age at
plasma sampling or duration of disease did not affect this result. Additionally adjusting for clinical
manifestation as FTLD or ALS did not affect this result.
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3.4

DISCUSSION
In the current study, we find that TMEM106B is a genetic modifier for C9orf72+ FTLD,

demonstrating a significantly earlier age at death for TMEM106B rs1990622 minor allele (C)
carriers. This effect appears to be specific to C9orf72+ FTLD, since C9orf72-expansion-negative
FTLD cases do not differ in age at death depending on rs1990622 genotype.

Finally, among

C9orf72 expansion carriers, we do not see a clear effect of rs1990622 genotype on plasma
progranulin levels.
We observe that TMEM106B genotypes exert a genetic modifier effect in C9orf72+ FTLD.
Examples of common risk variants acting as genetic modifiers in Mendelian subgroups of disease
are increasingly being described. In the field of neurodegeneration, one well-known example is the
age-at-onset modifying effect of Apolipoprotein E (APOE) isoform in PSEN2-related-Alzheimer's
Disease (Wijsman et al., 2005). Moreover, in GRN+ FTLD, TMEM106B has been reported as a
genetic modifier affecting both age-at-onset and circulating levels of progranulin (Cruchaga et al.,
2011; Finch et al., 2011).
What is more unusual in this case is the direction of the genetic modifier effect. Specifically,
the TMEM106B allele that is associated with decreased risk of developing FTLD-TDP (Van Deerlin
et al., 2010) (and later age at onset in GRN+ FTLD (Cruchaga et al., 2011)) appears to accelerate
the disease phenotype (associating with earlier age at death and onset) in C9orf72+ FTLD. This
effect may be an example of the general phenomenon of sign epistasis, in which a genetic variant
is beneficial on some genetic backgrounds but deleterious in others. Sign epistasis has been
demonstrated in lower organisms such as bacteria (Silva et al., 2011), but may certainly generalize
to higher organisms as well (Kern and Kondrashov, 2004; Kondrashov et al., 2002). In the few
reported empirically-derived examples of sign epistasis, the two (or more) genetic loci involved
converge mechanistically in, for example, antibiotic resistance pathways (Schenk et al., 2013) or
enzyme-substrate interactions (Zhang et al., 2012).

Thus, the observed epistasis between

TMEM106B and C9orf72 suggests that these two proteins may have convergent functions in the
pathophysiology of FTLD-TDP. Intriguingly, TMEM106B has been linked to endosomal-lysosomal
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pathways (Brady et al., 2013; Chen-Plotkin et al., 2012; Lang et al., 2012; Nicholson et al., 2013).
The largely uncharacterized protein C9orf72 is structurally related to DENN protein family members
(Levine et al., 2013). DENN proteins function in the regulation of Rab GTPases, which in turn
regulate the many membrane trafficking events needed for proper function of the endosomallysosomal pathway.
We note that TMEM106B rs1990622 genotypes differ in allelic frequencies between
C9orf72+ FTLD-TDP and normal controls; this situation in which a common variant shows allelic
association with disease even in a monogenic, highly-penetrant subgroup of disease has been
reported in GRN+ FTLD-TDP as well (Finch et al., 2011; Van Deerlin et al., 2010). In the case of
the GRN mutants, a potential explanation may lie in ascertainment bias, since TMEM106B risk
variant carriers may manifest disease at an earlier age (Cruchaga et al., 2011), making it more
likely for them to be included in a cross-sectional sampling of diseased individuals. Such an
argument cannot explain our current result, however, since the rs1990622 major allele (found by
genome-wide association to be enriched in FTLD-TDP) appears to delay age at death and age at
onset in C9orf72+ FTLD cases.

An alternate explanation may lie in the fact that C9orf72

expansions have a broad range of phenotypic expression, manifesting as ALS, FTLD, or a
syndrome combining both motor neuron disease and dementia. We have previously shown that
ALS patients who are major allele carriers at rs1990622 are more likely to demonstrate cognitive
impairment (Vass et al., 2011). Thus, it is possible that TMEM106B genotype modulates the
phenotypic expression of C9orf72 expansions, with rs1990622 major allele carriers more likely to
manifest clinically with dementia.

Whether an effect of directing regional pathology towards

cognitive regions rather than motor regions also underlies the apparently protective effect on age
at death for TMEM106B rs1990622 major allele carriers with C9orf72 expansions remains to be
seen.
It is notable that we were able to replicate the genetic modifier effect of TMEM106B
genotype in C9orf72+ FTLD in a 30-site, international cohort of subjects. Undoubtedly, site-to-site
variation in methods of ascertaining age at onset would contribute to noise, and site-to-site variation
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in practice with respect to aggressiveness of clinical care with a fatal neurodegenerative disease
would contribute to differences in age at death in such a dataset. The ability to see a significant
epistatic effect of TMEM106B on C9orf72 in such a cohort, nonetheless, may have been helped by
the fact that our replication cohort was homogeneous with respect to neuropathology (all FTLDTDP) and genome-wide genotyping in these individuals allowed us to exclude individuals with
cryptic familial relationships that might cloud the picture. In any case, the international, multi-site
nature of our replication cohort increases our confidence that our findings are not due to artifact.
The current study has several limitations. First, while we did not see an age-at-deathmodifying effect for TMEM106B in C9orf72 expansion-associated ALS, our sample size was small
(n=39) and likely underpowered to adequately address this question.

Thus, future studies

examining this relationship in more C9orf72-expansion-related ALS cases would be a valuable
addition to the data presented here. Second, we did not see a clear modifier effect of TMEM106B
genotype in the GRN+ FTLD-TDP cases in this study, as has been previously reported (Cruchaga
et al., 2011). However, our study had only one rs1990622 minor allele homozygote in the GRN+
FTLD subgroup, precluding our ability to examine TMEM106B genotype effect in a major-alleledominant model. Third, we were able to obtain plasma samples on 24 C9orf72 expansion carriers,
in whom we measured progranulin levels. Plasma progranulin levels did not differ by TMEM106B
genotype in this set of samples, which could reflect either insufficient sample size or a biologicallyrelevant finding. Should further studies in larger sample sizes corroborate our result, this would
suggest that C9orf72 expansions may interrupt the means by which TMEM106B affects circulating
progranulin levels.
In conclusion, we demonstrate here that TMEM106B is the first reported genetic modifier
in C9orf72 expansion-related FTLD. Our findings suggest a previously unsuspected link between
these two proteins in the pathophysiology of FTLD and open up new directions for the development
of disease-modifying therapy.
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3.5

METHODS

Patient cohorts
FTLD and ALS cases with C9orf72 expansions of greater than 30 hexanucleotide repeats
were identified from among cases in the Integrated Neurodegenerative Disease Database at the
University of Pennsylvania (UPenn) to form a discovery cohort (Toledo et al., 2013; Xie et al., 2011).
Patients were initially seen at the UPenn Frontotemporal Degeneration Center (FTDC),
Amyotrophic lateral sclerosis Center (ALSC), or Alzheimer's Disease Center (ADC); all were
collected with Institutional Review Board Approval. In addition to having a C9orf72 expansion, the
criteria for selection of FTLD cases was a pathological diagnosis of FTLD-TDP (n=10) or a clinical
diagnosis of FTLD or FTLD-MND (n=19), according to published criteria (Gorno-Tempini et al.,
2011; Litvan et al., 1996; Mackenzie et al., 2011; McKhann et al., 2001; Rascovsky et al., 2011;
Strong et al., 2009). C9orf72+ ALS cases (n=55) all met El Escorial-revised criteria (Brooks et al.,
2000). Twenty of the 55 ALS cases had autopsy confirmation of ALS pathology. For both FTLD
and ALS cases, only probands were selected. In situations where patients exhibited both dementia
and motor neuron disease (MND), cases were assigned to FTLD-MND if the initial presentation
was cognitive and to ALS if the initial presentation was MND. All C9orf72+ FTLD and C9orf72+
ALS cases meeting these criteria were included without bias for familial-vs.-apparently-sporadic
patterns of inheritance, and without prior knowledge of TMEM106B genotype.
The C9orf72+ FTLD cohort is 93.5% white (6.5% unknown ethnicity) and 54.8% male. The
C9orf72+ ALS cohort is 87.2% white, 5.6% black, 3.5% Latino, and 3.7% unknown ethnicity with
59.8% males. Age at onset and age at death were collected, but both were not available on all
subjects (e.g. no age at death for living subjects, and sometimes no known age at onset for autopsy
cases), therefore the numbers of cases from each cohort vary depending on the data needed for
analysis.
The previously published and publicly available FTLD-TDP GWAS from the International
Collaboration for Frontotemporal Lobar Degeneration was used as a replication cohort (Van Deerlin
et al., 2010). A subset of the FTLD-TDP cases were known from the original study to have a
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pathogenic GRN mutation (n=116) and is used here as a comparison group (Chen-Plotkin et al.,
2012; Van Deerlin et al., 2010). Cases lacking a GRN or VCP mutation (n=421) were screened for
C9orf72 expansions either by the contributing site (n=199) or by UPenn (n=142), using published
methods (DeJesus-Hernandez et al., 2011; Renton et al., 2011).

Some cases (n=84) were

presumed to lack an expansion due to a BB genotype at rs2814707 and were not tested to conserve
resources (Strong et al., 2009). 80 FTLD-TDP cases with C9orf72 expansions were identified from
30 clinical sites that agreed to collaborate on this project. Contributing sites that provided C9orf72
genetic data included: Erasmus University, Rotterdam, The Netherlands; Indiana University,
Indianapolis, Indiana; Banc de Teixits Neurologics-Biobanc-Hospital Clinic-IDIBAPS, Barcelona,
Spain; Kings College, London, UK; UCL Institute of Neurology, Queen Square, London, UK;
Ludwig-Maximilians University, Munich, Germany; University of New South Wales, Sydney,
Australia; VIB, University of Antwerp, Antwerp, Belgium; Massachusetts General Hospital, Boston,
Massachusetts; University of Sheffield, Sheffield, UK; Institut National de la Santé et de la
Recherche Laboratoire de Neuropathologie, Paris, France. Contributing sites with C9orf72+ cases
identified at UPenn included: Sydney Brain Bank, Australia; Boston University, Boston,
Massachusetts; Duke University, Durham, North Carolina; Emory University, Atlanta; Georgia;
Karolinska Institute, Stockholm, Sweden; Mt. Sinai School of Medicine, Bronx, New York; Oregon
Health Sciences University, Portland, Oregon; University of Pittsburgh, Pittsburgh, Pennsylvania;
Rush University, Chicago, Illinois; University of Texas Southwestern, Dallas, Texas; University of
Toronto, Toronto, Canada; University of California (Davis, Irvine, San Diego campuses), California;
University of Michigan, Ann Arbor, Michigan; University of Kuopio, Finland; University of Southern
California, Los Angeles, California; Washington University, St. Louis, Missouri; University of
Pennsylvania, Philadelphia, Pennsylvania. Of the 80 cases, 5 UPenn cases overlapped with the
UPenn discovery cohort and were removed, leaving 75 C9orf72 expansion cases for analysis in
the replication cohort. 325 cases remained after identification of GRN and VCP mutation carriers,
and C9orf72 expansion carriers. Of these, 241 cases had been formally tested for (and found
negative for) C9orf72 expansions, and these were used as the mutation-negative FTLD-TDP
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cohort; an additional 84 cases may also be negative for C9orf72 expansions (due to their genotype
at rs2814707), but since they were not formally tested, they were excluded from analysis.
Genotyping
DNA from UPenn cases, extracted from blood or brain samples as previously described
(Van Deerlin et al., 2010),was tested for rs1990622 genotype using one of two methods: TaqMan
chemistry-based allelic discrimination assays as previously described (Chen-Plotkin et al., 2012;
Van Deerlin et al., 2010), or a custom Sequenom MassArray genotyping panel that includes PCR
and extension primers for rs1990622. PCR and extension primer sequences for the Sequenom
panel are available on request.

Both genotyping methods were compared and found to be

concordant (data not shown) (Toledo et al., 2013).
Plasma progranulin measurement
Plasma samples were collected from UPenn ALS and FTLD discovery cohort patients,
aliquotted, and stored at -80°C as previously described (Chen-Plotkin et al., 2011). Progranulin
levels were measured using a commercially available sandwich ELISA (Human progranulin ELISA
kit, AdipoGen), according to manufacturer instructions.
Statistical analyses
Linear regression analyses evaluating the association of TMEM106B genotype with age at
death or age at disease onset were performed in R, with or without covariates as described in the
text.

Two-tailed p-values are reported for the discovery cohort, and one-tailed p-values are

reported for the FTLD-TDP GWAS replication cohort, since the expected directionality was known.
For the combined dataset, survival analyses (Kaplan-Meier method) were also performed in Prism,
and two-tailed p-values from the log-rank test for trend are reported.
Where indicated, codominant, major-allele-dominant, and minor-allele dominant models of
genetic effect were investigated.
In addition, we tested for association between TMEM106B genotype and disease for
genetically-defined subsets of FTLD (C9orf72+ FTLD, GRN+ FTLD, or individuals without C9orf72
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expansions or GRN mutations). Chi-square statistics were calculated for rs1990622 using the
FTLD-TDP GWAS cases and controls (Van Deerlin et al., 2010).
For plasma progranulin analyses, Kruskal-Wallis tests were used to compare plasma
progranulin measures among carriers of different TMEM106B genotypes under a codominant
model, and Mann-Whitney tests were used to compare different TMEM106B genotypes under
major-allele-dominant and minor-allele dominant models.

In addition, multivariate linear

regressions predicting plasma progranulin levels from TMEM106B genotype were used to adjust
for sex, age, duration of disease, or clinical manifestation as described in the text.
R-scripts for analyses are available upon request.
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INTERNATIONAL COLLABORATION FOR FRONTOTEMPORAL LOBAR DEGENERATION
The International Collaboration for Frontotemporal Lobar Degeneration consisted of 45 clinical sites
collaborating to collect cases for an FTLD-TDP genome-wide association study (GWAS); this
GWAS led to the discovery that common variants in TMEM106B are a genetic risk factor for FTLDTDP. Members of the Collaboration who contributed C9orf72+ FTLD-TDP cases for this study
include Irina Alafuzoff, Anna Antonell, Nenad Bogdanovic, William Brooks, Nigel Cairns, Johnathan
Cooper-Knock, Carl W. Cotman, Patrick Cras, Marc Cruts, Peter P. De Deyn, Charles DeCarli,
Carol Dobson-Stone, Sebastiaan Engelborghs, Nick Fox, Douglas Galasko, Marla Gearing, Ilse
Gijselinck, Jordan Grafman, Paivi Hartikainen, Kimmo J. Hatanpaa, J. Robin Highley, John Hodges,
Christine Hulette, Paul G. Ince, Lee-Way Jin, Janine Kirby, Julia Kofler, Jillian Kril, John J. B. Kwok,
Allan Levey, Andrew Lieberman, Albert Llado, Jean-Jacques Martin, Eliezer Masliah, Christopher
J. McDermott, Catriona McLean, Ann C. McKee, Simon Mead, Carol A. Miller, Josh Miller, David
Munoz, Jill Murrell, Henry Paulson, Olivier Piguet, Martin Rossor, Raquel Sanchez-Valle, Mary
Sano, Julie Schneider, Lisa Silbert, Salvatore Spina, Julie van der Zee, Tim Van Langenhove,
Jason Warren, Stephen B. Wharton, Charles L. White III, Randall Woltjer.
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CHAPTER 4: A DEMENTIA-ASSOCIATED RISK VARIANT NEAR TMEM106B
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4.1

ABSTRACT
Neurodegenerative diseases pose an extraordinary threat to the world’s aging population;

unfortunately, no disease-modifying therapies are available.

While genome-wide association

studies (GWAS) have identified hundreds of novel risk loci for neurodegeneration, the mechanisms
by which these loci influence disease risk are largely unknown. Here, we show that common
genetic variants associated with risk for frontotemporal dementia correlate with increased
expression of the gene TMEM106B.

Furthermore, incremental increases in TMEM106B

expression result in incremental increases in cell toxicity. Using both bioinformatic and benchbased approaches, we find that a noncoding variant, rs1990620, influences CTCF-mediated longrange interactions between distal regulatory elements, suggesting a causal mechanism for allelespecific expression and disease association at this locus. We further show that genetic variants
associated with risk for neurodegenerative diseases beyond frontotemporal dementia are enriched
in brain CTCF-binding sites genome-wide, implicating CTCF-mediated gene regulation in risk for
neurodegeneration more generally.
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4.2

INTRODUCTION
Neurodegenerative diseases are a leading cause of disability and death in the developed

world, with numbers affected by these diseases poised to increase as the world population ages.
There are still no disease-modifying therapies for the major late-onset neurodegenerative diseases
such as Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal lobar degeneration,
and amyotrophic lateral sclerosis (Chen and Zheng, 2012). To generate novel leads in tackling
this growing problem, many genome-wide association studies (GWAS) have been performed in the
various neurodegenerative diseases, involving >100,000 patients, and identifying >200 genetic risk
loci (Welter et al., 2014). While genetic risk loci have been utilized, singly or in aggregate, to refine
predictions for risk of developing disease (Abraham and Inouye, 2015; Nalls et al., 2014), the
greatest potential for these GWAS-identified loci may lie in the identification of novel disease
mechanisms (Ramanan and Saykin, 2013).
However, the interpretation of disease-associated risk loci is complicated. The “sentinel”
variant, usually a single nucleotide polymorphism (SNP) identified by GWAS, is rarely the specific
change in DNA sequence – or “causal” variant – that results at the molecular level in a mechanistic
change. Instead, in most cases, tens or hundreds of genetic variants at each locus are in strong
linkage disequilibrium (LD) with the sentinel variant, constituting a set of co-inherited variants – or
haplotype – any of which may be the underlying cause for increased disease risk (Edwards et al.,
2013). Indeed, the risk-associated haplotype may span multiple genes, making even the gene to
which a GWAS signal belongs unclear. Given these complexities, it is perhaps unsurprising that,
with one exception pertaining to common variants near the SNCA gene, which was already
implicated prior to the GWAS era in the development of PD (Soldner et al., 2016), none of the
neurodegenerative disease risk loci identified by GWAS have been characterized in molecular
detail. Yet such a molecularly precise understanding of a GWAS-identified genetic risk locus is a
likely prerequisite for downstream therapeutic development.
Frontotemporal lobar degeneration (FTLD) is a neurodegenerative dementia affecting ~1020 per 100,000 persons between the ages of 45 and 64, making FTLD the second most common
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early-onset dementia (Bang et al., 2015; Seelaar et al., 2011). FTLD is a fatal, untreatable disease,
with death typically occurring within 8 years after diagnosis (Bang et al., 2015). Noncoding single
nucleotide polymorphisms (SNPs) on chromosome 7p21 have been associated with risk for the
major neuropathological subtype of FTLD, characterized by pathological inclusions of the protein
TDP-43 (FTLD-TDP) (Van Deerlin et al., 2010). The association of this locus with FTLD-TDP has
been replicated (Finch et al., 2011; Hernandez et al., 2015; van der Zee et al., 2011), and the major
T allele of the sentinel SNP, rs1990622, yielded an odds ratio of ~1.6 for disease development
(Van Deerlin et al., 2010). Genotype at rs1990622 also affects age at disease onset in Mendelian
forms of FTLD-TDP (Cruchaga et al., 2011; Finch et al., 2011; Gallagher et al., 2014), as well as
risk for development of cognitive impairment in the related disorder amyotrophic lateral sclerosis
(ALS) (Vass et al., 2011). We and others have implicated a gene in this region, TMEM106B, as
being causal (Brady et al., 2013; Chen-Plotkin et al., 2012; Lang et al., 2012). However, studies to
date have not explained how genetic variation at the 7p21 locus affects the function of TMEM106B
or another gene, thereby contributing to the pathogenesis of FTLD-TDP.
In this study, we demonstrate that (1) common GWAS-implicated variants associated with
FTLD-TDP are correlated with expression levels of TMEM106B, with increased expression
correlating with the risk haplotype, (2) incremental increases in TMEM106B expression are
associated with incremental increases in cell toxicity, (3) the risk allele of a candidate causal variant
(rs1990620) in complete LD with rs1990622, the GWAS sentinel SNP, increases recruitment of the
chromatin organizing protein CCCTC-binding factor (CTCF), and (4) long-range chromatin looping
interactions at the TMEM106B locus are stronger on the chromosome bearing the risk-associated
allele. Together, these data provide a molecularly detailed mechanism for the effect of common
genetic variation at this locus on risk for neurodegenerative disease.
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4.3

RESULTS

4.3.1

Genetic variation at the 7p21 locus associates with TMEM106B expression
It is increasingly recognized that many GWAS-implicated variants associated with disease

risk may confer their effects by altering the expression levels of nearby genes (Maurano et al.,
2012; Schaub et al., 2012). In the case of 7p21, several studies have demonstrated such an
expression quantitative trait locus (eQTL) effect for TMEM106B in multiple human tissue types,
including brain and Epstein-Barr virus (EBV)-immortalized B lymphoblastoid cell lines (LCLs)
(Dixon et al., 2007; Liang et al., 2013; Stranger et al., 2012; Yu et al., 2015). We therefore
systematically investigated the 7p21 locus for all eQTL effects, in order to confirm the TMEM106B
eQTL effect and to exclude other potential causal genes at this locus.
Analysis of data from The Genotype-Tissue Expression (GTEx) Project (GTEx Consortium,
2015) demonstrated a robust association between genotype at rs1990622, the GWAS sentinel
SNP, and TMEM106B expression in several cell types from normal individuals (Figure 4.1A),
including LCLs (n=114, P=1.9x10-6) and transformed fibroblasts (n=272, P=3.0x10-7). No other
transcript genome-wide was significantly associated with rs1990622 genotype. The association
between rs1990622 and TMEM106B levels has also been previously reported in human brain (Yu
et al., 2015); GTEx data confirms this relationship in the hippocampal and nucleus accumbens
brain regions (Figure 4.1B). In all cell types, the risk allele was consistently associated with
increased TMEM106B expression.
The 7p21/TMEM106B locus is harbored within a 36kb LD block in samples from individuals
of European ancestry, the population in which the original FTLD-TDP GWAS was performed
(Figure 4.1C).

This LD block encompasses the TMEM106B promoter, the entirety of the

TMEM106B gene, and extends ~10kb downstream of the gene. According to 1000 Genomes data
(1000 Genomes Project Consortium et al., 2015), the block contains 104 genetic variants that are
in strong, but not perfect, LD with rs1990622 (r 2>0.8, Figure 4.1C). Indeed, in-depth examination
of the eQTL effect in human hippocampal (Figure 4.1D) or LCL (Figure S4.1) samples from GTEx
reveals multiple variants in strong LD with rs1990622 that are associated with TMEM106B
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expression to a similar degree. We thus asked whether more than one eQTL signal occurs in this
region, whether the eQTL association can be distinguished from association with FTLD-TDP, and
what the candidate causal variant(s) underlying association with disease or expression might be.
We began by honing the region of eQTL association. To do this, we performed a second
eQTL analysis of LCLs from eight ethnic populations (Stranger et al., 2012), reasoning that the
different haplotype structures seen in disparate populations might refine the 36kb LD block of
association seen in individuals of European ancestry. We found that with the addition of these
populations, the region of association with TMEM106B expression could be truncated on the 5’
end, effectively removing the promoter and first two exons of the gene, and reducing the number
of potential causal variants to 84 (75 SNPs and 9 indels, Figure 4.1E).
We then performed conditional analyses using the refined region of association from the
multi-ethnic analysis (Stranger et al., 2012). Conditioning on either the GWAS sentinel SNP,
rs1990622, or the most significant eQTL SNP, rs6948844 (r 2=1 with rs1990622), yielded no
variants within a 2Mb region that demonstrated any residual association with TMEM106B
expression (Figure 4.1F), demonstrating that there is only one eQTL signal at this locus, and that
the causal variant underlying association with TMEM106B expression may be the same as the
causal variant underlying association with disease.
4.3.2

Increased levels of TMEM106B expression correlate with increased cellular toxicity
If the causal variant responsible for association with TMEM106B expression levels confers

risk for neurodegeneration, one would expect incremental changes in TMEM106B expression to
lead to incremental effects on cellular health. We and others have previously shown that overexpression

of

TMEM106B

results

in

the

development

of

enlarged

LAMP1+

late

endosomes/lysosomes appearing as vacuolar structures in multiple cell types, including neurons,
with associated impairment in lysosomal degradative function (Brady et al., 2013; Busch et al.,
2016; Chen-Plotkin et al., 2012; Stagi et al., 2014). However, the magnitudes of reported eQTL
effects in human tissues are often modest (Dimas et al., 2009; GTEx Consortium, 2015), and so
we sought to understand the effects of incremental increases in TMEM106B expression on
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Figure 4.1. Analysis of expression quantitative trait locus (eQTL) effect at TMEM106B.
(A,B) Boxplots from the Genotype-Tissue Expression (GTEx) Project data demonstrate association
of TMEM106B levels with rs1990622 genotype (A=risk allele) in peripheral cell types (A) as well as
human brain regions (B). Data from LCLs (n=114), fibroblasts (n=272), hippocampus (n=81) and
nucleus accumbens (n=93) are shown. Black lines indicate median expression, lower and upper
bounds of boxes indicate 25th and 75th percentile expression levels, respectively, and circles
outside whiskers denote outliers.
(C) LD structure at TMEM106B in Caucasians, with gene structure indicated above LD plot. Coding
exons are in dark green, UTRs are in light green, and SNPs associated by GWAS with
frontotemporal lobar degeneration (FTLD) are indicated with stars, including the sentinel SNP,
rs1990622.
(D,E) The TMEM106B eQTL effect extends across the 36kb LD block (shown in (D) for GTEx
hippocampus data, with GRCh37/hg19 coordinates) that can be truncated on the 5’ end with the
addition of ethnicities with different haplotype structures (E).
(F) Multi-ethnic conditional eQTL analysis of TMEM106B locus. Each circle represents a SNP, with
genomic position on the x-axis and association with TMEM106B levels on the y-axis (log10transformed Bayes factor). TMEM106B gene and regions of eQTL association are indicated above
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the plot. The primary multi-ethnic analysis (red) demonstrates a strong association between a SNP
cluster and TMEM106B expression. Conditioning this analysis on either the top eQTL SNP (blue)
or the sentinel GWAS SNP (green) results in loss of an association signal at this locus (i.e. there
are no highly-associated SNPs shown in blue or green), suggesting that there is only one eQTL
signal and that the causal variant underlying association with TMEM106B expression may be the
same as the causal variant underlying association with FTLD.

disease-relevant measures such as (1) development of the previously-reported vacuolar phenotype
and (2) cell toxicity.
To do this, we employed three different TMEM106B constructs that reliably produced a
spectrum of over-expression ranging from ~2X to ~20X (Figures 4.2A and 4.2B). In HeLa cells,
we found that with each incremental increase in TMEM106B expression over baseline, the
percentage of cells exhibiting the vacuolar phenotype of enlarged lysosomes increased (Figures
4.2C and 4.2D), along with increased cell death (Figure 4.2E). Together, these findings suggest
that genetic variation at the 7p21 locus may influence risk for neurodegeneration by altering
TMEM106B expression-dependent effects on lysosomal function and cell health.
4.3.3

A candidate causal regulatory region
We next sought to identify the causal variant or variants responsible for allele-specific

regulation of TMEM106B expression and, by extension, risk for FTLD-TDP. TMEM106B steadystate transcript levels depend on both the production of mRNA and its stability. We first considered
the possibility of differential mRNA stability. In multiple LCLs homozygous at the TMEM106B locus,
we found that mRNA stability did not differ between risk haplotype homozygotes and protective
haplotype homozygotes (Figure S4.2A), suggesting that differences in the production of mRNA
account for the observed eQTL effect.
To identify variants that may have transcriptional regulatory effects, we examined the 84
candidate variants (75 SNPs and 9 indels) located within the refined region of eQTL association
(Figures 4.1E and 4.1F). We used ENCODE (ENCODE Project Consortium et al., 2012) and NIH
Roadmap Epigenome (Roadmap Epigenomics Consortium et al., 2015) data to determine whether
each variant is located in a predicted LCL cis-regulatory element (CRE), as determined by DNase
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Figure 4.2. TMEM106B expression levels show dose-dependent effects on cell toxicity.
(A) Representative Western blot of TMEM106B levels in the absence (1X) and presence (2X, 5X,
20X) of various TMEM106B over-expression constructs transfected into HeLas. The bands at
~75kD and ~40kD represent dimeric and monomeric forms of TMEM106B. A non-specific band is
indicated by the asterisk.
(B) Quantification of blots from six independent experiments (+/- SEM) demonstrate reliable
expression levels of each construct.
(C) Representative bright-field images demonstrate a dose-dependent vacuolar phenotype in cells.
Yellow arrowheads indicate cells exhibiting the phenotype.
(D,E) Quantification of the number of cells exhibiting (D) the vacuolar phenotype and (E) cell death
is shown for each expression paradigm, across three independent experiments. Asterisks denote
statistical significance (p<0.001 by ANOVA).

I hypersensitivity (DHS), transcription factor binding, or the active histone marks H3K27ac,
H3K4me1 or H3K4me3.
Surprisingly, only seven SNPs spanning three candidate regulatory regions met these
permissive conditions (Figure 4.3 and Tables S4.1 and S4.2). Three SNPs located in intron 4 of
TMEM106B overlap a region of DHS, transcription factor binding, and the enhancer-associated
histone mark H3K4me1 in LCLs, while a fourth SNP downstream of TMEM106B overlaps a binding
site for the transcription factor PU.1 in LCLs. Upon empirical testing in luciferase reporter assays,
however, these regions displayed little or no enhancer activity in LCLs. Furthermore, the risk and
protective haplotype versions of these regions did not differ in activity, suggesting that none of the
overlapping SNPs affect regulatory activity (Figures S4.2B-D).

The remaining candidate

regulatory region contains the remaining three completely linked SNPs, one of which is rs1990622,
the GWAS sentinel SNP. Moreover, in virtually all ENCODE-tested cell types, including neuronal
and glial lines, this putative CRE displays binding for the mammalian chromatin organizing protein
CTCF. Therefore, we investigated this region for potential allele-specific effects (Figure 4.3).
4.3.4

Common variation at rs1990620 affects binding of CTCF at the TMEM106B locus
Given the observed eQTL effect at TMEM106B in multiple tissues, and the CTCF binding

site within this potential CRE, we next sought evidence for allele-specific binding of CTCF to our
candidate regulatory region. To do this, we analyzed ENCODE CTCF ChIP-seq and DNase digital
genomic footprinting (DGF) experiments. CTCF ChIP-seq was performed on 99 ENCODE cell
lines, 95 of which show a CTCF peak at the putative CRE. We were able to confirm 20 of these
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Figure 4.3. Prioritization of cis-regulatory elements (CREs) harboring candidate
functional variants.
The 84 variants from the eQTL fine-mapping (left) were prioritized based on overlap with
predicted CREs in LCLs (red boxes and text), neuronal and glial cell lines (green), or all three
(blue), based on ENCODE and NIH Roadmap Epigenome project data (see flow chart at right
of image). This analysis yields 7 SNPs in 3 potential CREs as candidate causal variants. Only
one CRE – an intergenic CTCF binding site (CTCF motif represented as yellow rectangle) – is
predicted to be active in brain tissue; this CTCF-binding CRE contains three SNPs in complete
LD, including the GWAS sentinel SNP, rs1990622.
cell lines as TMEM106B haplotype heterozygotes by examining reads containing rs1990620, the
SNP closest to the CTCF core motif (48bp from core motif) and covered by the most reads (Figure
4.4A and Table S4.3).

By analyzing the reads covering rs1990620, we found significant

enrichment of CTCF binding to the risk-associated A allele (P=0.043, Figure 4.4B). In addition,
we identified 6 cell lines heterozygous at rs1990620 that were interrogated by DNase DGF. In
these lines, we found that the chromosome bearing the risk A allele was significantly more sensitive
to DNase cleavage (P<0.001, Figure 4.4B), consistent with an open chromatin state and potential
regulatory activity (Maurano et al., 2015).
We corroborated these data with in vitro investigations of CTCF binding by electromobility
shift assays (EMSA). Utilizing a competition EMSA approach, we found that the risk allele of
rs1990620 was indeed more effective at shifting a protein complex in extracts from HEK293 cells
(Figure 4.4C), LCLs, (Figure 4.4D), and human brain (Figures 4.4E and S4.3). Addition of CTCF
antibody resulted in both a supershift and disappearance of the original EMSA band, demonstrating
that the complex preferentially binding to the A allele of rs1990620 contains CTCF (Figure 4.4F).
Thus, ChIP-seq-based investigation of differential CTCF binding by allele, coupled with gel shift
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assays, together indicate that common variation at a single SNP, rs1990620, may underlie
haplotype-specific effects on CTCF recruitment.
4.3.5

Long-range interactions involving TMEM106B demonstrate haplotype-specific

effects
Rapidly emerging evidence suggests that CTCF plays a major role in the shaping of the
three-dimensional architecture of the mammalian genome (Merkenschlager and Nora, 2016; Ong
and Corces, 2014). In particular, CTCF has been reported to contribute to the formation of
topologically associated domains (TADs), which may be central to enhancer-promoter interactions
and insulator function (Dixon et al., 2012; Dowen et al., 2014; Guo et al., 2015; Lupianez et al.,
2015; Nora et al., 2012). Indeed, interrogation of high resolution in situ Hi-C data from LCLs (Rao
et al., 2014) suggests that the CTCF binding region containing rs1990620 is located within a small
~250kb TAD (sub-TAD) that is part of a larger ~1Mb TAD, and is involved in multiple long-range
looping interactions (Figure S4.4). Moreover, one of the major interactions occurs between this
region and the TMEM106B promoter, implicating a role for this CTCF site in TMEM106B regulation
(Figure 4.5A). Interestingly, there are also strong Hi-C interactions between the promoter and a
predicted enhancer of TMEM106B (Andersson et al., 2014) located ~13kb downstream of the
CTCF site. This enhancer also lies within the sub-TAD and harbors no disease-associated genetic
variants. Given the observed allele-specific effects on CTCF recruitment, we hypothesized that
rs1990620 may influence TMEM106B expression and, by extension, neurodegenerative disease
risk, through differential effects on CTCF-mediated interactions between distal regulatory elements
(Tang et al., 2015) (Figure 4.5B).
To test this, we adapted a recently-developed variation of chromosome conformation
capture (Capture-C) (Hughes et al., 2014) to agnostically capture all interactions involving the
CTCF-binding region, as well as the TMEM106B promoter. Specifically, we coupled 3C library
preparation with a probe capture step to enrich for interactions involving our two regions of interest
(Table S4.4). Importantly, we designed our capture probes not to overlap SNPs (thus, giving

125

Figure 4.4. The risk allele of rs1990620 preferentially recruits CTCF in human tissues.
(A) Schematic of approach for determining allelic bias in CTCF ChIP-seq and DNase digital
genomic footprinting (DGF) experiments. The rs1990620 SNP (48bp from the CTCF core
motif) was analyzed for number of reads containing the risk vs. protective allele in samples
showing a CTCF ChIP-seq or DNase DGF peak at this region.
(B) The risk allele of rs1990620 increases CTCF binding and DNase hypersensitivity at this
region, based on data from 20 and 6 cell types heterozygous at this locus, respectively
(Table S4.3).
(C-E) A 5’ biotinylated probe (P) containing the rs1990620 risk allele was incubated with
nuclear extract (NE) from HEK293s (C), LCLs (D), and human brain (E). In each extract, the
shifted probe/protein complex (red arrowheads) was more efficiently competed with an
unlabeled competitor oligonucleotide (at 10X, 50X, 200X, or 1000X (1KX) the concentration
of the labeled probe) containing the risk allele vs. the protective allele, indicating preferential
binding of a nuclear factor to the risk allele.
(F) A 3’ biotinylated probe (P) containing the rs1990620 risk allele is shifted by addition of
nuclear extract (NE) from HEK293s, LCLs and brain (red arrowheads). Addition of an antiCTCF antibody (Ab) results in disappearance of the shift and a supershift (double arrowheads),
indicating that the complex binding to the probe contains CTCF.
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probes equal opportunity to bind to either allele), while also localizing to regions within 60bp of one
or more marker SNPs (thus allowing for analysis of captured interactions in a haplotype-specific
manner). We performed our Capture-C experiments in three different cell lines – two different LCLs
and the T cell leukemia-derived Jurkat cell line (the TMEM106B eQTL effect has also been reported
in T cells (Peters et al., 2016; Raj et al., 2014)) – with all three lines heterozygous for the
TMEM106B haplotype.
When analyzing all long-range (>2kb) interactions mapping to chromosome 7, we found
that significant interactions (based on an FDR threshold of 1% using fourSig (Williams et al., 2014))
were largely centered around the ~1Mb TAD containing TMEM106B (Figure S4.5).

When

restricting the application of fourSig to regions within the TAD (thus increasing the background
model), all statistically significant interactions mapped to the sub-TAD (Figure S4.6). Thus, our
data confirm the hierarchical nature of the chromatin architecture previously reported at this locus
by in situ Hi-C. Importantly, all pair-wise interactions between the five sub-TAD CTCF sites,
including the TMEM106B promoter, and the enhancer, were statistically significant in every sample,
under both analyses (Figure S4.6), with the outermost CTCF sites in convergent orientation and
delineating the boundaries of a topological domain.
To obtain a finer-grained understanding of the most meaningful interactions at our locus,
we further restricted the fourSig analysis to the ~250kb sub-TAD, which further increased the
background threshold for significance. Under these conditions, significant interactions between the
TMEM106B promoter, the rs1990620-containing CTCF site, and the enhancer emerged (Figures
4.5C and 4.5D).

These results implicate the CTCF site and the enhancer as potential key

regulators of TMEM106B.
Recent studies suggest that genes involved in CTCF-associated long-range interactions
tend to be more transcriptionally active than genes not involved in such interactions (Rao et al.,
2014; Tang et al., 2015). Therefore, we asked whether the number of long-range chromatin looping
interactions involving the risk haplotype, which preferentially binds CTCF and expresses
TMEM106B at higher levels, is significantly higher than the interactions involving the protective
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Figure 4.5. Haplotype-specific long-range chromatin interactions at the TMEM106B locus.
(A) Schematic representation of the TMEM106B sub-TAD and interactions among distal regulatory
elements, based on published LCL Hi-C data. The black CTCF site is located at the TMEM106B
promoter; the blue CTCF site contains rs1990620; the gold rectangle labeled “E” represents a
transcriptionally active enhancer. Note that the CTCF motifs present at the sub-TAD boundaries
(12.107 and 12.362) follow the convergent orientation (arrows indicate direction and strand) most
commonly reported for interacting CTCF sites. Darker lines in bottom of panel indicate interactions
between CTCF sites in convergent orientation.
(B) Model illustrating how allele-specific CTCF binding at rs1990620 might affect sub-TAD structure
and long-range interactions at this locus, with more contact among distal regulatory elements
bearing the risk-associated haplotype.
(C,D) Capture-C experimental data for representative Jurkat and LCL samples, with raw read
coverage shown on the y-axis for interactions captured by probes for (C) the TMEM106B promoter
and (D) the rs1990620-containing CTCF site. Significant interactions within the sub-TAD for each
cell line and replicate (3 cell lines with 2 replicates each) are indicated with red bars, below the
coverage plots, with darker shades of red indicating higher confidence interactions. Yellow circles
marked “V” indicate viewpoints (capture sites). Red arrows indicate interactions between the
promoter, the rs1990620 CTCF site, and enhancer.
(E) Allelic bias in long-range interactions involving the TMEM106B promoter across all of
chromosome 7 (left), the 1Mb TAD (middle), and the 250kb sub-TAD (right) containing TMEM106B.
Read count proportions from capture experiments containing either the risk (blue) or protective
(orange) allele of a marker SNP are shown; in each case, more interactions with the TMEM106B
promoter involve the risk haplotype. *p<0.01; **p<0.001; ***p<0.0001; n.s.=non-significant.

haplotype, in these heterozygous cell lines (Figure 4.5A). In all three cell lines, we observed
significantly more interactions captured with the promoter probes occurring on the risk haplotype,
with consistent effects whether we analyzed all interactions mapping to chromosome 7, or restricted
the analysis to interactions within the TAD or sub-TAD (Figure 4.5E). When interactions were
captured with probes targeting the rs1990620-containing CTCF binding site, fewer reads were
obtained, and no apparent difference in raw reads involving the risk vs. protective haplotype were
detected.
Given that various sources of technical bias (e.g. capture bias, alignment bias, bias in
duplicate removal) can influence allele-specific high-throughput sequencing analyses, we next
compared the number of long-range interactions involving each haplotype (“true” interactions)
against the number of reads from each haplotype aligning to regions directly adjacent to the bait
regions (“false” interactions,). We assumed that regions directly adjacent to the bait regions are
subject to artefactual ligations due simply to chromosomal proximity (Cairns et al., 2016). While
some true functional interactions may be lost in this way (creating false negatives), this approach
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let us test for false-positive differences in interactions between the two haplotypes by capturing
biases in read alignment or other technical steps of the Capture-C protocol.
After adjustment for technical bias, we still observed significant enrichment of promotercaptured interactions on the risk haplotype in two out of three cell lines (P=1.98x10-2 for Jurkats
and P=5.78x10-3 for LCL Line 2 for significant deviation from expected proportions). Moreover, the
same two cell lines demonstrated a significant enrichment of CTCF-associated interactions on the
risk haplotype as well, whether probes captured interactions adjacent to the rs1990620 SNP
(P=3.28x10-3 for Jurkats and P=4.37x10-3 for LCL Line 2) or the rs1990621 SNP (P<1.00x10-6 for
Jurkats and P=2.38x10-2 for LCL Line 2, see Figures 4.3 and 4.4A for SNP locations).
Taken together, these data suggest that SNP-specific effects on CTCF recruitment may
alter the genomic architecture at the TMEM106B locus, with ensuing alterations in gene expression.
4.3.6

Common genetic variants associated with neurodegenerative diseases are enriched

in brain CTCF binding sites
CTCF is emerging as a master regulator of mammalian gene expression through its
widespread influences on genomic architecture (Merkenschlager and Nora, 2016; Ong and Corces,
2014; Won et al., 2016).

Having uncovered an allele-specific effect on the expression of

TMEM106B, a frontotemporal dementia-associated genetic risk factor, likely mediated by CTCF,
we hypothesized that CTCF-mediated effects may play a more general role in conferring risk for
neurodegeneration.
To test this, we identified all published SNPs associated at a genome-wide statistical
significance level with risk for four major neurodegenerative diseases (FTLD, AD, PD, and ALS).
200 neurodegenerative disease risk SNPs were identified (Table S4.5) from the GWAS Catalog
(Welter et al., 2014), and this set of SNPs, as well as their LD proxies, were investigated for the
extent of overlap with brain CTCF binding sites identified by ChIP-seq (ENCODE Project
Consortium et al., 2012).
Seven human brain-relevant CTCF ChIP-seq datasets were identified from ENCODE
project data (ENCODE Project Consortium et al., 2012). Across the combined set of all seven
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datasets, using the Genomic Regulatory Elements and GWAS Overlap algorithm (GREGOR
(Schmidt et al., 2015)), we found a highly-significant ~1.5-fold enrichment of neurodegenerative
disease SNPs and their LD proxies overlapping CTCF binding sites (P<0.0001 at an LD threshold
of r2>0.7, Figure 4.6A). Evaluating each ChIP-seq dataset individually, CTCF binding sites found
in brain-derived microvascular endothelial cells (1.6-fold enrichment, P<0.001), cerebellar
astrocytes (1.4-fold enrichment, P=0.006), and neuroblastoma cells (1.5-fold enrichment, P=0.008)
were most highly enriched for the presence of neurodegenerative risk SNPs, whereas CTCF
binding sites found in other brain-derived cell types, including choroid plexus epithelial cells,
showed no significant enrichment (Figure 4.6B). Our results are thus compatible with a wider role
for CTCF-mediated effects in modulating risk for neurodegeneration.
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Figure 4.6. Neurodegenerative disease risk SNPs are enriched in brain CTCF binding
sites.
We determined the overlap between all SNPs identified by GWAS to confer risk for four different
neurodegenerative diseases, as well as their proxies (at LD thresholds of r 2>0.7, >0.8 or >0.9),
with brain CTCF binding sites. We then compared this “observed” overlap with an “expected”
overlap with brain CTCF binding sites, based on 500 control SNPs matched to each GWAS
SNP for minor allele frequency, number of LD proxies at each threshold, and distance to
nearest gene, using the GREGOR algorithm. Statistically significant enrichments of
neurodegenerative disease risk SNPs at CTCF binding sites were seen in the combined data
sets at each LD threshold for proxy determination (A), and in 5 out of 7 brain-relevant cell types,
shown at an LD threshold of r2>0.7 (B). *p<0.05; **p<0.005; ***p<0.0005; n.s.=non-significant.
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4.4

DISCUSSION
Here, we functionally dissect a locus first linked to the human neurodegenerative disease

FTLD by GWAS. Through a combination of data-mining and bench-based experimental studies of
human-derived tissues, we demonstrate that common variants linked to FTLD by GWAS associate
with haplotype-specific expression of TMEM106B in multiple tissues including human brain; that
this effect may depend on haplotype-specific effects on recruitment of CTCF, with corresponding
haplotype-specific effects on long-range chromatin interactions; and that incremental changes in
TMEM106B expression have effects on cell toxicity (Figure 4.7). Thus, we provide molecular
characterization of the TMEM106B locus, elucidating a mechanism by which a causal variant at
this locus may exert downstream effects on risk for FTLD.
We note that the effects we describe are incremental, rather than all-or-none. Similar
incremental effects have been reported for many cases of allele-specific expression (Dimas et al.,
2009; GTEx Consortium, 2015; Tewhey et al., 2016), including allele-specific expression
differences associated with neuropsychiatric disease variants (Sekar et al., 2016; Soldner et al.,
2016). Conceptually, such an incremental effect is not surprising for common genetic variants that
confer only slightly increased odds for developing a disease, yet may still shed light on important
disease mechanisms.
Aspects of the work presented here may be more broadly applicable to common variant effects on
risk for many neurodegenerative diseases or, even more broadly, for many common variant-trait
associations. For example, here, genotype at the causal noncoding variant rs1990620 alters FTLD
risk through an incremental effect on TMEM106B expression.

The enrichment of disease-

associated variants in predicted cis-regulatory regions (Maurano et al., 2012; Schaub et al., 2012)
and the overlap between these variants and variants associated with gene expression levels
(eQTLs) (Nicolae et al., 2010; Zhu et al., 2016) suggest that many common variants identified by
GWAS may act by modulating gene expression. Moreover, most post-GWAS functional studies
have identified putative causal variants that are thought to affect disease risk by altering the
expression of nearby or distant genes (Adrianto et al., 2011; Bauer et al., 2013; Claussnitzer et al.,
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Figure 4.7. Working model of molecular mechanism underlying 7p21 association with
dementia.
The risk-associated allele of the causal variant (rs1990620) preferentially recruits CTCF,
resulting in haplotype-specific effects on long-range chromatin interactions, with downstream
effects of increased TMEM106B expression. Increased TMEM106B expression leads to
increased cytotoxicity and corresponding risk for neurodegeneration.
2015; Harismendy et al., 2011; Huang et al., 2014; Musunuru et al., 2010). Indeed, we find here
that SNPs associated with risk for neurodegeneration by GWAS are enriched in brain CTCF binding
sites, suggesting that allele-specific modulation of gene expression programs influenced by CTCF
may underlie additional risk factors for other neurodegenerative diseases.
We note that the degree of molecular precision provided here is largely absent in the
characterization of neurodegenerative disease loci first discovered by GWAS. Yet this level of
mechanistic detail illuminating the genetic regulation and biological function of GWAS-derived loci
is certainly needed if we are to translate the thousands of “leads” obtained in this way into potential
avenues for therapeutic interventions. In this context, the strategy illustrated here of prioritization
of variants based on the wealth of newly available genomic data, followed by targeted investigation
in cell culture systems, may be more broadly applicable to the study of common variants associated
with other human diseases.
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Figure S4.1. Multiple linked 7p21 variants are associated with TMEM106B expression in
LCLs.
All GTEx SNPs tested for association with TMEM106B levels in LCLs within a 60kb window
are shown (GRCh37/hg19 coordinates). SNPs are color coded according to linkage
disequilibrium with rs1990622, the GWAS sentinel SNP (shaded in blue and indicated with
arrow). X-axis indicates genomic position, with TMEM106B gene structure indicated as a
reference; y-axes indicate p-value of association with TMEM106B levels (left) and
recombination rate (right, indicated by blue line under eQTL plot).
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Figure S4.2. TMEM106B genotype does not affect mRNA stability.
Lymphoblastoid cell lines homozygous for the risk (n=3) and protective (n=3) TMEM106B
haplotypes were treated with Actinomycin D to inhibit transcription. RNA was isolated at 0h,
1h, 2h, 4h, 8h, and 24h after treatment, and TMEM106B was quantified by RT-qPCR. Data
were analyzed with a two-way ANOVA.
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Figure S4.3. Intronic and intergenic candidate cis-regulatory elements (CREs) do not
harbor functional variants.
(A) Schematic of luciferase reporter constructs used to test candidate CREs for enhancer
activity. Empty vector construct contains no enhancer (negative control); SV40 enhancer
construct serves as a positive control; test constructs contain putative CREs with either the risk
or protective SNP alleles cloned upstream of the SV40 promoter. P=SV40 promoter;
luc=luciferase; E=SV40 enhancer.
(B,C) The intronic CRE displays weak ~1.5-fold enhancer activity with both SNP haplotypes
(p<0.001), whereas neither SNP haplotype of the intergenic CRE displays any activity.
n.s.=non-significant.
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Figure S4.4. The risk allele of rs1990620 preferentially recruits a nuclear factor in brain
nuclear extract.
A 5’ biotinylated probe containing the rs1990620 protective allele was incubated with human
brain nuclear extract, resulting in a similar shift (red arrowheads) to that seen with the
rs1990620 risk allele (Fig. 4.4E). The shifted complex was better competed with excess
amounts of unlabeled oligo containing the risk allele of rs1990620 than that containing the
protective allele.
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Figure S4.5. Lymphoblastoid cell line in situ Hi-C data reveals the chromatin architecture
at the TMEM106B locus.
Hi-C heatmap for chromosome 7p21 displays a ~250kb topologically associating domain (subTAD) within a larger ~1Mb TAD, containing TMEM106B and no other genes. TMEM106B also
interacts with genomic regions extending several hundred kilobases upstream of the TAD
(inter-TAD interactions).
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Figure S4.6. Capture-C recapitulates the predicted chromatin architecture at the TMEM106B
locus.
When analyzing all long-range interactions mapping to chromosome 7 from the (top) TMEM106B
promoter or (bottom) CTCF site viewpoint, statistically significant interactions are limited mostly to
coordinates agreeing with the Hi-C TAD (solid red lines) and upstream inter-TAD interactions
(dashed red line indicates endpoint of interactions observed in the Hi-C data, see Figure S4.5).
The top of each panel shows raw read coverage for each sample and replicate (3 cell lines, with 2
replicates each), and the bottom of each panel shows statistically significant interactions (red bars
indicate statistical significance, with darker shades of red indicating higher confidence interactions).
Data are viewed in the UCSC Genome Browser, with read counts on the y-axis of each track.
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Figure S4.7. Capture-C identifies key interactions between cis-regulatory elements at the
TMEM106B locus.
When analyzing only the interactions mapping to the ~1Mb TAD, statistically significant
interactions from the (A) promoter and (B) CTCF site viewpoint map entirely to the Hi-C subTAD coordinates (solid red lines). Key interacting regions from Figure 4.5A are indicated below
each browser snapshot. Yellow circles marked with a “V” indicate the Capture-C viewpoint.
Data are viewed in the UCSC Genome Browser, with read counts on the y-axis of each track.
Red arrows highlight increase in read counts, corresponding to interactions with the rs1990620containing CTCF site and nearby enhancer (A) and the TMEM106B promoter (B).
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Putative
CRE

rsid

hg19

DNase HS

TF binding

Histone marks

LCL

Brain

LCL

Brain

LCL

Brain

LD with
rs1990622

intronic
CRE

rs1435527

12262571

Yes

No

NFIC
RUNX3
NFYB

No

H3K4me1

No

0.96

intronic
CRE

rs1435525

12262717

Yes

No

NFIC
RUNX3
NFYB

No

H3K4me1

No

0.96

intronic
CRE

rs1435524

12262801

Yes

No

NFIC
RUNX3
NFYB

No

H3K4me1

No

0.96

intergenic
CRE

rs1548884

12279761

No

No

PU.1

No

No

No

0.98

CTCF site

rs1990622

12283787

No

Yes

CTCF

CTCF

No

No

N/A

CTCF site

rs1990621

12283873

No

Yes

CTCF

CTCF

No

No

0.99

CTCF site

rs1990620

12284008

No

Yes

CTCF

CTCF

No

No

1

Table S4.1. Functional annotations of tested top eQTL SNPs variants.
The 7 SNPs overlapping either DNase hypersensitivity (HS), transcription factor (TF) binding, or
active histone marks in lymphoblastoid cell lines (LCLs) are listed by location. CTCF binding at the
region containing the GWAS sentinel SNP, rs1990622, and two other linked SNPs, is seen in brain
cell types as well as LCLs.
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rsid

hg19

LD with rs1990622 (r2)

rs6460902

12255511

0.93

rs35982495

12258665

no info

rs3823612

12258755

0.96

rs11509880

12261911

0.67

rs3800847

12262242

0.96

rs11368032

12262968

no info

rs5882346

12263183

0.94

rs11974335

12263378

0.94

rs11974304

12263437

0.94

rs10950392

12263538

0.96

rs10950393

12263546

0.96

rs10950394

12263587

0.96

rs11509153

12263800

0.96

rs3800843

12264297

0.96

rs10950395

12264467

0.96

rs10950396

12264666

0.96

rs10950397

12264737

0.98

rs10950398

12264871

0.95

rs76854159

12265059

0.95

rs150465020

12265192

0.96

rs6948844

12265848

0.96

rs6966757

12265952

0.96

rs6966915

12265988

0.98

rs7804433

12266706

0.95

rs7804234

12266814

0.96

rs7804736

12266867

0.98

rs4721057

12267221

0.96
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rs4721058

12267256

0.96

rs4721059

12267495

0.97

rs4721060

12267552

0.97

rs4721061

12267559

0.97

rs7792410

12267614

0.97

rs7809700

12267734

0.97

rs13229988

12267837

0.98

rs34046032

12268082

no info

rs28549831

12268117

0.98

rs13230513

12268243

0.98

rs12667950

12268468

0.98

rs5011431

12268551

0.98

rs5011434

12268717

0.96

rs5011436

12268758

0.95

rs5011437

12268792

0.97

rs5011438

12268798

0.97

rs5011439

12268811

0.97

rs3839691

12269256

0.97

rs3173615

12269417

0.98

rs13237715

12269575

0.98

rs13237518

12269593

0.97

rs12699332

12269762

0.98

rs12699333

12269804

0.98

rs12668625

12269817

0.98

rs3815535

12270519

0.98

rs3214372

12270565

no info

rs2302635

12270625

0.98

rs2302634

12270770

0.98
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rs2302633

12270815

0.98

rs7808568

12271252

0.96

rs12669919

12271997

0.98

rs1042949

12272116

0.98

rs3800841

12272568

0.97

rs34252347

12272862

no info

rs1054168

12273413

0.98

rs1054169

12273496

0.98

rs35337387

12274413

no info

rs1468804

12275508

0.96

rs5882347

12275624

no info

rs1468803

12275675

0.96

rs1060700

12275818

0.96

rs1468802

12276011

0.96

rs1468801

12276045

0.96

rs2356065

12276885

0.98

rs7797705

12277773

0.98

rs10281425

12280730

0.98

rs6460905

12283227

1

rs6460906

12283276

1

rs7791726

12283329

1

rs12699338

12285140

0.98

Table S4.2. List of untested top eQTL variants.
The top eQTL SNPs that had no functional annotations in LCLs are listed by location. The linkage
disequilibrium (LD) of each variant with rs1990622 according to HaploReg v4.1 is indicated.
Variants without r2 values were not annotated in HaploReg v4.1, but have nearly identical minor
allele frequencies as all other variants, suggesting that they are also in strong LD. hg19=genomic
coordinates from the GRCh37/hg19 human reference genome build.
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Experiment

Cell lines

CTCF ChIP-seq

BE2_C, Caco-2, GM06990, GM12864,
GM12872, GM12873, GM12874,
GM12891, GM12892, GM19238, H1hESC, HBMEC, HCFA, HEK293,
HepG2, HRPEpiC, HUVEC, HVMF,
NHDF, RPTEC

DNase digital genomic footprinting

AoAf, HCFaa, NHDF-neo, HMVEC-dBlAd, H7-hESC, HMVEC-dLy-Neo

Table S4.3. Cell lines used for CTCF ChIP-seq and DNase digital genomic footprinting
analyses.
All cell lines were confirmed to be heterozygous at rs1990620 by analyzing reads containing
rs1990620. Major and minor allele rs1990620 reads were enumerated and pooled across samples
for each experiment. Deviation from an expected ratio of 50:50 was tested using a two-tailed
binomial sign test. Cell lines are listed by their ENCODE identifiers, or spelled out if no identifiers
exist.
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Probe

Sequence

Promoter probe 1

GAGTTGCTGTGTCGCCTCTAATGAGGCCCAGCCAGGGAACAC
TCGGCTTCGGCCCAAGCC

Promoter probe 2

ACCTCTGGGTTGCCTCTAGGCCCTCACACCTTGAGCGCCAGG
TGGCCCTCTTCCTTTTGC

Promoter probe 3

CTAGGCCCTCACACCTTGAGCGCCAGGTGGCCCTCTTCCTTTT
GCTGTTGATGAATGTTC

Promoter probe 4

TTGAGCGCCAGGTGGCCCTCTTCCTTTTGCTGTTGATGAATGT
TCTTGCCGTGGTGCCGG

CTCF site probe 1

CAATGGAGAACAGAGCTGCAGTACAACTATAGCATTTTGAG
GGGCTGGGAGAACGGGATA

CTCF site probe 2

TACAGTACTACAATGGAGAACAGAGCTGCAGTACAACTATA
GCATTTTGAGGGGCTGGGA

CTCF site probe 3

ATGAAGAGTCTAAGCAGAACTTTCCAGTCATTGTACTACAAT
GGGTTGCAGGCGTGCCAG

CTCF site probe 4

TTTCCAGTCATTGTACTACAATGGGTTGCAGGCGTGCCAGCC
CTCTGGTGGCCACATAAG

CTCF site probe 5

ATGGGTTGCAGGCGTGCCAGCCCTCTGGTGGCCACATAAGTC
CTGGAGTGGCTGGTCATC

CTCF site probe 6

GCCCTCTGGTGGCCACATAAGTCCTGGAGTGGCTGGTCATCT
CAGACTGGGAGCTTCCTC

Table S4.4. Probe sequences used for Capture-C.
Four and six 60bp biotinylated probes were used to capture interactions involving the
TMEM106B promoter and rs1990620-containing CTCF site, respectively.
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SNP

REPORTED GENE(S)

DISEASE/TRAIT(S)

P-VALUE

ODDS
RATIO or
BETA

rs10122902

intergenic

Amyotrophic lateral sclerosis

5.00E-11

NR

rs10260404

DPP6

Amyotrophic lateral sclerosis

5.00E-08

1.30

rs10498633

SLC24A4, RIN3

Alzheimer's disease (late onset)

6.00E-09

1.10

rs10513789

MCCC1, LAMP3

Parkinson's disease

3.00E-10

1.25

rs10792832

PICALM

Alzheimer's disease (late onset)

9.00E-26

1.15

rs10797576

SIPA1L2

Parkinson's disease

5.00E-10

1.13

rs10838725

CELF1

Alzheimer's disease (late onset)

1.00E-08

1.08

rs10948363

CD2AP

Alzheimer's disease (late onset)

5.00E-11

1.10

rs11023139

RRAS2, PSMA1,
SPON1

Alzheimer's disease (cognitive decline)

7.00E-11

0.31

rs11060180

CCDC62

Parkinson's disease

6.00E-12

1.11

rs11061269

GPR133

Amyotrophic lateral sclerosis
(sporadic)

8.00E-10

3.78

rs11136000

CLU

Alzheimer's disease

9.00E-10

1.16

rs11154851

PDE7B

Alzheimer's disease (cognitive decline)

1.00E-08

0.25

rs11158026

GCH1

Parkinson's disease

6.00E-11

1.11

rs11218343

SORL1

Alzheimer's disease (late onset)

1.00E-14

1.30

rs11225434

MMP-1

Matrix metalloproteinase levels

9.00E-29

0.39

rs11226373

MMP-1, MMP-3

Matrix metalloproteinase levels

2.00E-18

0.44

rs11248051

GAK

Parkinson's disease

3.00E-09

1.46

rs11248060

GAK, DGKQ

Parkinson's disease

3.00E-12

1.21

rs112724034

PGAM5P1, MAN2A1

Alzheimer's disease (cognitive decline)

9.00E-13

0.31

rs115102486

CLMN

Alzheimer's disease (cognitive decline)

2.00E-08

0.31

rs11711441

MCCC1, LAMP3

Parkinson's disease

8.00E-12

1.19

rs11724635

BST1

Parkinson's disease

9.00E-18

1.13

rs11744876

CTNND2

Amyotrophic lateral sclerosis
(sporadic)

3.00E-08

NR

rs11754661

MTHFD1L

Alzheimer's disease (late onset)

2.00E-10

2.10

rs11767557

EPHA1

Alzheimer's disease (late onset)

6.00E-10

1.11
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rs11771145

EPHA1

Alzheimer's disease (late onset)

1.00E-13

1.11

rs117896735

INPP5F

Parkinson's disease

4.00E-13

1.62

rs117964204

CACNA1G

Alzheimer's disease (cognitive decline)

1.00E-09

0.28

rs11931074

SNCA

Parkinson's disease

7.00E-17

1.37

rs12075

FCER1A, OR10J1,
DARC, OR10J5

Obesity-related traits

1.00E-21

0.10

rs12185268

MAPT

Parkinson's disease

3.00E-14

1.30

rs12203592

IRF4

Progressive supranuclear palsy

6.00E-15

1.48

rs12456492

RIT2

Parkinson's disease

8.00E-12

1.11

rs12608932

UNC13A

Amyotrophic lateral sclerosis

3.00E-14

1.25

rs12636651

CCR3, CCR2

Obesity-related traits

7.00E-09

0.05

rs12637471

MCCC1

Parkinson's disease

2.00E-21

1.19

rs12726330

GBA

Parkinson's disease

5.00E-08

1.71

rs12817488

CCDC62, HIP1R

Parkinson's disease

3.00E-13

1.14

rs12989701

BIN1

Alzheimer's disease (late onset)

3.00E-10

1.23

rs13048019

SOD1

Amyotrophic lateral sclerosis

3.00E-08

2.02

rs1318862

FAT3

Subcortical brain region volumes

6.00E-09

26.86

rs1411478

STX6

Progressive supranuclear palsy

4.00E-11

1.27

rs14235

BCKDK, STX1B

Parkinson's disease

2.00E-12

1.10

rs1442190

LRRK2

Parkinson's disease

2.00E-27

3.72

rs1474055

STK39

Parkinson's disease

1.00E-20

1.21

rs1476679

ZCWPW1

Alzheimer's disease (late onset)

6.00E-10

1.10

rs148763909

SAP30L

Alzheimer's disease (cognitive decline)

1.00E-08

0.15

rs1491942

LRRK2

Parkinson's disease

6.00E-15

1.17

rs1541160

KIFAP3

Amyotrophic lateral sclerosis

2.00E-08

0.58

rs1555399

TMEM229B

Parkinson's disease

7.00E-14

1.11

rs1562990

MS4A

Alzheimer's disease

4.00E-11

1.14

rs157580

APOE

Alzheimer's disease

8.00E-89

1.69

rs157582

APOE

Psychosis and Alzheimer's disease

9.00E-52

2.30

150

rs1582763

MS4, MS4A6A,
MS4A4A, MS4A6E

Alzheimer's disease in APOE e4carriers

2.00E-09

1.15

rs1605070

IQCF5

Amyotrophic lateral sclerosis
(sporadic)

2.00E-09

3.95

rs1630500

GBA

Parkinson's disease

2.00E-08

1.75

rs17125944

FERMT2

Alzheimer's disease (late onset)

8.00E-09

1.14

rs17314229

FRMD4A

Alzheimer's disease

1.00E-10

1.68

rs17393344

MYO16

Alzheimer's disease (cognitive decline)

2.00E-08

0.26

rs17577094

MAPT

Parkinson's disease

8.00E-09

1.56

rs17649553

MAPT

Parkinson's disease

2.00E-48

1.30

rs1768208

MOBP

Progressive supranuclear palsy

5.00E-17

1.37

rs17817600

PICALM

Alzheimer's disease

2.00E-08

1.33

rs1795240

FMO3, FMO6P

Lentiform nucleus volume

5.00E-08

112.27

rs190982

MEF2C

Alzheimer's disease (late onset)

3.00E-08

1.08

rs1925690

ZNF292

MRI atrophy measures

3.00E-08

0.00

rs1936246

GAPDHP15, RBBP4P4

Alzheimer's disease (APOE e4
interaction)

2.00E-13

1.04

rs1990622

TMEM106B

FTLD-TDP

1.00E-11

1.60

rs199347

GPNMB

Parkinson's disease

1.00E-12

1.11

rs1994090

LRRK2

Parkinson's disease

3.00E-08

1.39

rs199515

WNT3

Parkinson's disease

3.00E-17

1.32

rs199533

NSF

Parkinson's disease

1.00E-14

1.28

rs1997111

intergenic

Cerebrospinal T-tau levels

1.00E-08

NR

rs2075650

APOE, TOMM40

Alzheimer's disease

2.00E-157

2.53

rs2102808

STK39

Parkinson's disease

4.00E-10

1.18

rs2228467

CCBP2

Cerebrospinal fluid levels of
Alzheimer's disease-related proteins

4.00E-18

NR

rs2279590

CLU

Alzheimer's disease

6.00E-10

1.22

rs2338971

HUSEYO

Parkinson's disease

4.00E-10

1.35

rs2373115

GAB2

Alzheimer's disease (late onset)

1.00E-10

4.06

rs2414739

VPS13C

Parkinson's disease

1.00E-11

1.11
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rs242557

MAPT

Progressive supranuclear palsy

9.00E-18

1.43

rs2446581

FRMD4A

Alzheimer's disease

1.00E-10

1.68

rs2494250

FCER1A, OR10J3

Select biomarker traits

1.00E-14

NR

rs2685056

ALCAM

Amyotrophic lateral sclerosis
(sporadic)

4.00E-08

2.58

rs2707466

WNT16

Cortical thickness

2.00E-10

0.11

rs2718058

NME8

Alzheimer's disease (late onset)

5.00E-09

1.08

rs2736990

SNCA

Parkinson's disease

2.00E-16

1.23

rs2814707

IFNK, MOBKL2B,
C9orf72

Amyotrophic lateral sclerosis

7.00E-09

1.22

rs28834970

PTK2B

Alzheimer's disease (late onset)

7.00E-14

1.10

rs2899472

CYP19A1

Cerebrospinal AB1-42 levels

2.00E-09

NR

rs2942168

MAPT

Parkinson's disease

1.00E-28

1.27

rs3026968

CADM3

Inflammatory biomarkers

9.00E-14

NR

rs329648

MIR4697

Parkinson's disease

1.00E-11

1.11

rs34311866

TMEM175, GAK,
DGKQ

Parkinson's disease

1.00E-43

1.27

rs34372695

SYT11

Parkinson's disease

4.00E-12

1.47

rs34517613

SALM1

Amyotrophic lateral sclerosis
(sporadic)

9.00E-09

1.20

rs34972666

TGM6

Alzheimer's disease (cognitive decline)

3.00E-08

0.23

rs35349669

INPP5D

Alzheimer's disease (late onset)

3.00E-08

1.08

rs356182

SNCA

Parkinson's disease

4.00E-73

1.32

rs356219

SNCA

Parkinson's disease

6.00E-65

1.29

rs356220

SNCA

Parkinson's disease

8.00E-35

1.38

rs35749011

GBA, SYT11

Parkinson's disease

1.00E-29

1.82

rs3764650

ABCA7

Alzheimer's disease

5.00E-17

1.23

rs3818361

CR1

Alzheimer's disease

4.00E-14

1.18

rs3849942

IFNK, MOBKL2B,
C9orf72

Amyotrophic lateral sclerosis

9.00E-11

2.16

rs3849943

C9orf72

C9orf72

6.00E-10

1.22

rs3851179

PICALM

PICALM

1.00E-09

1.16

152

rs3865444

CD33

CD33

2.00E-09

1.10

rs393152

MAPT, C17orf69,
KIAA1267, LOC644246

MAPT, C17orf69, KIAA1267,
LOC644246

2.00E-16

1.30

rs4128725

OR10J1

OR10J1

4.00E-12

NR

rs4129267

IL6R

IL6R

2.00E-57

NR

rs4147929

ABCA7

ABCA7

1.00E-15

1.15

rs429358

APOE

APOE

5.00E-14

NR

rs4420638

APOE, TOMM40,
APOC1

Alzheimer's disease

8.00E-149

3.45

rs4538475

BST1

Parkinson's disease

3.00E-09

1.24

rs4663105

BIN1

Alzheimer's disease in APOE e4carriers

2.00E-12

1.19

rs4676049

intergenic

Alzheimer's disease (late onset)

4.00E-08

1.76

rs4700060

ANKRD55

Alzheimer's disease (cognitive decline)

1.00E-08

0.21

rs471470

PICALM

Alzheimer's disease in APOE e4+
carriers

3.00E-08

1.16

rs4796217

CCL4L2

Protein quantitative trait loci

4.00E-21

NR

rs4866650

intergenic

Left inferior lateral ventricle volume
(Cerebrospinal fluid biomarker status
interaction)

1.00E-09

6.15

rs4906844

LOC100128714

Cortical thickness

1.00E-08

0.07

rs4938933

MS4A4A

Alzheimer's disease (late onset)

8.00E-12

1.12

rs495366

MMP

Matrix metalloproteinase levels

6.00E-34

0.44

rs4968782

CYB561, ACE

Cerebrospinal fluid levels of
Alzheimer's disease-related proteins

4.00E-12

NR

rs514716

GLIS3

Alzheimer's disease biomarkers

3.00E-09

0.07

rs519113

APOE, CEACAM16,
BCL3, PVRL2,
TOMM40, PPP1R37

Alzheimer's disease (late onset)

5.00E-39

2.09

rs536841

PICALM

Alzheimer's disease

3.00E-09

1.16

rs56131196

APOC1

Alzheimer's disease biomarkers

4.00E-12

NR

rs561655

PICALM

Alzheimer's disease (late onset)

7.00E-11

1.15

rs569214

CLU

Alzheimer's disease

4.00E-08

1.14

153

rs573521

MMP3, MMP12,
WTAPP1, MMP13,
DCUN1D5

Cerebrospinal fluid levels of
Alzheimer's disease-related proteins

2.00E-44

NR

rs58370486

BZW2, TSPAN13

Alzheimer's disease (cognitive decline)

6.00E-11

0.36

rs59007384

TOMM40

Alzheimer's disease biomarkers

7.00E-09

NR

rs610932

MS4A4E, MS4A6A

Alzheimer's disease

2.00E-14

1.11

rs61144803

CRADD

Alzheimer's disease (cognitive decline)

5.00E-08

0.16

rs61812598

IL6R, TDRD10, SHE,
UBE2Q1, ADAR

Cerebrospinal fluid levels of
Alzheimer's disease-related proteins

6.00E-63

NR

rs62256378

SUCLG2

Cerebrospinal AB1-42 levels in
Alzheimer's disease dementia

3.00E-12

0.71

rs62341097

GALNT7

Neuritic plaque

6.00E-09

1.15

rs6430538

ACMSD, TMEM163

Parkinson's disease

9.00E-20

1.14

rs6532194

SNCA

Parkinson's disease

5.00E-11

1.29

rs6547705

CD8B

Progressive supranuclear palsy

1.00E-08

1.28

rs6599388

GAK

Parkinson's disease

4.00E-12

1.16

rs6599389

GAK

Parkinson's disease

4.00E-08

1.31

rs6656401

CR1

Alzheimer's disease (late onset)

6.00E-24

1.18

rs6701713

CR1

Alzheimer's disease (late onset)

5.00E-10

1.16

rs6703183

CAMK1G

Amyotrophic lateral sclerosis

3.00E-08

1.31

rs6733839

BIN1

Alzheimer's disease (late onset)

7.00E-44

1.22

rs6738962

CTNNA2

Alzheimer's disease (cognitive decline)

1.00E-08

0.18

rs679515

CR1

Alzheimer's disease in APOE e4+
carriers

4.00E-09

1.22

rs6808835

CCRL2, CCR5, CCR2,
LTF, CCR3

Cerebrospinal fluid levels of
Alzheimer's disease-related proteins

2.00E-13

NR

rs6812193

SCARB2, FAM47E

Parkinson's disease

3.00E-11

1.10

rs6857

PVRL2

Dementia and core Alzheimer's disease
neuropathologic changes

2.00E-62

1.61

rs6859

APOE, PVRL2,
TOMM40

Alzheimer's disease

6.00E-14

NR

rs6887649

FTMT

Left inferior lateral ventricle volume
(Cerebrospinal fluid biomarker status
interaction)

2.00E-08

5.68

154

rs6922617

TREM, NCR2

Alzheimer's disease biomarkers

4.00E-08

0.09

rs7081208

FRMD4A

Alzheimer's disease

1.00E-10

1.68

rs7117082

LOC100128095,
OPCML

Amyotrophic lateral sclerosis
(sporadic)

8.00E-09

2.79

rs7274581

CASS4

Alzheimer's disease (late onset)

3.00E-08

1.14

rs72832584

BCAS3

Alzheimer's disease (cognitive decline)

1.00E-11

0.30

rs744373

BIN1

Alzheimer's disease

3.00E-14

1.17

rs7561528

BIN1

Alzheimer's disease (late onset)

4.00E-14

1.17

rs7571971

EIF2AK3

Progressive supranuclear palsy

4.00E-13

1.33

rs75932628

TREM2

Alzheimer's disease

2.00E-12

2.90

rs76904798

LRRK2

Parkinson's disease

5.00E-14

1.16

rs769449

APOE, TOMM40

Alzheimer's disease biomarkers

2.00E-18

0.09

rs7849530

SPTLC1

Left inferior lateral ventricle volume
(Cerebrospinal fluid biomarker status
interaction)

3.00E-10

6.40

rs8045064

FLJ45256

Alzheimer's disease (cognitive decline)

4.00E-08

0.21

rs8070723

MAPT

Progressive supranuclear palsy

2.00E-118

5.11

rs8118008

DDRGK1

Parkinson's disease

3.00E-11

1.11

rs8141797

SUSD2, CABIN1, GGT5

Amyotrophic lateral sclerosis

2.00E-09

1.52

rs823118

NUCKS1, RAB7L1

Parkinson's disease

2.00E-16

1.12

rs855913

ZNF746

Amyotrophic lateral sclerosis

4.00E-08

1.08

rs9327881

NUDT12

Amyotrophic lateral sclerosis
(sporadic)

5.00E-09

NR

rs9329300

PFKP

Amyotrophic lateral sclerosis
(sporadic)

2.00E-09

3.10

rs9331888

CLU

Alzheimer's disease

6.00E-10

1.22

rs9331896

CLU

Alzheimer's disease (late onset)

3.00E-25

1.16

rs9349407

CD2AP

Alzheimer's disease (late onset)

9.00E-09

1.11

rs947211

SLC45A3, PARK16,
PM20D1, NUCKS1,
RAB7L1, SLC41A1

Parkinson's disease

2.00E-12

1.30

rs9525638

TNFSF11, RANKL

Cortical thickness

4.00E-09

0.09

155

rs9825420

ITGA9

Amyotrophic lateral sclerosis
(sporadic)

3.00E-08

3.03

rs983392

MS4A6A

Alzheimer's disease (late onset)

6.00E-16

1.11

rs9877502

UTS2D, SNAR-I,
GEMC1, OSTNIL1RAP, CCDC50

Alzheimer's disease biomarkers

5.00E-09

0.05

rs997277

DIRC1, COL3A1

Parkinson disease and Lewy body
pathology

5.00E-08

1.63

rs9977018

TMPRSS2

Amyotrophic lateral sclerosis
(sporadic)

2.00E-09

NR

Table S4.5. SNPs associated with risk for neurodegenerative disease and related
phenotypes by GWAS.
For each SNP, the reported gene(s), associated disease/traits, and p-value, odds ratio or beta
corresponding to the association are listed. For SNPs associated with multiple traits, the information
listed pertains to the trait with which the SNP is most significantly associated (lowest p-value).
NR=not reported.

156

4.5

METHODS

eQTL analyses
The GWAS sentinel SNP, rs1990622 (Van Deerlin et al., 2010), was queried for association
with all transcripts genome-wide using The Genotype-Tissue Expression (GTEx) eQTL database
(GTEx Consortium, 2015), consisting of 7,051 samples and representing 44 different tissues from
449 healthy donors.

GTEx eQTL plots were generated with SNiPA (Arnold et al., 2015).

Conditional analyses and fine-mapping were performed using HapMap3-imputed genotypes from
a published multi-ethnic LCL eQTL study (Stranger et al., 2012), as previously described (Brown
et al., 2013). In brief, gene expression data were normalized to the empirical average quantiles
across all samples. Subsequently, the distribution of each gene expression trait was transformed
to the quantiles of the standard normal distribution, separately within each population. The effects
of known and unknown covariates were controlled for by principal component analysis. A cis-eQTL
scan was performed by regressing the additive effect of each SNP within 1Mb of TMEM106B on
gene expression by Bayesian regression, as implemented in SNPTEST (Wellcome Trust Case
Control Consortium, 2007).
Analysis of LD structure at the TMEM106B locus
HapMap Phase I, II and III combined CEU genotype data (International HapMap 3
Consortium et al., 2010) were visualized in HaploView to assign LD blocks (Barrett et al., 2005),
filtering out SNPs with MAF<0.001 and requiring that 90% of informative pairwise LD values within
a block must represent strong LD. Pairwise LD between variants at the TMEM106B locus was
determined using both HapMap and 1000 Genomes data (1000 Genomes Project Consortium et
al., 2012), visualized either in HaploView or on the HaploReg v4.1 web resource (Ward and Kellis,
2012).
Cell culture
HeLas

were

cultured

in

DMEM

with

10%

FBS,

1%

L-glutamine,

and

1%

penicillin/streptomycin. LCLs were obtained from the Coriell Institute for Medical Research in
Camden, NJ, and were cultured in RPMI with 15% FBS, 1% L-glutamine and 1%
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penicillin/streptomycin. Jurkats were cultured in RPMI with 10% FBS, 1% L-glutamine and 1%
penicillin/streptomycin.
TMEM106B overexpression experiments
TMEM106B expression constructs designed to over-express at 2-fold, 5-fold, and 20-fold
expression, as previously described (Chen-Plotkin et al., 2012), were transfected into HeLas with
Lipofectamine 2000, as per manufacturer protocols. 48 hours post-transfection, ten brightfield
images were taken across three biological replicates for each condition at 100X on a Life
Technologies EVOS FL microscope. Image files were assigned random identifiers and a blinded
individual counted the number of cells in each image that displayed the vacuolar phenotype,
defined by having at least one clear punctate vacuolar structure. This experiment was repeated
three times and the results were pooled. To assess cytotoxicity, the same transfection protocol
was carried out, but at 48h post-transfection cells were spun down and resuspended in Trypan
Blue-containing DMEM culture media, and the proportion of Trypan Blue-positive cells were
determined with a hemocytometer. This experiment was also carried out three times. Western
blots were performed for all six experiments as described previously (Chen-Plotkin et al., 2012),
and the data were pooled together for the quantification shown in Figure 4.2B.
Cell line haplotype phasing
In order to confirm all cell lines used for mRNA stability experiments, ASE analysis, and
Capture-C as TMEM106B haplotype heterozygotes, we first performed TaqMan SNP Genotyping
assays, as previously described (Gallagher et al., 2014), for rs1990622 and marker SNPs in strong
or complete LD with rs1990622 (rs3807865, r2=0.9; rs6966915, r2=1; rs3173615, r2=1; rs1468803,
r2=1), to confirm heterozygosity. For the cell lines used for the Capture-C experiments, the CTCF
binding region was also analyzed by Sanger sequencing to confirm heterozygosity for the three
completely

linked

potential

causal

variants:

rs1990622,

rs1990621,

and

rs1990620.

Heterozygosity of the promoter SNP rs4721056 (r 2=0.5 with rs1990622) was confirmed by
genotyping as well, but because of the lower LD of this SNP with rs1990622, we PCR amplified the
region containing rs4721056 and three SNPs in strong LD with rs1990622 (rs7781670, r 2=0.9;
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rs1019309, r2=0.9; and rs1019307, r2=0.89) in the three Capture-C cell lines. This amplicon was
cloned into the MCS of the pGL3 Promoter vector, and Sanger sequencing of individual clones
confirmed that no cell lines had mixed haplotypes comprising these SNPs, thus linking the risk
allele of rs4721056 to the risk haplotype in all cell lines.
mRNA stability experiments
Three LCLs homozygous for the TMEM106B risk haplotype, and three LCLs homozygous
for the protective haplotype, were treated with 1μg/μL Actinomycin D, and RNA was extracted at
0h, 1h, 2h, 4h, 8h and 24h post-treatment. RT-qPCR was performed as previously described
(Chen-Plotkin et al., 2012) to quantify TMEM106B levels at each time point, normalized to 18S
RNA, which decayed by only ~14% in 24hr. Decay curves for mRNA stability were compared using
two-way ANOVAs. This experiment was performed on each of the six cell lines twice, for a total of
six biological replicates for each haplotype.
Epigenomic prioritization of candidate cis-regulatory elements
We used the UCSC Genome Browser (GRCh37/hg19) (Hinrichs et al., 2016) to visualize
ENCODE DNase hypersensitivity, transcription factor ChIP-seq, and the H3K4me1, H3K4me3, and
H3K27ac histone mark tracks in the GM12878 LCL line (ENCODE Project Consortium et al., 2012).
We also visualized these histone marks in all LCLs included in the NIH Roadmap Epigenome
Project (Roadmap Epigenomics Consortium et al., 2015) using the WashU Epigenome Browser
(Zhou and Wang, 2012). First, we determined which of the top eQTL SNPs from the fine-mapping
overlapped a cis-regulatory element (CRE) predicted to be active in LCLs, based on the presence
of at least one of the features mentioned above. This permissive filtering process yielded only three
candidate CREs with seven candidate causal variants. Two putative CREs displaying either DNase
hypersensitivity, transcription factor binding, and/or H3K4me1 were tested for enhancer activity in
LCL reporter assays. The third CRE contains three candidate causal variants and displays CTCF
binding in LCLs, neuronal and glial cell lines, and was further investigated for allele-specific effects.
Reporter assays
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To test the two putative LCL CREs for enhancer activity, we cloned each region with either
the risk or protective haplotype SNP alleles, based on 1000 Genomes Phase I (1000 Genomes
Project Consortium et al., 2010) haplotype information, into the upstream multiple cloning site
(MCS) of the pGL3 Promoter luciferase reporter vector (Promega Cat. #E1761). We transfected
2.5x106 LCLs using program Y-001 and nucleofection solution V on the Lonza Nucleofector 2b,
using the pGL3 Basic vector (with no enhancer) (Promega Cat. #E1751) as a negative control, and
the pGL3 Control vector (with an SV40 enhancer) (Promega Cat. #E1741) as a positive control
(Figure S4.3B). Three or four biological replicates were included for each construct in each
experiment, and four independent experiments were performed for each candidate CRE. Cell
lysates were isolated 24h post-transfection for luciferase readout using the Promega DualLuciferase Reporter Assay System (Promega Cat. #E1910), as described previously (Chen-Plotkin
et al., 2012). We used two-tailed t-tests to test for statistically significant differences in reporter
activity.
ENCODE data-mining for CTCF binding and DNase hypersensitivity
We downloaded the BAM read alignment files for all CTCF ChIP-seq experiments that
showed a CTCF peak at the region containing rs1990620, as well as for the DNase digital genomic
footprinting experiments performed in cell lines that show a DNase-seq peak at this region
(https://www.encodeproject.org/, Table S4.3). We analyzed raw sequencing reads containing
rs1990620 to identify cell lines heterozygous at this locus. We summed risk allele reads across all
cell types, as well as protective allele reads across all cell types, assessing for deviation from a
50:50 proportion using a two-tailed binomial sign test.
Electrophoretic mobility shift assays
Nuclear extract was obtained from healthy human occipital cortex, LCLs, and HEK293s
using the Thermo Fisher Scientific Nuclear and Cytoplasmic Extraction Reagents kit (Cat. #78833).
A 61bp biotinylated DNA probe containing the risk or protective allele of rs1990620 at position 31
and 30bp of genomic sequence on either side was incubated with extract and competed with
excess amounts of unlabeled oligo containing either the risk or protective allele of rs1990620. 2μL
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of anti-CTCF antibody (EMD Millipore Cat. #07-729) was added to the reaction to test for
supershifts. EMSAs were performed in accordance with the Thermo Fisher Scientific LightShift
Chemiluminescent EMSA kit (Cat. #20148).
Capture-C
Capture-C was performed similarly to previous reports (Hughes et al., 2014). Briefly, 3C
libraries were generated by fixing 10x106 cells with formaldehyde, followed by DpnII digestion and
ligation. Phenol/chloroform-extracted DNA was sonicated to produce 200-300bp fragments, and
sequencing libraries were prepared with the NEBNext DNA Library Prep Master Mix Set (Illumina
Cat. #E6040). 10μg of each capture library underwent multiplexed PCR with unique index oligos.
Hybridization with 60bp biotinylated capture probes (Table S4.4) was performed with the SeqCap
EZ Hybridization and Wash Kit (Roche Cat. #05634261001). Briefly, 3C libraries were air-dried
with heat in a thermocycler, and resuspended with hybridization reagents. 2μL (3pmoles) of pooled
capture probes for each bait region were added to the resuspended libraries, and incubated for 72h
in a thermocycler at 47 degrees C. After isolation of captured material using streptavidin beads
and PCR, an additional 24h capture was performed. The capture probes, ordered from Integrated
DNA Technologies, flank DpnII cut sites that are proximal to marker SNPs in the TMEM106B
promoter region and CTCF site, designed for captured ligation products to contain marker SNPs
distinguishing between haplotypes. Promoter capture experiments used rs4721056 to distinguish
haplotypes, and CTCF site capture experiments used rs1990620 and rs1990621 to distinguish
haplotypes (see “Cell line haplotype phasing” section). Samples were pooled and sequenced on
one lane of an Illumina HiSeq 2500 with 125bp paired end reads, yielding ~230 million read pairs.
Two LCLs and Jurkat cells were captured at both regions, with two technical replicates for each
capture, performed by different individuals in tandem.
Capture-C data analyses
Quality

control

was

performed

(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/)

and

with
pre-processing

FastQC
and

read

alignment were performed as previously described (Davies et al., 2016). Briefly, the paired-end
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reads were reconstructed into single reads using FLASH, in silico-digested using the DpnII2E.pl
script (https://github.com/telenius/captureC/releases), and mapped with Bowtie1(Langmead et al.,
2009).

The

aligned

reads

were

then

(https://github.com/telenius/captureC/releases).

analyzed

with

the

CCanalyser3.pl

script

Interactions were tested for significance with

fourSig (Williams et al., 2014), using default parameters and a window size of five. First, we tested
interactions for significance using all reads mapping to chromosome 7. Then we restricted our
analyses to interactions within the TAD and sub-TAD to test for significant interactions within these
regions, respectively.
To determine if the long-range interactions captured by the hybridization probes show
allelic bias, we first estimated the technical (non-biological) bias for each SNP, which may reflect
capture bias, mapping bias, or other sources of technical bias. We estimated technical bias using
two independent approaches. For the first approach, we enumerated the risk vs. protective allele
reads containing each marker SNP directly adjacent to the probe sequences (i.e. mapping to the
5kb window containing the probe sequences or the immediately adjacent 5kb windows at each
capture site) for each experiment. In the second approach, we enumerated the risk vs. protective
allele reads containing each marker SNP mapping at a great distance from TMEM106B (i.e. outside
of the TMEM106B TAD, as defined by the LCL Hi-C heatmap (Rao et al., 2014)). In each case,
we assumed that the interactions too close or too far from TMEM106B do not represent functional
interactions. For the adjacent interactions, ligations may occur artefactually due to chromosomal
proximity (Cairns et al., 2016).

For the interactions outside the TMEM106B TAD, low read

count/interaction suggests that these are not true interactions, consistent with the fourSig results.
Technical bias estimated by these two approaches is likely conservative – some true biological
interactions may be “discounted” in this way, creating false negatives in order to most reliably
account for false positive interactions. Despite different underlying assumptions, technical bias
estimates derived from the two methods agree with each other to within <1% for both promoter and
CTCF site marker SNPs.
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In each case, read counts for interactions originating from each haplotype were compared
(1) with an expected proportion of 0.5 (in analyses without normalization for technical bias) or (2)
with the proportions observed using the estimates of technical bias described above (in analyses
normalized for technical bias), using a binomial test.
CTCF site SNP enrichment analysis
We identified all SNPs that have been associated with risk for FTLD, Alzheimer’s disease,
Parkinson’s disease, amyotrophic lateral sclerosis, and related conditions, at a genome-wide
significant level (P<5x10-8), using the EMBL-EBI/NHGRI GWAS catalog (Welter et al., 2014). This
list contains 200 SNPs associated with 29 traits (Table S4.5). We downloaded all available optimal
irreproducible discovery rate (IDR) thresholded peak (Landt et al., 2012) BED files from ENCODE
CTCF

ChIP-seq

experiments

(https://www.encodeproject.org/;

performed

hippocampal

in

brain-relevant

astrocytes,

cerebellar

cell/tissue

types

astrocytes,

BE2_C

neuroblastoma, retinoic acid-treated SK-N-SH neuroblastoma, choroid plexus epithelial cells, H54
glioblastoma, and brain microvascular endothelial cells). We used the GREGOR pipeline (Schmidt
et al., 2015) to determine if the disease-associated SNPs or their LD proxies (at r2 values of >0.7,
>0.8 and >0.9) were enriched in brain CTCF binding sites compared to control SNPs that were
matched for minor allele frequency, number of LD proxies, and distance to the nearest gene
(Schmidt et al., 2015). 14 of the neurodegenerative risk SNPs were not identifiable by GREGOR,
resulting in a final list of 186 disease-associated SNPs and proxies.
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CHAPTER 5: DISCUSSION
5.1

Genetic variation at TMEM106B affects risk for neurodegeneration
Since the publication of the first genome-wide association study (GWAS) in 2005 (Klein et

al., 2005), GWAS have been widely used to identify common genetic risk factors for complex traits
and diseases (Edwards et al., 2013). Complex diseases, by definition, do not have single causes
(Ghosh and Collins, 1996), which has made it challenging to 1) understand the mechanisms
underlying these diseases, and 2) develop therapeutic interventions. Indeed, while thousands of
SNP-trait associations have been identified by GWAS (Welter et al., 2014), only a small proportion
have been investigated mechanistically (see Chapter 1.2). Such a knowledge gap between 1)
known disease-associated loci and 2) the mechanisms by which these loci affect disease risk also
exists for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease
(PD), amyotrophic lateral sclerosis (ALS), and frontotemporal lobar degeneration (FTLD).
Specifically, while GWAS approaches have identified ~200 variants that are associated with the
various neurodegenerative diseases (Welter et al., 2014), few novel biological insights from these
loci have been gained. There are currently no disease-modifying treatments for these fatal
diseases, and the prevalence of neurodegenerative disease is expected to increase rapidly as the
world population ages (Chen and Zheng, 2012; Katsnelson et al., 2016). Thus, there is an urgent
need for advances in our understanding of their underlying pathophysiology.
In 2010, common genetic variants at the TMEM106B locus on chromosome 7p21 were
found to be significantly associated with risk for FTLD by GWAS (Van Deerlin et al., 2010). In
addition, these

variants

have been associated

with

various

other

neurological

and

neurodegenerative phenotypes, suggesting that genetic variation at the TMEM106B locus plays an
important role in the pathophysiology of neurodegeneration. As FTLD is an untreatable, fatal
disease (Bang et al., 2015; Seelaar et al., 2011), it is important to understand how genetic variation
at the TMEM106B locus affects disease risk, which is the focus of Chapter 5.2. In this section, I
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discuss the discovery and replication of FTLD-associated variants on chromosome 7p21, and the
subsequent discovery of the 7p21 locus as a genetic modifier of Mendelian forms of FTLD.
5.1.1

Genetic variation at TMEM106B affects risk for frontotemporal lobar degeneration
The first GWAS performed to identify genetic risk factors for FTLD consisted of a

neuropathologically homogeneous cohort of FTLD-TDP cases and ancestry-matched controls (Van
Deerlin et al., 2010). Since neuropathologically distinct forms of FTLD (FTLD-TDP, FTLD-tau or
FTLD-FUS) may result from different underlying disease mechanisms (Mackenzie and Neumann,
2016), the homogeneity of this cohort may have increased power to detect genetic risk factors of
relatively small effect (Van Deerlin et al., 2010).

Of >500,000 genotyped single nucleotide

polymorphisms (SNPs), three SNPs reached a genome-wide significant association with FTLDTDP.

All three SNPs are located in or near the TMEM016B gene, which was completely

uncharacterized at the time of the discovery (Van Deerlin et al., 2010). The SNPs are in strong
linkage disequilibrium (LD) with each other (pairwise r2=0.7 to 1), and are also in strong LD with
>100 other genetic variants, together comprising a 36kb haplotype block in individuals of Western
European ancestry (1000 Genomes Project Consortium et al., 2010). The lack of association of
these other strongly linked variants with disease is due to the absence of these variants on the
genotyping arrays used in the study, which is a common problem in GWAS, since genotyping
arrays only genotype ~5% of known human SNPs (Edwards et al., 2013). Thus, the three FTLDTDP-associated SNPs are simply tagging a much larger FTLD-TDP risk haplotype, and
theoretically, any one (or more) of the 100+ variants in strong LD may be the cause of the
association (the “causal variant(s)”). The risk alleles of these linked variants have allele frequencies
of ~60% in populations of Western Europeans ancestry (1000 Genomes Project Consortium et al.,
2015) (Figure 1.2), suggesting that the causal variant or variants may be very common.
Interestingly, the association of TMEM106B SNPs with FTLD-TDP was stronger in GRN+ FTLDTDP cases than in FTLD-TDP cases without GRN mutations (Van Deerlin et al., 2010), suggesting
a potential genetic modifier effect of TMEM106B haplotype in the presence of highly penetrant
GRN mutations.

165

Importantly, the association of two of the three SNPs with FTLD-TDP was replicated in an
independent cohort in the original GWAS study (one SNP, rs6966915, could not be successfully
genotyped in the replication phase) (Van Deerlin et al., 2010), and was also replicated by two
independent research groups using largely clinically-defined FTLD cases (Finch et al., 2011; van
der Zee et al., 2011). One replication study in particular confirmed that the association was
strongest in GRN+ FTLD-TDP cases (Finch et al., 2011). A third replication study, Rollinson et al.
(2011), did not detect an association between the TMEM106B SNPs and FTLD in a cohort of 312
clinical FTLD cases and 248 controls (Rollinson et al., 2011a). However, this case cohort did not
include any GRN mutation carriers or autopsy-confirmed TDP-43 cases, and thus was likely more
heterogeneous (and thus underpowered) than the other studies. It is worth mentioning, however,
that this study did observe a trend towards association for one of the three GWAS SNPs, in the
same direction reported in the GWAS and other replication studies (Rollinson et al., 2011a).
Furthermore, a recent meta-analysis combining the GWAS and all published replication studies
confirmed a statistically significant association between rs1990622 and FTLD, with all studies
demonstrating the same direction of effect; specifically, the major allele of rs1990622 associates
with increased risk for FTLD (Hernandez et al., 2015). Thus, TMEM106B is a validated risk locus
for FTLD, and appears to be particularly strongly associated with disease risk when analyzing only
GRN+ FTLD-TDP cases, or FTLD-TDP cases more generally.
A second FTLD GWAS was published in 2014, but rather than using a neuroapthologicallydefined cohort, as in the FTLD-TDP GWAS, the authors used multiple cohorts defined by their
clinical symptoms (Ferrari et al., 2014). Specifically, the cohorts consisted of anywhere from 115
to 1,634 individuals with FTLD, all with a specific clinical subtype, and 7,444 controls. As with the
FTLD-TDP GWAS, all individuals were of Western European ancestry.

The study identified

significant associations between genetic variants at the HLA-DRA/HLA-DRB and BTNL2 loci with
FTLD (no significant sub-type-specific associations were found), but did not observe a significant
association with variants at or near TMEM106B (Ferrari et al., 2014). However, the use of clinicallydefined cases very likely increases neuropathological heterogeneity (see Chapter 1.1), and thus
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might preclude the ability to detect a risk factor that affects risk for a specific neuropathological
subtype, e.g. TMEM106B for FTLD-TDP. Indeed, clinical FTLD subtypes are generally not good
predictors of FTLD neuropathological subtypes (Seelaar et al., 2011). In addition, the authors
excluded GRN+ FTLD-TDP cases, which, as discussed earlier, is a major driver of the association
between TMEM106B haplotype and FTLD-TDP (Finch et al., 2011; Van Deerlin et al., 2010). Thus,
it is not surprising that this GWAS did not detect an association at the TMEM106B locus.
Interestingly, the most significant (sentinel) GWAS SNP, rs1990622, has also been
associated with various other neurological and neurodegenerative phenotypes. Shortly after the
publication of the FTLD-TDP GWAS, the risk allele of rs1990622 was found to be associated with
increased risk of cognitive impairment in ALS (Vass et al., 2011), a disease that shares TDP-43
pathology with FTLD-TDP (Neumann et al., 2006). Two other studies demonstrated that the risk
allele was associated with reduced plasma levels of PGRN (Cruchaga et al., 2011; Finch et al.,
2011), the protein encoded by the GRN gene, thus providing further evidence of an epistatic
interaction between TMEM106B genotype and GRN. Since GRN mutations cause FTLD through
loss-of-function mechanisms (Kleinberger et al., 2013; Petkau and Leavitt, 2014), the risk haplotype
at TMEM106B may increase disease risk in part by altering PGRN levels. Subsequent studies
demonstrated an association between the rs1990622 risk allele and more severe TDP-43
pathology in the brain, both in neurologically normal individuals (Yu et al., 2015) and in individuals
with AD (Rutherford et al., 2012), as well as increased risk of hippocampal sclerosis of aging, a
common neurodegenerative condition (Nelson et al., 2015). Finally, the rs1990622 risk allele
associates with decreased brain functional network connectivity in asymptomatic GRN mutation
carriers (Premi et al., 2014) and reduced temporal lobe gray matter volume, anterior commissure
cross-sectional area, and posterior corpus callosum size (Adams et al., 2014). Thus, the FTLDTDP risk haplotype at TMEM106B affects not only molecular and cellular phenotypes related to
neurodegeneration, but macroscopic brain phenotypes as well.
In summary, common genetic variation at the TMEM106B locus is significantly associated
with risk for developing FTLD-TDP, as well as several other related neurological and
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neurodegenerative phenotypes. Furthermore, the risk allele of rs1990622, the GWAS sentinel
SNP, is highly overrepresented in GRN+ FTLD-TDP cases, suggesting that TMEM106B genotype
may 1) modify disease in the presence of pathogenic GRN mutations, and 2) affect disease risk at
least partially through effects on GRN. However, these associations do not indicate which genetic
variant or variants are causing the associations, nor how one or more functional variants might be
acting in order to influence disease risk. Indeed, it is not clear from the association whether
TMEM106B is actually the gene responsible for conferring disease risk, or whether variation at the
TMEM106B locus might be affecting disease risk through effects on other genes, e.g. through longrange regulatory interactions. These questions, which are of significant scientific and clinical
importance, are discussed in Chapter 5.2.
5.1.2

Genetic

variation

at

TMEM106B

affects

clinical

prognosis

of

Mendelian

frontotemporal lobar degeneration
The enrichment of the rs1990622 risk allele in GRN+ FTLD-TDP cases, as described
above, was initially surprising, given that GRN mutations are highly penetrant (Cruts et al., 2006;
Gass et al., 2006). Why would a disease risk allele that exerts only a small effect on disease risk
(the odds ratio for the risk allele of rs1990622 is 1.64), be overrepresented (or underrepresented)
in individuals with a Mendelian disease-causing mutation?

One potential explanation is that

TMEM106B genotype plays a disease-modifying role in the presence of pathogenic GRN
mutations. Such a mechanism is plausible, given the extremely wide range of ages at which GRN
mutation carriers develop FTLD symptoms (Benussi et al., 2015). Consistent with this hypothesis,
two studies published shortly after the FTLD-TDP GWAS reported that the rs1990622 risk allele is
associated with a ~12-13 year earlier age at disease onset in GRN+ FTLD-TDP cases (Cruchaga
et al., 2011; Finch et al., 2011). An epistatic interaction between TMEM106B and GRN is further
supported by the findings summarized in Chapter 5.1.1, as well as the cellular co-localization of
TMEM106B and PGRN within LAMP-1+ organelles (Chen-Plotkin et al., 2012), which mark late
endosomes and lysosomes (Lamb et al., 2013). Thus, TMEM106B genotype not only affects risk
of developing FTLD-TDP, but also affects the clinical presentation of a Mendelian form of FTLD-
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TDP. Finch et al. (2011) reported that while 19.1% of control individuals are homozygous for the
rs1990622 protective allele, only 2.6% of GRN+ FTLD-TDP individuals have this specific genotype
(P=0.009) (Finch et al., 2011). While it is unclear whether the protective haplotype simply delays
age at onset or reduces the penetrance of the GRN mutations, these results suggest an interaction
between TMEM106B and GRN in FTLD-TDP pathogenesis.
As discussed in Chapter 1, the three major genetic causes of FTLD are mutations in the
MAPT, GRN, and C9orf72 genes, with C9orf72 being the most common cause of FTLD, ALS, and
FTLD/ALS (Tan et al., 2017). Importantly, disease-causing hexanucleotide repeat expansion
(HRE) mutations result in TDP-43 pathology (Al-Sarraj et al., 2011), and, similar to GRN mutations,
are likely not fully penetrant, given that they are present in some sporadic FTLD cases (Tan et al.,
2017) and have been found in neurologically normal individuals of advanced age (Beck et al., 2013;
Harms et al., 2013; Majounie et al., 2012). Thus, it is possible that TMEM106B haplotype affects
the clinical manifestation of C9orf72-associated FTLD (C9orf72+ FTLD-TDP) in addition to GRN+
FTLD-TDP.
To test this hypothesis, I investigated whether there is an association between rs1990622
genotype and age at onset or age at death in C9orf72+ FTLD-TDP cases (DeJesus-Hernandez et
al., 2011; Renton et al., 2011). In both discovery and replication cohorts, I observed a statistically
significant association between rs1990622 and both age at death and age at disease onset.
Surprisingly, each copy of the rs1990622 risk allele delayed age at death and age at disease onset,
which is opposite the direction seen in GRN+ FTLD-TDP (Gallagher et al., 2014). In other words,
in the presence of pathogenic C9orf72 HREs, the genotype that increases risk for FTLD-TDP more
generally is actually protective against disease manifestation.
These results were specific to C9orf72+ FTLD-TDP, as rs1990622 genotype had no effect
on age at death or age at onset in mutation-negative FTLD-TDP. At the same time, I also observed
a significant enrichment of the rs1990622 risk allele in C9orf72 HRE carriers, and confirmed the
previously published enrichment of the risk allele in GRN+ and mutation-negative FTLD-TDP
patients (Gallagher et al., 2014). Importantly, an independent study from another group confirmed
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the enrichment of the rs1990622 risk allele in C9orf72+ FTLD-TDP (van Blitterswijk et al., 2014).
This group did not observe an effect of rs1990622 genotype on age at disease onset, but the
authors performed their analyses by combining C9orf72+ FTLD and ALS cases, thus potentially
precluding the ability to detect a disease-specific effect (van Blitterswijk et al., 2014).
As mentioned above, the protective effects of the rs1990622 risk allele in C9orf72+ FTLDTDP seem counterintuitive, especially given that the risk allele is enriched in C9orf72 HRE carriers.
How could a particular genetic variant (representing a particular haplotype) increase risk of
developing disease in large cohorts consisting of both Mendelian and non-Mendelian cases (Finch
et al., 2011; Van Deerlin et al., 2010; van der Zee et al., 2011), while at the same time protect
against the manifestation of disease in individuals with a specific disease-causing mutation? In the
case of GRN mutation carriers, the enrichment of the rs1990622 risk allele is consistent with the
earlier age at disease onset seen in risk allele carriers – an individual with a GRN mutation is more
likely to develop FTLD-TDP at any given age if he/she has the TMEM106B risk haplotype, thus
creating ascertainment bias in the clinic. Indeed, the scarcity of protective allele homozygotes
among GRN+ FTLD-TDP cases (Finch et al., 2011) suggests that some individuals with the
protective haplotype might never present with clinical FTLD symptoms. However, this type of effect
cannot explain the C9orf72 result, in which the rs1990622 risk allele is 1) enriched in C9orf72+
FTLD-TDP cases, but 2) appears to delay both age at disease onset and age at death.
Several possible explanations may be compatible with these results. First, we may be
observing an artifact of limited sample size. We note, however, that our study, with 30 clinical sites
around the world, is very large (and likely the largest possible in this disease), and the differences
in local clinical practice would tend to bias towards a negative result. Alternatively, the enrichment
of the rs1990622 risk allele in C9orf72 HRE carriers, combined with the protective effects of the
risk allele with regards to disease manifestation, may indicate that the TMEM106B FTLD-TDP risk
haplotype confers a fitness advantage in individuals with the C9orf72 HRE.
While epistatic interactions have been reported for other Mendelian diseases, specifically
cystic fibrosis (Cutting, 2010) and sickle cell disease (Sankaran et al., 2010), the interaction
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between TMEM106B and C9orf72 appears to be a rarer case of “sign epistasis”, in which the
phenotypic outcome of the interaction depends on genetic background (Weinreich et al., 2005).
Specifically, the TMEM106B risk haplotype appears to be deleterious in the absence of the C9orf72
HRE (thus, its association with increased risk of FLTD-TDP), whereas in the presence of the
C9orf72 HRE, it is beneficial. Interestingly, recent cell biological experiments performed in my lab
support a sign epistatic relationship for TMEM106B and C9orf72. As will be discussed in more
detail in Chapter 5.3, overexpression of TMEM106B in various cell types leads to enlarged LAMP1+ late degradative organelles. These organelles fail to acidify properly, resulting in impaired
protein degradation and cell death (Brady et al., 2013; Busch et al., 2016; Chen-Plotkin et al., 2012;
Stagi et al., 2014; Suzuki and Matsuoka, 2016). However, siRNA-mediated knockdown of C9orf72
rescues these phenotypes (Busch et al., 2016), and it is worth noting that human C9orf72 HRE
carriers have reduced C9orf72 protein levels, presumably because the expanded allele cannot be
efficiently translated into functional protein (Ciura et al., 2013; DeJesus-Hernandez et al., 2011;
Donnelly et al., 2013; Gijselinck et al., 2012; Tran et al., 2015). These results suggest that both
TMEM106B and C9orf72 play roles in lysosomal function, and that in the presence of C9orf72
HREs, which reduce C9orf72 protein levels, the TMEM106B risk haplotype (and resulting increased
TMEM106B levels, see Chapter 5.2) may help restore lysosomal homeostasis. In summary,
evidence from human genetics, as well as cellular biological experiments, support a diseasemodifying role of TMEM106B in C9orf72+ FTLD-TDP.
Importantly, the association between rs1990622 genotype and age at onset and/or age at
death in both C9orf72+ and GRN+ FTLD-TDP also strongly suggests that the causal variant
influencing disease risk and manifestation at the TMEM106B locus is common, since these genetic
modifier effects were observed in cohorts of only ~50-100 individuals (Cruchaga et al., 2011; Finch
et al., 2011; Gallagher et al., 2014). As mentioned above, the TMEM106B risk SNP alleles are
very common in the population; thus, a causal variant in strong LD with the GWAS risk SNPs could
potentially explain these genetic modifier effects, whereas a rare causal variant could not. This is
an important point, since an alternative interpretation of GWAS is that common variants may
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associate with disease risk as a result of being in low or partial LD with a rare causal variant of
strong effect (Gibson, 2012). Thus, it can be difficult to determine a priori whether a GWAS causal
variant is in strong LD with the disease-associated SNPs (which is typically assumed, but not
proven), or driven by a “synthetic association” due to partial LD with a rare causal variant. However,
since the associations of TMEM106B SNPs with FTLD-TDP 1) risk and 2) age at onset and death
are likely driven by the same functional variant(s), these genetic modifier effects effectively rule out
the possibility of a rare causal variant at this locus.
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5.2

Increased TMEM106B levels are implicated in frontotemporal lobar

degeneration
The discovery of SNPs at the TMEM106B locus that are associated with risk for FTLDTDP, clinical prognosis in Mendelian forms of FTLD-TDP, several other neurodegenerative
phenotypes, and macroscopic brain phenotypes, raises two critical questions: 1) which genetic
variant or variants are responsible for influencing these phenotypes, and 2) what are the
mechanisms involved? To summarize Chapter 1.2, the challenges in determining the mechanisms
underlying a disease-associated risk locus result mainly from two phenomena: first, genetic variants
associated with disease by GWAS are typically in strong LD with tens, hundreds, or even thousands
of variants that were not genotyped in the GWAS study – thus, the association does not tell you
which variant is causing the association (the “causal variant”) (Edwards et al., 2013). Second, the
association alone does not tell you how the causal variant is acting to influence disease risk. For
example, in the case of the TMEM106B FTLD-TDP risk locus, the fact that the disease-associated
SNPs are located at or near TMEM106B does not necessarily mean that the causal variant is
affecting TMEM106B, rather than any other gene in the genome. Furthermore, the association
does not reveal which molecular mechanisms might be affected by the causal variant, e.g. altering
the amino acid sequence of TMEM106B, altering the genetic regulation of TMEM106B and/or other
genes, etc.
For these reasons, the interpretation of disease-associated loci is challenging, and has
lagged far behind the pace of the discovery of SNP-trait associations by GWAS, which now number
in the thousands (Welter et al., 2014) (see Chapter 1.2). However, in order for a GWAS-identified
risk locus to improve our understanding of the pathophysiology of a particular disease, the
molecular and cellular mechanisms involved must be determined. Unfortunately, while ~200 SNPs
have been associated with risk for AD, PD, ALS, FTLD, and related phenotypes (Welter et al.,
2014), only the PD SNCA risk locus has been investigated mechanistically with regards to the
underlying genetic basis of disease risk (Soldner et al., 2016), and the SNCA gene was already
known to play a key role in PD (Polymeropoulos et al., 1997; Spillantini et al., 1997). Thus, further
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studies are required to determine the mechanisms by which validated risk loci act to confer risk for
neurodegenerative disease, as well as for complex traits in general.
In the case of the 7p21 FTLD-TDP risk locus, two important lines of evidence suggest that
TMEM106B may be the gene responsible for conferring disease risk; specifically, the risk alleles of
the GWAS SNPs, as well as other variants in strong LD with them (i.e. the risk haplotype), are
significantly associated with increased TMEM106B mRNA levels in human cell lines and brain
(GTEx Consortium, 2015; Lappalainen et al., 2013; Liang et al., 2013; Stranger et al., 2012; Yu et
al., 2015), and this expression quantitative trait locus (eQTL) effect does not exist for any other
transcripts genome-wide (GTEx Consortium, 2015; Liang et al., 2013). Thus, the FTLD-TDP causal
variant(s) may increase disease risk by increasing TMEM106B expression. These findings are
consistent with the widely accepted notion that many, if not most, loci associated with disease by
GWAS act to influence disease risk through effects on gene expression levels (Maurano et al.,
2012; Schaub et al., 2012).

Indeed, of the several dozen published studies that have

experimentally identified putative GWAS causal variants, nearly all of them are non-coding and
affect gene expression levels (see Chapter 1.2). In addition, TMEM106B expression levels are
increased in FTLD-TDP brains, compared to controls (Chen-Plotkin et al., 2012; Van Deerlin et al.,
2010). Thus, two independent lines of evidence suggest that increased TMEM106B levels may
play a role in FTLD-TDP pathogenesis.
In the next section, I will discuss the discovery of an upstream genetic regulator that
appears to be at least partially responsible for the elevated levels of TMEM106B seen in FTLDTDP brains. In Chapter 5.2.2, I will discuss the results of an unbiased, comprehensive functional
characterization of all candidate causal variants at the 7p21 FTLD-TDP risk locus, resulting in the
identification of a single SNP that appears to affect transcription factor binding, long-range
chromatin interactions, and transcriptional regulation at TMEM106B.
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5.2.1

TMEM106B expression is elevated in the brains of frontotemporal lobar

degeneration patients
After the discovery and replication of genetic variation at TMEM106B as a risk factor for
FTLD-TDP (Finch et al., 2011; Rollinson et al., 2011a; Van Deerlin et al., 2010; van der Zee et al.,
2011), initial follow-up studies investigated the potential role of TMEM106B in FTLD-TDP
pathogenesis. In the original GWAS, it was observed that TMEM106B mRNA levels were elevated
in FTLD-TDP brains, particularly in GRN+ FTLD-TDP cases, compared to neurologically healthy
controls (Van Deerlin et al., 2010). This effect, reported initially in prefrontal cortex samples, was
independent of TMEM106B genotype, and was later confirmed in temporal and occipital cortex
samples (Chen-Plotkin et al., 2012). Elevated TMEM106B protein levels were also confirmed in a
small sample of GRN+ FTLD-TDP prefrontal cortex samples, compared to controls (Chen-Plotkin
et al., 2012).
These observations led to the hypothesis that increased TMEM106B levels in brain may
either contribute to disease, result from disease, or both. While I discuss in detail the potential
pathogenic role of elevated TMEM106B expression levels in Chapter 5.3, here I discuss the
identification of an important TMEM106B-regulating microRNA that may at least partially explain
the increased TMEM106B levels seen in FTLD-TDP patient brains (Figure 5.1).
5.2.1.1 Dysregulation of the microRNA-132/212 cluster contributes to elevated TMEM106B
levels in frontotemporal lobar degeneration
The observation that TMEM106B levels are elevated in FTLD-TDP, irrespective of
TMEM106B genotype (Van Deerlin et al., 2010), suggests that one or more upstream pathways
regulating the expression of TMEM106B is altered in disease. Taking into account the deleterious
effects of elevated TMEM106B levels in cell culture-based experiments (Brady et al., 2013; Busch
et al., 2016; Chen-Plotkin et al., 2012; Suzuki and Matsuoka, 2016), identifying upstream regulators
of TMEM106B may reveal potential therapeutic targets.
At the time the GWAS was published, it was becoming increasingly clear that microRNAs
(miRs) are critical regulators of gene expression levels, and play important roles in many cellular
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processes (Ameres and Zamore, 2013; Jonas and Izaurralde, 2015). With regards to the nervous
system, miRs have been implicated in neurite outgrowth, neuronal differentiation, synaptic
plasticity, and many other pathways. In addition, miR dysfunction has been implicated in several
neurodegenerative diseases, including AD, PD, ALS, and Huntington’s disease (Goodall et al.,
2013)
My lab performed a microarray-based screen to quantify all known human miRs in FTLDTDP and neurologically normal brains, and identified miR-132 as the most dysregulated miR.
Specifically, miR-132 is expressed at lower levels in FTLD-TDP brains (Chen-Plotkin et al., 2012),
and miR-132 expression has been shown to be required for learning, memory, and neuronal
dendritic branching (Aten et al., 2016). Furthermore, miR-132 has also been shown to be
downregulated in AD, Huntington’s disease, and schizophrenia (Aten et al., 2016); thus, miR-132
may be protective against neurological disease more generally. In addition, two other miRs that
are processed from the same primary transcript as miR-132, miR-132* and miR-212 (Vo et al.,
2005), were also significantly downregulated in FTLD-TDP brains (Chen-Plotkin et al., 2012),
suggesting that the locus from which they arise is less transcriptionally active in disease.
Surprisingly, out of 283 predicted target genes of miR-132 and miR-212 (both miRs have
the same “seed”, and thus many overlapping targets), TMEM106B was the top predicted target by
TargetScan (Lewis et al., 2003), an online microRNA target prediction tool. I confirmed this
prediction using several complementary cell-based assays, specifically demonstrating that miR132 and miR-212 repress TMEM106B mRNA and protein levels through two binding sites in its
3’UTR (Chen-Plotkin et al., 2012). Since miR-132 is expressed at ~100-fold higher levels than
miR-212 (Chen-Plotkin et al., 2012; Magill et al., 2010), it is likely more functionally important.
Therefore, reduced levels of miR-132 in FTLD-TDP may contribute to the elevated levels of
TMEM106B seen in disease brains (Figure 5.1).
While the identification of these miRs as regulators of TMEM106B is notable, several
questions remain: first, are there other, more important regulators of TMEM106B that contribute to
its upregulation in disease? Indeed, the most recent version of TargetScan identifies 287 predicted
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miR binding sites throughout TMEM106B, most of which have different predicted miR regulators
(Agarwal et al., 2015). While it is unlikely that all of these predicted target sites are truly functional,
this does indicate that there are likely multiple miRs that directly regulate TMEM106B levels.
Notably, the therapeutic potential of targeting miR-132 is questionable, since both overexpression
and knockdown approaches have impaired neurological function in vivo (Hansen et al., 2010; Magill
et al., 2010; Scott et al., 2012; Wayman et al., 2008).

In addition, there are likely many

transcriptional pathways that may be affected in FTLD-TDP that either directly or indirectly affect
TMEM106B levels. In support of this, the ENCODE Project has identified >70 transcription factors
that bind (and presumably regulate) the TMEM106B promoter (Gerstein et al., 2012), some of
which may themselves be alternatively regulated in FTLD-TDP. Second, does the downregulation
of miR-132/212 and upregulation of TMEM106B contribute to disease, result from disease, or both?
If this is truly a key pathway in FTLD pathogenesis, animal models may be required in order to
determine the specific role of these miRs, as well as TMEM106B levels, in disease pathogenesis.
For example, miR-132 is known to be induced by synaptic activity, in which BDNF signaling
activates CREB target genes (including miR-132/212) in order to facilitate neuronal plasticity (Vo
et al., 2005). Do defects in this signaling pathway contribute to the development of FTLD by altering
miR-132-mediated regulation of TMEM106B, and, potentially, other genes? Or, conversely, does
the presence of FTLD adversely affect these pathways?

It is also possible that increased

TMEM106B levels may act upstream of miR-132/212 dysregulation. For example, given the
deleterious effects of increased TMEM106B levels in cells (see Chapter 5.3), elevated TMEM106B
levels may first accelerate disease pathways leading to neurodegeneration, which then results in
impaired miR-132/212 regulatory pathways, possibly due to impaired BDNF signaling and/or
synaptic plasticity. In this way, TMEM106B upregulation may be reinforced through a positive
feedback loop involving impaired repression by miR-132/212.
In Chapter 5.3, I discuss the evidence supporting a deleterious effect of increased
TMEM106B levels on cells. Before that, however, I will discuss evidence that more than one route
may lead to the same intermediate step of increased TMEM106B expression (Figure 5.1).
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Specifically, I will discuss the primary data presented in Chapter 4, suggesting that the common
variant responsible for the association of the 7p21 locus with FTLD-TDP risk affects TMEM106B
expression levels through changes in chromatin architecture.
5.2.2

The TMEM106B risk haplotype is associated with increased TMEM106B levels
Chapter 1.2 discusses in detail the challenges regarding interpreting the biological

mechanisms underlying the association of a genetic locus with disease risk by GWAS. These
challenges were re-stated above, in Chapter 5.2, regarding 1) the concept of a haplotype block, in
which many co-inherited variants are often similarly associated with disease risk or other
phenotypes (Edwards et al., 2013), and 2) the difficulty in determining the molecular mechanisms
by which the “causal variant” influences disease risk, due in large part to the location of most
disease-associated variants in non-protein-coding regions of the genome (Maurano et al., 2012;
Schaub et al., 2012). Consequently, the questions that arise after the identification of a diseaseassociated locus are: 1) what is the causal variant, and 2) how does the causal variant act to
influence disease risk?
Fortunately, a plausible hypothesis regarding question 2 can sometimes be formulated
based on publicly available genome-wide studies. As discussed in Chapter 1.2, thousands of
genetic variants have been associated with gene expression levels in an unbiased, genome-wide
manner, in dozens of cell and tissue types (Albert and Kruglyak, 2015).

These expression

quantitative trait loci (eQTLs) show significant overlap with GWAS-identified risk variants (Fu et al.,
2012; Nicolae et al., 2010; Schaub et al., 2012), suggesting that some disease risk loci may act by
altering the expression levels of one or more genes. This result is consistent with the observation
that >90% of disease-associated variants reside in non-protein-coding regions of the genome, and
are enriched in predicted cis-regulatory elements, as determined by epigenomic features such as
chromatin accessibility, transcription factor (TF) binding, and specific post-translational histone
modifications (Farh et al., 2015; Maurano et al., 2012; Raj et al., 2014; Schaub et al., 2012).
In the FTLD-TDP GWAS, Van Deerlin and colleagues (2010) reported that the risk alleles
of the FTLD-TDP-associated SNPs had been associated with increased TMEM106B mRNA levels
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in an eQTL study performed in Epstein-Barr virus-immortalized B lymphoblastoid cell lines (LCLs)
(Dixon et al., 2007; Van Deerlin et al., 2010). This result has been replicated several times
(Lappalainen et al., 2013; Liang et al., 2013; Stranger et al., 2012), and has also been reported in
various primary immune cell types (Fairfax et al., 2014; Peters et al., 2016; Raj et al., 2014), as
well as several human brain regions (GTEx Consortium, 2015; Yu et al., 2015). Furthermore, the
GWAS SNPs are not significantly associated with the expression levels of any other genes (GTEx
Consortium, 2015; Liang et al., 2013). Thus, correlative data suggests that the TMEM106B risk
haplotype may increase disease risk by increasing TMEM106B levels. The establishment of an
eQTL effect also helps one begin to address question 1 above, since the causal variant underlying
such an effect is likely to be located in either a transcriptional regulatory element or a region of the
TMEM106B transcript that affects mRNA splicing or stability.
In the following section, I discuss the results of the functional characterization of all
candidate causal variants at the TMEM106B FTLD-TDP risk locus, as described in Chapter 4. By
combining trans-ethnic fine-mapping, bioinformatics, experimental approaches, and computational
analyses, I identify a putative noncoding causal variant that affects binding of the transcription factor
CCCTC-binding factor (CTCF) ~7kb downstream of TMEM106B, with resulting alterations in longrange chromatin interactions between multiple cis-regulatory elements. I also demonstrate that
SNPs associated with risk for neurodegenerative diseases in general are enriched in brain CTCF
binding sites, suggesting a more general role of CTCF-mediated gene expression programs in
neurodegeneration. These results provide an example of the functional dissection of a GWAS
locus, which has rarely been done in the field of neurodegeneration. I highlight below the key
strengths and weaknesses of our approach, comparing them with other examples from the rapidlydeveloping field of functional genomics.
5.2.2.1 A frontotemporal lobar degeneration-associated risk variant near TMEM106B affects
chromatin architecture and TMEM106B regulation
The FTLD-TDP risk haplotype spans ~36kb and contains >100 strongly linked variants,
including the three SNPs associated with disease risk by GWAS. In order to narrow down the list
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of candidate causal variants, I performed trans-ethnic fine-mapping of the TMEM106B eQTL signal
with a multi-ethnic LCL eQTL study (Stranger et al., 2012). Trans-ethnic fine-mapping takes
advantage of the smaller haplotype blocks present in African populations (Campbell and Tishkoff,
2008), and has successfully been used to refine regions of genomic association first identified in
individuals of Western European or Asian ancestry (Edwards et al., 2013; Glubb et al., 2015). In
addition, I used this multi-ethnic study to perform conditional analyses in order to demonstrate that
the association signals at the TMEM106B locus for 1) TMEM106B expression and 2) disease risk
are statistically indistinguishable. Thus, the same causal variant(s) likely underlie both signals,
suggesting that the eQTL effect is indeed the molecular phenotype that confers disease risk at this
locus.
I then investigated the functions of all three predicted LCL cis-regulatory elements (CREs)
that contain at least one of the fine-mapped eQTL variants. Two of the CREs display epigenetic
features associated with inactive or “poised” enhancers in LCLs (Creyghton et al., 2010; RadaIglesias et al., 2011); consistently, they showed little to no enhancer activity in LCL reporter assays,
regardless of which SNP alleles were present. Furthermore, these regions do not display any
activity-associated epigenetic marks in the various brain tissues analyzed by the Roadmap
Epigenome Project (Roadmap Epigenomics Consortium et al., 2015), suggesting that they are not
functional in brain. While there are several potential reasons that these results may be false
negatives, they are relatively unlikely: first, while some enhancers only become active in response
to certain cellular signals (Engel et al., 2016; Shlyueva et al., 2014), the TMEM106B eQTL effect
has reproducibly been detected in unstimulated LCLs (GTEx Consortium, 2015; Lappalainen et al.,
2013; Liang et al., 2013; Stranger et al., 2012). Thus, the mechanisms underlying the eQTL effect
should be present in unstimulated LCLs. Second, plasmid-based reporter assays test genomic
regions for regulatory activity in an artificial context. Many genomic features, such as association
with histones, the relative positions of genomic regions, and long-range chromatin interactions, are
absent in the context of a reporter plasmid; thus, such assays are subject to false positive and false
negative results (Inoue and Ahituv, 2015). While the epigenetic signatures of these potential
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enhancer regions at the TMEM106B locus are not consistent with an active state, genomic deletion
of these regions would be required to definitively demonstrate that they have either no effect, or no
allele-specific effect, on TMEM106B levels.
The third CRE contains three SNPs and displays binding of the transcription factor CTCF
in virtually all cell types tested, including LCLs, neuronal and glial cells. CTCF has been implicated
in various aspects of eukaryotic gene expression over ~25 years, including transcriptional
activation, enhancer blocking, and chromatin barrier functions (Ong and Corces, 2014). Over the
past ~10 years, however, genome-wide analyses of CTCF binding sites and chromatin architecture
in mammalian cells have begun to establish a more central theme regarding the role of CTCF in
gene regulation. These studies strongly suggest that the primary role of CTCF in mammals is to
organize the three-dimensional structure of the genome by facilitating long-range chromatin looping
interactions (Dixon et al., 2012; Kim et al., 2007b; Nora et al., 2012; Rao et al., 2014; Tang et al.,
2015; Zuin et al., 2014). These interactions result in the compartmentalization of the genome into
several tiers of organization, of which the best characterized is the “topologically-associated
domain”, or “TAD”, which typically ranges in size from ~40kb to ~3Mb (Dixon et al., 2012;
Merkenschlager and Nora, 2016; Nora et al., 2012; Rao et al., 2014).

Active genes and

enhancer/promoter (E/P) interactions tend to be located within TADs, and several studies have
demonstrated that particular CTCF binding sites are required for establishing TADs and enhancermediated gene regulation (Dowen et al., 2014; Guo et al., 2015; Lupianez et al., 2015; Rao et al.,
2014; Tang et al., 2015). Therefore, I hypothesized that one or more SNPs in this CTCF site might
regulate TMEM106B transcription through effects on long-range interactions between distal CREs.
In support of this hypothesis, one of the three SNPs located within the CTCF binding region,
rs1990620 (which is in complete LD with the sentinel GWAS SNP rs1990622), displays allelespecific recruitment of CTCF in nuclear extract, and these results are corroborated by CTCF ChIPseq experiments performed in various cell lines. The agreement between these two approaches,
which employ completely different methodologies, strengthens the conclusion that rs1990620
functionally affects CTCF binding at this region. Importantly, Capture-C experiments demonstrate
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that strong long-range interactions take place between the CTCF site, the TMEM106B promoter,
and a predicted active enhancer, and that these interactions take place within a ~250kb TAD
delineated by CTCF boundary sites.

Interestingly, this enhancer was confirmed to produce

bidirectional transcripts, a distinguishing feature of active enhancers (Li et al., 2016), in primary
human blood cells and brain samples by the FANTOM Consortium (Andersson et al., 2014).
Moreover, the transcriptional activity of the enhancer correlates significantly with the transcriptional
activity of TMEM106B across cell and tissue types (Andersson et al., 2014), which, combined with
the Capture-C data, suggest that this enhancer regulates TMEM106B. Thus, I hypothesized that
rs1990620 might affect TMEM106B transcription by altering CTCF-mediated long-range
interactions within the TAD, with indirect effects on interactions between TMEM106B and a putative
active enhancer. Consistently, analysis of the Capture-C data using haplotype marker SNPs
indeed suggests that the long-range interactions at the TMEM106B locus are stronger on the risk
haplotype in heterozygous cells. These data are consistent with the current model of TAD function,
in which CTCF sites facilitate E/P interactions within TADs, but prevent E/P interactions between
different TADs (Merkenschlager and Nora, 2016).
While several studies have demonstrated allele-specific long-range interactions between
putative CREs harboring nominated GWAS causal variants and their target promoters (Dunning et
al., 2016; Nakaoka et al., 2016; Painter et al., 2016; Stadhouders et al., 2014; Vicente et al., 2015),
these findings, to my knowledge, represent the first example of a GWAS causal variant affecting
the higher-order chromatin architecture within which enhancer/promoter interactions take place.
Indeed, few studies have investigated allele-specific CTCF-mediated interactions, and the genomewide approaches used to investigate them drastically reduce the sensitivity to detect them (Tang
et al., 2015). Thus, the Capture-C approach utilized in Chapter 4 will likely be an important tool for
investigating chromatin architecture in more detail at specific loci.
While the results discussed here are consistent with a role of one particular CTCF site in
allele-specific long-range interactions and transcriptional regulation (Figure 5.1), several key
questions remain unresolved. First, which specific interactions are required for allele-specific
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expression of TMEM106B? Our experiments lacked the sequencing depth required to detect allelespecific differences in specific interactions, such as between the TMEM106B promoter and the
CTCF site, or between the promoter and the enhancer. However, the traditional chromosome
conformation capture (3C) approach, which employs qPCR primers specific for pre-selected
interacting regions, might be sufficiently quantitative to detect such effects (Denker and de Laat,
2016). Second, the magnitude of the allele-specific interaction differences are small: from the
promoter viewpoint, I observe a 6-13% difference that is reduced to a 4-8% difference after
adjusting for the estimated technical bias; from the CTCF site viewpoint, I observe a 5-15%
difference after adjustment for bias, depending on which marker SNP is used. These results are
highly significant since they are based on thousands of sequencing reads, but it is unclear whether
such small changes in long-range interaction frequencies would be sufficient to cause a meaningful
difference in target gene expression levels. As mentioned above, very little is known about the
nature of allele-specific long-range interactions. It is also possible that at the TMEM106B locus,
only one, or a few, specific interactions are truly allele-specific, in which case totaling all the
interactions across large genomic intervals, as was done in the analyses presented in Chapter 4,
would dilute the estimated magnitude of the effect. Third, the allele-specific differences in longrange interactions could be unrelated to the allele-specific expression of TMEM106B, and could be
due to either technical or biological noise. Fourth, no experiments (with the exception of EMSAs)
were performed in brain-relevant tissue or cell lines. Indeed, while the eQTL effect has been
reported in several brain regions (GTEx Consortium, 2015; Yu et al., 2015), it is not clear which cell
type(s) the eQTL effect is coming from. I discuss potential follow-up experiments to address these
questions in detail in Chapter 5.4.
In summary, I performed a comprehensive prioritization and functional characterization of
all candidate causal variants at the 7p21 FTLD-TDP risk locus. The association of the FTLD-TDP
risk SNPs with TMEM106B expression and no other genes, combined with the fine-mapping and
conditional analyses, suggest that one or more causal variants at this locus influence disease risk
by altering TMEM106B expression. After ruling out effects on mRNA stability and prioritizing

183

candidate causal variants based on epigenomic annotations in LCLs and brain-relevant cell lines,
I identified three potential CREs, only one of which displays evidence of activity in brain. This CRE
contains a putative functional SNP that affects recruitment of CTCF, and potentially other TFs,
downstream of TMEM106B, and this appears to affect long-range regulatory interactions between
multiple CREs spanning hundreds of kilobases. While the specific mechanisms linking allelespecific long-range interactions with allele-specific expression of TMEM106B have yet to be
determined, I also demonstrated that SNPs associated with risk for neurodegenerative diseases
are enriched in brain CTCF binding sites, as determined by ENCODE ChIP-seq experiments.
Thus, CTCF-mediated gene expression programs may play a more general role in risk for
neurodegeneration.
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5.3

Increased TMEM106B levels lead to lysosomal abnormalities and cell death
In Chapter 5.2, I summarized two independent mechanisms by which increased

TMEM106B levels may be involved in FTLD pathogenesis. First, TMEM106B levels are increased
in FTLD-TDP brains, particularly in GRN+ FTLD-TDP cases, and this at least partially results from
the downregulation of microRNA-132 and microRNA-212, which repress TMEM106B levels directly
(Chen-Plotkin et al., 2012; Van Deerlin et al., 2010). Second, the FTLD-TDP risk haplotype is
associated with increased TMEM106B mRNA levels in human cell lines and brain (GTEx
Consortium, 2015; Lappalainen et al., 2013; Liang et al., 2013; Stranger et al., 2012; Yu et al.,
2015), and this appears to result from allele-specific recruitment of the transcription factor CTCF to
a cis-regulatory region downstream of TMEM106B.

The CTCF binding site, as well as the

TMEM106B promoter, are involved in long-range interactions between distal cis-regulatory
elements, and these interactions are stronger on the risk haplotype. Given that several recent
studies have implicated such long-range interactions in transcriptional activation, (Merkenschlager
and Nora, 2016; Rao et al., 2014; Tang et al., 2015), this may be the mechanism by which
TMEM106B levels are increased in risk haplotype carriers. While these results suggest a putative
mechanism by which disease-associated genetic variation at this locus affects disease risk, they
do not demonstrate whether increases in TMEM106B levels are deleterious.
In the following sections, I will discuss published and un-published work that suggest that
the TMEM106B protein is involved in endolysosomal pathways, and that increased TMEM106B
levels result in endolysosomal abnormalities, impaired protein degradation, and cell death (Figure
5.1). I will also discuss the role of C9orf72 in modifying these phenotypes, as this may underlie the
ability of TMEM106B genotype (and thus, genotype-dependent TMEM106B expression levels) to
modify disease course in C9orf72+ FTLD-TDP cases (Gallagher et al., 2014).
5.3.1

Increased TMEM106B levels cause endolysosomal phenotypes and cell death
When the TMEM106B locus was first associated with FTLD-TDP by GWAS (Van Deerlin

et al., 2010), nothing was known about the TMEM106B gene, or the encoded protein. While the
GWAS association does not prove that TMEM106B is the gene responsible for conferring risk for
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disease (Edwards et al., 2013), no other genes are located within ~380kb upstream and ~85kb
downstream of TMEM106B (Hinrichs et al., 2016). Thus, initial studies focused on characterizing
the TMEM106B protein, under the assumption that TMEM106B was indeed the gene responsible
for the GWAS association. As discussed in Chapter 5.2, the reported associations between the
FTLD-TDP-associated SNPs and the expression levels of TMEM106B, but no other genes, support
this assumption.
Multiple studies have characterized the molecular and cellular roles of TMEM106B, and
most have reached similar conclusions. First, TMEM106B is a heat-sensitive, glycosylated, 31kDa
protein that exists in both monomeric and dimeric forms, and localizes mainly to late LAMP-1+
organelles, which consist of late endosomes and lysosomes (Brady et al., 2013; Busch et al., 2016;
Chen-Plotkin et al., 2012; Lang et al., 2012; Nicholson et al., 2013; Schwenk et al., 2014; Stagi et
al., 2014).

Thus, TMEM106B may be involved in protein degradation pathways, such as

endocytosis and autophagy (Lamb et al., 2013). More specifically, TMEM106B is an integral
endo/lysosomal membrane protein oriented in a Type II manner, with the N-terminus facing the
cytoplasm (Lang et al., 2012; Stagi et al., 2014). TMEM106B expression has been detected in
various human cancer cell lines, mouse and rat primary neurons, and non-human primate
fibroblasts, and immunohistochemistry has confirmed TMEM106B expression in both neuronal and
non-neuronal cell types in human brain tissue sections (Brady et al., 2013; Busch et al., 2013;
Busch et al., 2016; Chen-Plotkin et al., 2012; Lang et al., 2012; Nicholson et al., 2013; Schwenk et
al., 2014; Stagi et al., 2014).
Second, TMEM106B co-localizes extensively with PGRN (Brady et al., 2013; Chen-Plotkin
et al., 2012; Nicholson et al., 2013), suggesting a potential interaction between these two FTLDassociated proteins (Cruts et al., 2006; Gass et al., 2006). Several studies have reported that
overexpression of TMEM106B results in the intracellular (and sometimes extracellular)
accumulation of PGRN (Brady et al., 2013; Chen-Plotkin et al., 2012; Nicholson et al., 2013). These
results are interesting, given the reported associations between TMEM106B genotype and plasma
PGRN levels, as well as the ability of TMEM106B genotype to modify age at disease onset in GRN+
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FTLD-TDP cases (Cruchaga et al., 2011; Finch et al., 2011). Thus, TMEM106B genotype may
affect disease manifestation in GRN+ FTLD-TDP, as well as risk for FTLD-TDP more generally,
through effects on PGRN levels.
Third, manipulation of TMEM106B levels alters lysosomal morphology and function. Many
studies have reported that overexpression of TMEM106B results in a significant enlargement of
LAMP-1+ late endosomes and lysosomes, referred to from here on as lysosomes for simplicity
(Brady et al., 2013; Busch et al., 2016; Chen-Plotkin et al., 2012; Stagi et al., 2014), whereas
TMEM106B knockdown does not appear to affect lysosomal size (Stagi et al., 2014). Interestingly,
the enlarged lysosomes seen in TMEM106B-overexpressing cells fail to acidify properly (Brady et
al., 2013; Busch et al., 2016; Chen-Plotkin et al., 2012), and we and others have reported impaired
degradation of the epidermal growth factor receptor after treatment of cells with its ligand, epidermal
growth factor (Brady et al., 2013; Busch et al., 2016). Thus, increased TMEM106B levels may
adversely affect protein degradation through effects on the endolysosomal pathway.
Finally, TMEM106B overexpression has also been reported to induce cell death through
caspase-dependent pathways, and possibly lysosomal pathways as well (Busch et al., 2016;
Suzuki and Matsuoka, 2016). TMEM106B-induced cytotoxicity and impaired lysosomal function is
dependent upon localization of TMEM106B to lysosomes, as overexpression of a mutant form of
TMEM106B that fails to localize to lysosomes does not cause these phenotypes, despite high
expression levels (Busch et al., 2016). Furthermore, I demonstrate in Chapter 4 that even modest
(~2-fold) increases in TMEM106B levels are sufficient to produce these phenotypes, and I have
found that even lower levels (~1.2-fold) of overexpression are sufficient to cause the enlarged
lysosome phenotype (unpublished data). These results suggest that the modest expression level
changes associated with the TMEM106B eQTL effect (estimated magnitudes range from ~15-60%,
depending on cell type (GTEx Consortium, 2015; Liang et al., 2013; Peters et al., 2016; Stranger
et al., 2012)), which likely underlies the effect of this locus on disease risk, are sufficient to produce
deleterious phenotypes in human cells (Figure 5.1).
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To further investigate the effects of TMEM106B levels on lysosomes in neurons, Schwenk
et al. (2014) knocked down TMEM106B in primary rat hippocampal neurons, and observed
enhanced retrograde transport of lysosomes and impaired dendritic branching (Schwenk et al.,
2014). The effect on dendritic branching was phenocopied by overexpressing a dominant-negative
form of Rab7a, which blocks cargo transport from early to late endosomes and lysosomes, and
inhibits lysosomal biogenesis (Mukhopadhyay et al., 1997; Press et al., 1998). Thus, TMEM106B
may be required for proper dendritic branching through effects on lysosomal function. In order to
identify TMEM106B-interacting partners, the authors immunoprecipitated TMEM106B from P15 rat
brain, and performed mass spectrometry to identify other proteins that were pulled down along with
it.

With this approach, they identified microtubule-associated protein 6 (MAP6) as the only

TMEM106B-interacting protein found in three independent experiments, subsequently confirming
its interaction with TMEM106B with co-immunoprecipitation experiments (Schwenk et al., 2014).
Interestingly, overexpression of MAP6 phenocopied the effects of TMEM106B, whereas MAP6
knockdown rescued these effects in TMEM106B knockdown cells (Schwenk et al., 2014). Thus,
TMEM106B and MAP6 may play opposing roles in lysosomal transport and dendritic branching.
Stagi et al. (2014) independently investigated potential TMEM106B-interacting partners by
performing a yeast two-hybrid screen (Stagi et al., 2014). They performed two separate screens,
with one using the cytosolic N-terminal fragment (amino acids 1-96) of TMEM106B as the bait, and
the other using the luminal C-terminal fragment (amino acids 118-274) as the bait. While it is
possible that splitting the protein into two parts in this manner could result in false positives and
false negatives due to effects on secondary and tertiary structure, the authors confirmed
interactions identified in the screen with subsequent co-immunoprecipitation experiments. Using
this approach, they identified the endocytic adaptor proteins adaptor related protein complex μ 1
subunit (AP2M1) and clathrin heavy chain (CLTC) as TMEM106B N-terminal interacting partners
(Stagi et al., 2014). In addition, transmembrane protein 106C (TMEM106C), which shares only
47% amino acid homology with TMEM106B, was also shown to interact with TMEM106B, resulting
in heterodimers at the lysosomal membrane; unfortunately, nothing is known about the cellular
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Figure 5.1. Model for how increased TMEM106B expression levels increase risk for
FTLD.
Increased levels of TMEM106B in the brain result from 1) decreased levels of the negative
regulator microRNA-132, and/or 2) the risk allele of rs1990620, which increases CTCFmediated long-range regulatory interactions. At the cellular level, increased TMEM106B levels
impair lysosomal function and cellular health, which increases risk for neurodegeneration and
the development of FTLD symptoms.
functions of TMEM106C. While the authors did not determine the functional implications of these
interactions, they went on to demonstrate that TMEM106B overexpression and knockdown
impaired and enhanced lysosomal transport in both anterograde and retrograde directions,
respectively, in mouse cortical neurons (Stagi et al., 2014). They also showed that TMEM106B
overexpression activates the transcription factor EB (TFEB)-mediated lysosomal stress response,
in which TFEB localizes to the nucleus to activate lysosomal stress response genes (Sardiello et
al., 2009; Stagi et al., 2014).
In conclusion, multiple studies have confirmed a role for TMEM106B in lysosome function,
protein degradation and cellular health. TMEM106B also co-localizes with PGRN and affects
PGRN levels, which may underlie the TMEM106B genetic modifier effect in GRN+ FTLD-TDP
cases. While potential TMEM106B interacting partners have been proposed, the two relevant
studies employed different approaches and obtained non-overlapping results. Taken together,
further studies will be required in order to identify the precise molecular function of TMEM106B,
and how altered TMEM106B levels affects lysosomal and other cellular phenotypes.
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5.3.2

TMEM106B and C9orf72 interact to affect endolysosomal phenotypes and cell

death
Given the genetic modifier effects of TMEM106B genotype in GRN+ FTLD-TDP and
C9orf72+ FTLD-TDP cases, the molecular and cellular relationships between TMEM106B, PGRN
and C9orf72 are an important area of inquiry. As mentioned above, TMEM106B and PGRN colocalize at LAMP-1+ organelles, and TMEM106B overexpression affects PGRN levels. Thus,
expression levels of TMEM106B, which are influenced by TMEM106B genotype, may influence
disease manifestation through effects on PGRN levels.
Based on the discovery that TMEM106B genotype also affects the course of disease in
C9orf72+ FTLD-TDP (Gallagher et al., 2014), my lab has investigated the potential cellular
relationship between TMEM106B and C9orf72. This area of investigation is particularly important
given the surprising direction of the genetic modifier effect in C9orf72+ FTLD-TDP; specifically, the
major allele of rs1990622, the sentinel GWAS SNP, is associated with increased risk of FTLD-TDP
in cohorts consisting of both Mendelian and non-Mendelian cases (Finch et al., 2011; Hernandez
et al., 2015; Van Deerlin et al., 2010; van der Zee et al., 2011), but delays age at disease onset
and age at death in C9orf72+ FTLD-TDP cases (Gallagher et al., 2014). Since the pathogenic
C9orf72 hexanucleotide repeat expansion (HRE) mutations are thought to result in both loss of
normal C9orf72 function (as a result of reduced wild-type C9orf72 mRNA and protein levels) and
one or more toxic gain-of-functions (Todd and Petrucelli, 2016), the genetic modifier role of
TMEM106B may be difficult to understand mechanistically.
Recent work from my lab and others, however, has suggested that TMEM106B and
C9orf72 may play similar roles in lysosomal function and lysosome-related cellular phenotypes. As
mentioned in Chapter 5.1.2, my lab has shown that the deleterious effects of TMEM106B
overexpression (enlarged, poorly acidified lysosomes, and cytotoxicity) are rescued upon C9orf72
knockdown, and thus, depend on the presence of C9orf72 (Busch et al., 2016). These experiments
suggest that the normal functions of C9orf72 (vs. the aberrant toxic functions conferred by the RNA
foci and dipeptide repeat proteins originating from the HRE) may lie in the same lysosomal
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pathways as those involving TMEM106B. Indeed, several recent studies have implicated C9orf72
in lysosomal/autophagy pathways (Farg et al., 2014; Sellier et al., 2016; Sullivan et al., 2016;
Ugolino et al., 2016; Webster et al., 2016; Yang et al., 2016). Specifically, C9orf72 has been shown
to interact with several autophagy-associated proteins, such as RAB1, SMCR8, WDR41, and ULK1
(Ciura et al., 2016; Farg et al., 2014; Jung et al., 2017; Sellier et al., 2016; Sullivan et al., 2016;
Webster et al., 2016; Yang et al., 2016); indeed, SMCR8 has been shown to regulate ULK1 kinase
activity, with both proteins implicated in autophagosome biogenesis (Jung et al., 2017; Webster et
al., 2016; Yang et al., 2016). Moreover, a C9orf72-SMCR8 complex appears to act as a Rab
guanine nucleotide exchange factor (GEF) for RAB8 and RAB39 (Ciura et al., 2016; Sellier et al.,
2016; Yang et al., 2016), and loss of C9orf72 has been reported to increase starvation-induced
autophagic flux (Ugolino et al., 2016).
Taken together, these studies suggest a lysosomal/autophagic function for both
TMEM106B and C9orf72. Whether the involvement of normal C9orf72 in lysosomal functions
contributes to the development of FTLD-TDP and ALS in C9orf72 HRE carriers, however, remains
unclear.
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5.4

Unanswered questions and future directions
In the preceding sections of this dissertation, I have made a case for the importance of

CTCF- and miR-132-based mechanisms in the upregulation of TMEM106B, with resulting
increases in TMEM106B levels increasing risk for FTLD by affecting lysosomal and autophagic
pathways. I conclude here by considering alternative interpretations of our data, as well as outlining
potential future research directions.
My work suggests that genetic variation at a single causal SNP, rs1990620, contributes to
FTLD-TDP risk through effects on the transcriptional regulation of TMEM106B. However, it is
possible that genetic variation at TMEM106B affects disease risk through effects on protein
function, rather than gene expression. In such a scenario, the eQTL effect at TMEM106B would
not be responsible for conferring disease risk, but would rather be an independent phenomenon.
While the conditional analyses performed in Chapter 4 are consistent with the eQTL effect being
driven by the same causal variant that affects disease risk, they do not rule out the possibility that
the two associations might be the result of two different causal variants that are in strong LD. For
example, several groups have investigated the potential function of the nonsynonymous SNP
rs3173615, which causes a serine (protective allele) to threonine (risk allele) substitution in exon 6
of TMEM106B, and is in complete linkage disequilibrium (LD) (r2=1) with rs1990622. While this
SNP does not appear to affect lysosomal phenotypes or PGRN levels (Brady et al., 2013; Nicholson
et al., 2013; Stagi et al., 2014), it may affect other molecular and cellular functions that have not
yet been thoroughly characterized. For example, one recent study reported that the risk allele of
rs3173615 impairs autophagic flux and protein degradation rates compared with the protective
allele (Jun et al., 2015), but these results need to be confirmed by independent groups. Another
group has reported that the risk allele of rs3173615 increases TMEM106B monomer stability, and
thus may increase steady-state protein levels (Nicholson et al., 2013), but other groups have failed
to replicate this effect (Jun et al., 2015). Furthermore, this study focused only on monomers and
ignored TMEM106B dimers, which have been reported to exist by multiple groups (Brady et al.,
2013; Chen-Plotkin et al., 2012). Indeed, using our well-characterized antibody that recognizes
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both TMEM106B monomer and dimer species, I repeated the Nicholson et al. (2013) experiments
and found that while rs3173615 may affect TMEM106B dimerization, and thus the dimer to
monomer ratio, total steady-state protein levels were unaffected (unpublished data). Future studies
are needed to investigate the precise molecular and cellular functions of TMEM106B, and whether
this amino acid-altering polymorphism affects any of those functions.
Second, even if TMEM106B affects disease risk through the eQTL effect described in
Chapters 1 and 4, it is unclear whether one or more SNPs within the CTCF binding site truly alters
TMEM106B levels, or how this might occur. To further demonstrate that this CTCF site affects
TMEM106B expression in an allele-specific manner, one might utilize CRISPR/Cas9 genome
editing (Dominguez et al., 2016) in a cell type known to exhibit the TMEM106B eQTL effect, such
as LCLs. Specifically, CRISPR/Cas9-mediated homologous recombination could be employed to
mutate all three SNPs within the CTCF site to the alternative alleles, using a DNA donor template
(homology directed repair) (Dominguez et al., 2016). I would mutate these SNPs in both risk
haplotype homozygous and protective haplotype homozygous cell lines in order to confirm the
expected changes in TMEM106B expression with RT-qPCR.

Based on the direction of the

published eQTL effects, I predict that replacing the protective SNP alleles with the risk alleles would
increase TMEM106B expression, and vice versa. If mutating all three SNPs was sufficient to alter
TMEM106B levels, I would perform follow-up experiments to mutate one SNP at a time, starting
with rs1990620, the putative casual variant, in order to determine which variant or variants are truly
causal.
While these experiments could theoretically confirm which variant(s) are causing the eQTL
effect, additional experiments would add to our analysis of the mechanism. For example, one could
perform CTCF ChIP-qPCR and Capture-C to confirm that editing of the causal variant(s) affects
CTCF binding and long-range interactions, respectively. If the model presented in Chapter 4 is
correct, such that increased CTCF binding due to the risk allele of rs1990620 facilitates long-range
interactions in order to upregulate TMEM106B, I would expect that long-range interactions would
be strengthened after editing protective allele homozygotes to risk allele homozygotes, and vice
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versa. It is possible that increasing CTCF binding at the region containing rs1990620 might
increase the strength of all long-range interactions, or that only specific interactions might be
affected. Indeed, while CTCF sites that are located at TAD boundaries are known to be involved
in TAD formation and prevention of inter-TAD long-range regulatory interactions (Dowen et al.,
2014; Guo et al., 2015; Lupianez et al., 2015; Merkenschlager and Nora, 2016), the architectural
role of CTCF sites located within TADs has not been investigated. In order to address which longrange interactions are responsible for altering TMEM106B levels, I would complement the CaptureC results with chromosome conformation capture (3C) coupled with qPCR (Denker and de Laat,
2016), in order to investigate specific interactions that appear to be affected by Capture-C after
editing. Based on the Capture-C results described in Chapter 4, I predict that the most affected
interactions would involve the TMEM106B promoter, the CTCF site containing rs1990620, and the
enhancer. I would also perform Capture-C on unedited and edited heterozygous LCLs (which are
risk or protective allele homozygotes at the causal variant(s) after editing), with the expectation that
long-range interactions would be strongest in risk allele homozygotes, weakest in protective allele
homozygotes, and intermediate in strength in heterozygotes. I would also use Capture-C to confirm
that the allele-specific interactions seen in heterozygotes show equal interaction strength on both
chromosomes after editing the causal variant(s) to homozygosity. This approach, however, might
only be feasible for the TMEM106B promoter viewpoint (see Chapter 4), since the bait region of
the CTCF site might not have sufficient heterozygous marker SNPs after editing.
In addition, if my model is correct, and the risk allele of rs1990620 (and potentially other
SNPs within the CTCF site) increases TMEM06B expression by strengthening CTCF-mediated
enhancer/promoter (E/P) interactions, I would perform CRISPR-mediated deletion of the enhancer
in heterozygous cells, using paired single guide RNAs. I predict that deletion of the enhancer on
the risk haplotype chromosome, which has stronger E/P interactions according to the model
presented in Chapter 4, would result in a more significant decrease in TMEM106B levels than the
same deletion on the protective allele chromosome, which has weaker E/P interactions.
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Another limitation of the work presented in Chapter 4 that is worth considering is that with
the exception of electromobility shift assays (EMSAs) that demonstrate allele-specific recruitment
of CTCF to a probe containing rs1990620, no experiments were performed in brain-relevant cell
types or tissues. Indeed, while the TMEM106B eQTL effect has been reported in brain in multiple
studies (GTEx Consortium, 2015; Yu et al., 2015), it is unclear which cell type(s) the effect is coming
from. However, several lines of evidence suggest an intriguing candidate: microglia. First, the
TMEM106B eQTL effect has been detected in multiple white blood cell types, including LCLs,
primary T cells, monocytes, and neutrophils (Fairfax et al., 2014; Peters et al., 2016; Raj et al.,
2014). Second, the enhancer that may be responsible for the eQTL effect by engaging in allelespecific long-range interactions with the TMEM106B promoter appears to be transcriptionally active
primarily in white blood cells (Andersson et al., 2014). Third, several lines of evidence discussed
throughout Chapter 5 support a role of TMEM106B in modifying GRN-associated phenotypes. If
TMEM106B does indeed influence disease risk and manifestation through effects on GRN, these
effects may have a microglial origin, as microglia are one of the major producers and secretors of
PGRN in the brain, particularly in response to injury or disease (Petkau and Leavitt, 2014). Finally,
cell-based experiments have demonstrated that conditioned media from Grn null microglia is toxic
to neurons (Martens et al., 2012). Thus, TMEM106B genotype and expression levels may affect
PGRN in microglia, with resulting deleterious effects on neuronal health.
To definitively identify the cellular origin of the TMEM106B eQTL effect in brain, one might
perform RNA CaptureSeq (Mercer et al., 2014) in either embryonic stem cell- or induced pluripotent
stem cell-derived neurons and glia from individuals heterozygous at the TMEM106B haplotype, in
order to quantify TMEM106B levels in an allele-specific manner using exonic marker SNPs. In
such an approach, capture probes targeting the TMEM106B exons could be used to selectively
enrich for TMEM106B in order to drastically increase sequencing read depth, thus allowing for the
detection of modest allele-specific expression (ASE) differences. Any cell types exhibiting ASE
could also be used in the aforementioned editing, Capture-C and 3C experiments, although current
technologies to 1) produce brain-relevant cell lines from stem cells and 2) use them to perform
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experiments that require many weeks of passage in cell culture may be limiting (Brennand et al.,
2015). Thus, while it may not be technically feasible to perform all of these experiments at the
current time, work along these lines in the future might most definitively demonstrate which variant
or variants have functional effects on TMEM106B levels in human brain, as well as the mechanisms
involved.
Third, it is possible that more than one genetic variant is affecting disease risk at the
TMEM106B locus, through at least two possible mechanisms: first, multiple variants may underlie
the eQTL effect, which would imply that Chapter 4 was not successful in identifying all the functional
regulatory variants within the haplotype block; second, multiple variants might affect TMEM106B
through distinct mechanisms, such that one variant affects TMEM106B mRNA levels, e.g.
rs1990620, whereas another variant affects TMEM106B protein levels or function, e.g. rs3173615.
Indeed, there is significant evidence that some disease-associated loci may harbor multiple
“causal” variants, which may have additive or emergent effects on gene regulation, protein function,
or both (Corradin et al., 2016; Edwards et al., 2013). It is worth noting, however, that if increased
TMEM106B expression is truly the mechanism by which TMEM106B genotype influences disease
risk, a more disease-relevant line of inquiry may be to investigate how changes in TMEM106B
levels affect disease risk, rather than trying to understand the contributions of one or multiple
variants to TMEM106B steady-state levels.
Fourth, and following from the last paragraph, it remains to be determined how small
changes in TMEM106B levels affects risk for FTLD. While many groups have reported that
TMEM106B overexpression causes lysosomal phenotypes and cell death (Brady et al., 2013;
Busch et al., 2016; Chen-Plotkin et al., 2012; Schwenk et al., 2014; Stagi et al., 2014; Suzuki and
Matsuoka, 2016), and that these phenotypes result from as little as ~2-fold overexpression
(Chapter 4), it is unclear exactly how this happens, or which cell type in the brain these results are
relevant to. Thus, after determining which brain cell type(s) exhibit ASE of TMEM106B, one might
use the constructs described in Chapter 4 (Chen-Plotkin et al., 2012) to overexpress TMEM106B
at three different levels, and quantify the enlarged lysosomal phenotype and cell death.
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Finally, given the genetic modifier effects of TMEM106B in GRN+ FTLD-TDP (Cruchaga
et al., 2011; Finch et al., 2011) and C9orf72 FTLD-TDP (Gallagher et al., 2014) described earlier,
it is of particular scientific and clinical interest to study TMEM106B function in the context of PGRN
and C9orf72 function and/or loss-of-function. Indeed, while it is unlikely that a GWAS-nominated
risk factor of small effect, i.e. TMEM106B in sporadic FTLD-TDP, would make for an effective
therapeutic target in all patients, if the same genetic variants substantially modified penetrance or
age at death in a subset of individuals at high risk for development of disease (i.e. C9orf72 or GRN
mutation carriers), this subset of individuals might be reasonable candidates for TMEM106B-based
therapeutic interventions.
In summary, I conclude that genetic variants at the TMEM106B locus affect risk for FTLDTDP, and modify the clinical course of GRN+ FTLD-TDP and C9orf72+ FTLD-TDP. I also conclude
that this association is most likely due to one or more risk-associated genetic variants at this locus
increasing steady-state TMEM106B mRNA levels, thereby increasing TMEM106B protein levels
and impairing lysosomal function. It is possible, though perhaps not likely, that the amino acidaltering SNP rs3173615 affects disease risk independently by altering TMEM106B protein levels
or function. While our results strongly suggest that allele-specific CTCF binding and long-range
regulatory interactions may underlie the eQTL effect at TMEM106B and thereby affect disease risk,
further experimentation (namely, genome-editing combined with 3C-based approaches) in brainrelevant cell lines could more definitively prove this hypothesis.
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5.5

Summary
Frontotemporal lobar degeneration (FTLD) is a heterogeneous group of diseases

characterized by progressive degeneration of the frontal and temporal lobes of the brain. FTLD is
typically fatal within 5-8 years after symptom onset, and currently there are no disease-modifying
treatments (Bang et al., 2015; Seelaar et al., 2011). A genome-wide association study (GWAS)
identified common genetic variants at the TMEM106B locus on chromosome 7p21 that are
associated with risk for the most common neuropathological subtype of FTLD, FTLD with TDP-43
pathology (FTLD-TDP) (Van Deerlin et al., 2010), and this association has been replicated by three
independent groups (Finch et al., 2011; Hernandez et al., 2015; van der Zee et al., 2011).
Furthermore, FTLD-TDP-associated variants have been associated with TMEM106B expression
levels in human cell lines and brain (GTEx Consortium, 2015; Lappalainen et al., 2013; Liang et
al., 2013; Stranger et al., 2012; Yu et al., 2015), and TMEM106B levels are increased in FTLDTDP brains, compared to neurologically normal controls (Chen-Plotkin et al., 2012; Van Deerlin et
al., 2010). Thus, increased TMEM106B levels may play a key role in FTLD pathogenesis.
In this work, I demonstrate that the FTLD-TDP risk genotype at TMEM106B affects age at
disease onset and age at death in FTLD-TDP cases caused by Mendelian mutations in the C9orf72
gene (Gallagher et al., 2014). I also show that the single most dysregulated microRNA in FTLDTDP brains, microRNA-132, directly represses TMEM106B expression (Chen-Plotkin et al., 2012);
thus, downregulation of microRNA-132 in FTLD-TDP likely contributes to the increased TMEM106B
levels seen in disease. Furthermore, I perform an unbiased, comprehensive characterization of all
candidate causal variants at the TMEM106B locus, and demonstrate that 1) the TMEM106B risk
haplotype is associated with increased TMEM106B levels in human cell lines and brain, 2)
incremental increases of TMEM106B levels in cells cause incremental increases in lysosomal
abnormalities and cell death, and 3) a putative noncoding causal variant in complete LD with the
sentinel GWAS SNP affects binding of the transcription factor CTCF and associated long-range
chromatin looping interactions. These experiments suggest that I have identified the “causal
variant’ responsible for the association of the 7p21 locus with FTLD-TDP. Finally, I have shown
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that neurodegenerative risk SNPs are enriched in brain CTCF binding sites genome-wide,
implicating a more general role of CTCF-mediated gene expression programs in risk for
neurodegeneration.
In summary, this dissertation investigates the role of TMEM106B genotype and expression
levels in the pathogenesis of FTLD.

Specifically, I focus on understanding the mechanisms

underlying the association of common genetic variation at the TMEM106B locus with FTLD by
GWAS. Such a mechanistic understanding has only been accomplished for a few dozen of the
thousands of variant-trait associations in the genome, and for only one of the ~200 variants
associated with risk for neurodegenerative diseases.

However, understanding the biological

mechanisms underlying the thousands of disease-associated loci will be required in order to better
understand, and eventually treat, complex human diseases.
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